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1.1 Nanomedicine: O/W drug delivery systems 
The application of nanotechnology to clinical treatments brings to the birth of nanomedicine. 
Nanomedicine’s main aims are early diagnostics and targeted therapies in several human diseases, 
such as cancer therapy.1 The fusion between nanotechnology and biomedicine developed novel 
materials with highly specific and unique therapeutic properties. Compared to traditional therapies, 
nanotechnology devices offer new advantages, such as targeted delivery, controlled drug release, and 
improvement of cell barrier crossing.2,3 
Over the past decades, nanotechnology world, engineering nano-scaled devices, has led to the 
development of a lot of particle systems, such as gold nanoparticles (NPs), silica NPs, liposomes, and 
polymeric NPs.  Drug delivery systems’ aim is to obtain a particle design to improve drug specificity 
to the desired site of action, so higher efficacy and fewer adverse effects.4 In fact, literature strongly 
underlines that the use of polymeric nanocarriers to transport active compounds like small-molecular 
drugs, peptides, or genes found an increased attention throughout the different fields of natural 
sciences. Not only these nanocarriers enhance the properties of already existing drugs in terms of 
solubility, bioavailability, and prolonged circulation times, furthermore they can be tailor-made in 
such a manner that they selectively release their cargo at the desired site of action.3,5 It is known that 
thanks to drugs’ encapsulation, we can protect not only the cargo but also the living cells from the 
possible toxic effect of cargo. So we insist on the fact that nanomedicine could contribute with 
appropriated biocompatible multifunctional systems, to avoid these unwished effects. Structured 
nano-devices are able to navigate into living cells and can be activated for the local release of their 
cargo, increasing drug’s bioavailability too.2,6 
In the early 1990s, Decher and co-workers were the first to develop Layer-by-Layer (LbL) thin films 
(Figure 1.1).1 Their protocol consists in the preparation of multilayer ultrathin organic films by 
alternated deposition of oppositely charged polyelectrolytes on a charged solid subrate. So this 
technique is based on the electrostatic attractions polyanions and polycations. One of the advantages 
of LbL films is that the film thickness can be precisely tuned at the nanometer level by changing the 
number of deposited layers.2,4,7 In 1998, LbL technique was transferred from planar films to spherical 
colloidal particles by Donath and co-workers, referring to the strategy on planar substrate.1 Since their 
introduction in 1998, LbL capsules have obtained an increasing interest, largely because of the 
possibility to tailor their properties, such as size, composition, porosity, stability, surface 
functionality, colloidal stability (Figure 1.2). In addition, the LbL technique has a special protocol 
which enables to engineer new materials introducing unprecedented structure and function.3 The 
variety of templates and materials has given rise to an ever-expanding catalogue of LbL-assembled 
multi-layered particles varying in sizes, shapes, and chemical compositions. A main feature of the 
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LbL technique is the precision of the final particles. Thanks to such versatility, multilayered particles 
have become a powerful platform for drug encapsulation and triggered drug release.4 
 
 
Figure 1.1. (A) Schematic of the film deposition process. Steps 1 and 3 represent the adsorption of a polyanion and 
polycation, respectively, and steps 2 and 4 are washing steps. The four steps are the basic sequence for the simplest film 
architecture. (B) Simplified molecular picture “model” of the first two adsorption steps, starting with a positively charged 
substrate. Counter ions are omitted for clarity.8  
 
The LbL NPs were first reported by Caruso and his group. In their protocol they prepared via LbL 
some polyelectrolyte nanocapsules around a solid template, when obtained monodisperse emulsions 
by filling them with oil.9,10 So more in general, LbL technology is about polymeric nanocapsules and 
takes advantage of the charge–charge interaction between substrate and monolayers of 
polyelectrolytes to create multiple layered nano-architecture held together by electrostatic forces. The 
formation of LbL systems are attributed to electrostatic interactions, hydrogen bonding, hydrophobic 
interactions and van der Waals forces.5  
 
 
Figure 1.2. Example of layer by layer adsorption of two or more oppositely charged polyelectrolyte.11 
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In 2014, our team developed biodegradable oil-in-water (O/W) nano-emulsions coated with a 
molecular layer of biodegradable polyelectrolytes. In dependence of the polymer concentration, they 
controlled the level of coating that resulted in a tunable stability. Our O/W nano-emulsions consists 
of a biocompatible formulation: small lipidic droplets with soybean oil and Lipoid E80 lecithin 
dispersed in an aqueous medium. They have the ability to dissolve large quantities of hydrophobic 
drugs and protect their cargo from hydrolysis and enzymatic degradation. The stability over time and 
good behaviour of these systems, strictly connected to their monodisperisity, were obtained using a 
high-pressure homogenizer.10 In 2016, a protocol to obtain optimized liquid–liquid interfaces capable 
to sustain multiple depositions of biodegradable polymers has also been developed in our lab. With 
this protocol, it was possible to perform around the oil core of the nanoemulsions, progressive 
depositions of the natural polymers shells via the classical LbL technique but with control almost at 
the molecular scale (Figure 1.3).12  
 
 
Figure 1.3. Example of controlled deposition of polymeric multilayer film on oil core based nanocapsules.12 
 
In drug delivery field, from a circulation point of view, another important point, respected by our 
formulations, is that the ideal size of drug carriers is in a range below 200 nm.6,10 In fact, bigger 
capsules can obstruct the smallest blood capillaries and cannot reach the specific tissue.6 On the other 
hand, the selective delivery of a drug loaded nanocapsule through systemic administration routes is 
often attributed to passive targeting via the “enhanced permeability and retention” (EPR) effect which 
is mainly a molecular size-based phenomenon (Figure 1.4). This EPR effect is the basis for 
development of macromolecular anticancer therapy which was first introduced by Matsumura and 
Maeda in 1986. They showed that most solid tumors have blood vessels with defective architecture.  
This effect is attributed to poor tumor vascularization and lymphatic drainage.  So most solid tumors 
exhibit enhanced vascular permeability, which will ensure a sufficient supply of nutrients and oxygen 
to tumor tissues for rapid growth. The EPR effect is a unique anatomical–pathophysiological nature 
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of tumor blood vessels that facilitates transport of macromolecules into tumor tissues. In this way the 
nanocapsules manage to accumulate themselves within the tumor tissue. In contrast, this EPR effect-
driven drug delivery does not occur in normal tissues.4,13  
In addition to passive targeting, recent studies have demonstrated that cell selectivity in vitro can be 
improved conjugating targeting ligands to multilayer nanoparticles. This is called “active” targeting, 
because to promote specific interaction, nanocapsules can be decorated with functional ligands which 
recognize the tumor tissue, to delivery and release their drug selectively. This strategy can be an 
effective approach to complement the EPR effect.4 More in general, surface modifications are helpful 
not only to deliver the nanocapsules in specific sites but also to prevent the body from recognizing 
the capsules as foreign material.3 
 
 
Figure 1.4. Targeting of nanomedicines by the enhanced permeability and retention (EPR) effect. Notes: (A) normal and 
(B) tumor vessels.14  
 
For all said above, LbL polyelectrolytes deposition on nanoemulsion has emerged as one of the best 
techniques to deposit ultrathin polymer layers. However, it is known that electrostatic interactions are 
weak and easily breakable in physiological environment.15 To improve emulsion stability a strategy 
is the cross-linking between the polymer shells by click chemistry.10,16 In a previous work of our 
group, it has been shown that the stability of biopolymer multilayers (glycol chitosan and heparin) 
obtained via layer by layer can be enhanced introducing a covalent bonds among layers by means of 
a metal catalyst-free, light initiated ‘click’ reaction, namely the thiol-ene reaction. In particular, the 
reaction involves a thiol moiety on glycol chitosan and an allylic moiety on heparin. Interestingly, 
the reaction resulted effective even without a photoinitiator, mainly due to the high degree of 
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modification of the biopolymers, proving a completely non-cytotoxic final product (Figure 1.5). 
Cross-linked multilayers resulted in more stable systems than those stabilized with just electrostatic 
forces. In addition, the application of this approach to biopolymers surrounding an O/W 
nanoemulsion demonstrated that thiol-ene cross-linkage can be nicely exploited in the field of 
completely biocompatible and biodegradable nanocarriers.15  
 
 
Figure 1.5. Thiol-ene reaction between allylated heparin and thiolated glycol chitosan. Reaction was triggered throughout 
UV irradiation.15 
 
1.2 Endogenous and exogenous stimuli-responsive nanocarriers. 
Conventional chemotherapy is far from successful because of the lack of tumor selectivity, or toxicity 
of the drugs. So it is of extreme importance the development of highly selective systems for tumors, 
to reduce drug toxicity and enhance the therapeutic purpose.13,17 We have just discussed above about 
the EPR effect-based drug delivery connected to pathophysiological heterogeneity of the tumors. 
However, EPR effect is absent in the central area of metastatic cancers, and so there the accumulation 
is lower than in other parts.13 
Considering the difference between normal and pathological tissues, the design of stimuli-responsive 
nanocarriers is a promised approach for the future to improve the therapeutic effects in the tumor 
tissues and reduce the undesired ones in the healthy cells. The use of stimuli-responsive drug delivery 
nanocapsules could improve the cellular uptake and intracellular stability. According to the diagnostic 
or therapeutic purpose, these systems can include different organic and inorganic materials, such as 
polymers, liposomes, nanoemulsions, dendrimers and so on.18  
In the 1970s stimuli-responsive drug delivery was introduced with the use of thermosensitive 
liposomes for a controlled release of drugs through hyperthermia. Since then, stimuli-responsive 
nanocarriers for drug delivery became of particular interest.19  
About stimuli-responsive nanocarriers, Keun Sang Oh et.al. were the first to introduce LbL 
nanocarrier for cancer-targeting.  First of all, the LbL approach improves the target ability by 
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prolonging the nanocarries systemic circulation.20 LbL nanocapsules surface can be modified with 
the aim to prevent the recognition of these materials as foreign for the body and to deliver them to 
specific tissue by targeting. The application of micro-/nanocapsules as drug delivery vehicles shows 
great promise.3   
The easy of the preparation process and the variety of applications in drug delivery have recognized 
the stimuli-sensitive LbL systems as a promising approach .11 
Typically, stimuli-responsive mechanisms to release the drugs can be of two types (Figure 1.6): 
endogenous stimuli (e.g., pH, enzymes, redox potential, glucose concentration, ions) or exogenous 
stimuli (temperature, magnetic fields, electrical fields, ultrasound and light). The choice of release 
mechanism is connected to the desired application. Intracellular mechanisms are the basis of the 
endogenous stimuli mainly used to release the encapsulated drugs from biodegradable coated 
nanocarriers. Indeed, exogenous stimuli are mainly used for a remoted control of the opening of the 
nanocarries with external source.1,3,6 Among the variety of nanocarriers, polyelectrolytes LbL systems 
is a powerful method because of their versatility in shape, size, modulated swelling capacity.21 
 
 
 
Figure 1.6. On top: General scheme of a stimuli-responsive nanocarrier for the transport of active compounds.  
On bottom:  General scheme of stimuli-responsive release of a drug from a nanocarrier.5 
 
Before introducing the nucleus of this PhD project, which is based on a photo-responsive LbL O/W 
nanoemulsion, we carry on a brief summary of the different stimuli. 
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pH stimuli-responsive systems. In these systems the triggering of the drugs is based on the different 
pH gradient between the tumor tissues (pH 5.7-6.8) and the extracellular environment (pH 7.4), and 
the acid pH of endosomal and lysosomal compartments.18,22 So pH stimuli-responsive systems are 
based on pH sensitive polymeric materials. The change in pH environment lead to some changes in 
nanocapsules’ permeability with the followed release of the drugs.20 Typical pH-stimuli responsive 
polymers reported in literature include poly(acrylamide) (PAM), poly(acrylic acid) (PAA), 
poly(methacrylicacid) (PMAA), poly(diethylaminoethylmethacrylate) (PDEAEMA), 
poly(dimethylaminoethyl methacrylate) (PDMAEMA), polymers with phosphoric acid derivates, and 
some natural polymers such as albumin and gelatin.17 An example for pH-responsive nanocarriers 
was reported by Liang et al. In their studies the capsules were based on poly(2-diisopropylaminoethyl 
methacrylate) (PDPA). They combined PDPA with a minor component of lauryl methacrylate 
(PDPAC12). In this way they obtained the endocytic pH-induced degradation of their capsules. Their 
multilayers containing C12 groups in the PDPA increased the overall hydrophobicity, and so a non-
covalent stabilization of the multilayers at pH 7.4. On the other hand, the capsules degraded for the 
cellular pH shift.23 
Redox potential stimuli-responsive systems. Between the extracellular and intracellular compartments 
there is a different redox potential. In fact, the extracellular space is oxidative while the intracellular 
is reductive. This is due to the different concentration of glutathione (GSH) in these two 
compartments (~2–10 µM in the extracellular part and ~2–10 mM in the intracellular one) and in 
tumor tissues as compared to healthy ones.5,18,19 So the release of the drug in the cytosol can be 
triggered by this different redox potential.19 Since disulphide bonds can be cleavaged by reducing 
agent (GSH) and the thiol groups can return to disulphide by oxidation, it is possible to built redox-
sensitive carriers by incorporating disulphide bonds which release the drug as a consequence of the 
redox potential triggering.24 An example of redox potential stimuli-responsive nanocarrier was 
reported by  Lee and co-workers. Their synthesized biocompatible polymer micelles with disulfide 
bonds in their shells responded to the typical reduced conditions of the cancer environment.25 
Enzyme stimuli-responsive systems. In pathological states, such as cancer or inflammation, the 
expression of vary enzymes (e.g. protease, phospholipases or glycosidases) is altered. So in those 
sites, it is possible to design drug delivery systems acting via specific enzyme-mediation.19,24 For 
example, literature studies demonstrated that esterases or proteases can promote the cleavage of esters 
or short peptide sequences contained in the enzyme-responsive nanocarriers.5 Other examples of 
enzymes used for trigger are proteases, glucuronidase, or carboxylesterases, which are expressed 
differentially in the normal and tumor cells. To promote recognition of the nanocarriers by these 
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enzymes, specific enzyme substrates are encapsulated into the nanocarriers or linked to external 
segments containing the drugs and bonded to the nanocarriers.5 
Ion stimuli-responsive systems. In the case that there are coordinative bonds between the nanocarrier 
and the guest, it is possible to trigger the release by competitive ligands or ions. For example, in 
literature, it was reported that micelles based on PEG-PAsp and PEG-PGlu and loaded with cis platin 
coordinated to the carboxyl groups in the core of the micelle, did not show release in absence of 
competitive ligands. Instead, in a phosphate buffered saline, 50% of cis platin was released after 24 
h in the case of PEG-PAsp based micelles and after 72 h in the case of PEG-PGlu ones, this because 
chloride ions in the buffer were favorited ligands for cis platin than carboxyl groups.5 
Glucose stimuli-responsive systems. The introduction of enzymes such as catalase (CAT) and glucose 
oxidase (GOx) in the nanocapsules brings to the development of glucose stimuli-responsive systems. 
Generally, as reported by Qi et. al., these nanocarriers were loaded with insulin and were assembled 
by LbL depositions. Their shells contained imine bonds. The treatment with a glucose solution caused 
the conversion of glucose to gluconic acid. In fact, Qi et al.in 2009 noticed that CAT/GOD in the 
shells interaction with the glucose solution was responsible of a pH reduction in the 
microenvironment, connected to H+ production. In that acid conditions there was the cleavage of the 
imine bonds, an increase of capsules’ permeability and so insulin release.5,20  
Thermo stimuli-responsive systems. A thermosensitive polymer is characterized by a lower critical 
solution temperature (LCST) in aqueous solution. Such polymer is water soluble below its LCST and 
becomes water insoluble above that temperature.18 The behaviour of thermosensitive polymers is 
generated by the balance of hydrophilic and hydrophobic moieties constituted the amphiphilic 
polymer chain. It is known that there is a higher temperature of 1-2°C in the tumor microenvironment 
than that of normal tissue. So when the thermos-stimuli-responsive nanocarrier is in the tumor tissue, 
its thermal responsive polymers change their phase form into a hydrophobic collapsed one with the 
consequent release of the drug.24 For the past 20 years the study of hyperthermia to improve radiation 
or chemotherapy therapies, has grown. In addition, tumor cells exhibit more sensibility to heat-
induced damage than normal cells. So for example, in different clinical studies, liposomes and 
nanoparticles containing iron oxide particles were used to localize the tumor tissue by the magnetic 
properties of the iron oxide and to heat the specific tissue. Another advantage of the thermo responsive 
drug delivery systems is the creation of micro-emboli in the tumor vasculature, the lower intake of 
oxygen and nutrients into the tumor mass.18  
Magneto stimuli-responsive systems. A magnetic field can have different uses and provide different 
applications. A permanent magnetic field can be a magnetic guidance, an alternating magnetic field 
can increase temperature, or it is possible to have both the effects when both the strategies are 
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alternately used. So the same magnetic stimuli-responsive drug delivery system can be used for 
diagnostics and therapy within a single system (the so-called theranostic approach).19 For example, 
in literature studies the magnetic control of permeability of the nanocapsules was obtained by the 
introduction of ferromagnetic gold-coated cobalt in nanocarriers’ shells. Applying an oscillating 
magnetic fields, the rotation of the embedded nanoparticles caused the distortion of the nanocapsules’ 
structure and so an increase of their permeability. In addition, for nanocapsules based on 
polyelectrolytes, lipid bilayers, and magnetic nanoparticles, a local heating could be induced by the 
magnetic field. This changes the membranes phase and brings to an easier release of the encapsulated 
drugs.26 Lu et al. study is an example of magneto responsive drug delivery systems based on LbL 
assembly, where the magnetic field changed the permeability of the polyelectrolyte shells.17 Hu et al. 
studied LbL nanocapsules containing magnetic nanoparticles in their shells under a high-frequency 
magnetic field to trigger the release of the drug. They demonstrated that the magnetic field proved 
nanocavities in the shells and consequently the nanocapsules rupture.11 
Electrical stimuli-responsive systems. When an electrical stimulus is applied to a charged drug or to 
polyelectrolyte multilayers, an influx of counterions and solvent molecule takes place. These influxes 
increase the osmotic pressure between the shells and so bring to a volumetric expansion. The osmotic 
pressure is balanced by polymers’ deformation and swelling.11,20  Electro-sensitive polymers are 
generally polyelectrolytes. Only few natural polymers show this behaviour in non-conducting media. 
Typically in such systems it is necessary the functionalization with charged or polarizable component 
which respond to an electric field. For example, a lightly cross-linked poly(dimethyl siloxane) gel 
containing electrosensitive colloidal TiO2 particles was synthesized by Zrinyi and co-workers. TiO2 
particles were trapped in the matrix. So the gel deformation was obtained by the electrical force acting 
on these particles which was transferred to the polymer.25 
Photo stimuli-responsive systems. Photo-responsive polymers present specific functional groups 
which are light sensitive. So upon light irradiation of appropriate wavelength, these polymers change 
their structural properties. An important aspect is that the use of light is a non-invasive mechanism. 
Some examples of photo stimuli-responsive groups incorporated into polymer structures are 
azobenzene, spiropyran, cinnamate, which present a light-induced isomerization behaviour. Other 
groups have a photo-labile behaviour, i.e. light cleavages them changing their polarity, such as some 
photo-labile esters.25 Also metal nanoparticles, such as silver, platinum, gold and gold sulfide or 
magnetite are incorporated within polyelectrolyte multilayer capsule walls. These nanoparticles 
absorb light and dissipate adsorbed energy as heat. This behaviour causes irreversible changes in the 
shells integrity/permeability and capsules’ shell rupture.3,6,26 An example of photo stimuli-responsive 
polyelectrolyte capsules for a remote release of the encapsulated drugs is based on two different 
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components introduced into the polyelectrolyte shells. Either Ag nanoparticles or IR dyes adsorb 
light. Under laser illumination with a low-power near-infrared continuous-wave diode, the capsules 
containing Ag nanoparticles or IR dye were deformed or cut. In this way, with a remote control, there 
was the release of the encapsulated materials.27 Being our systems based on a photo-stimuli linker, in 
the next paragraph we are going to deepen more this typology of stimuli-responsive nanocarriers.  
Ultrasound stimuli-responsive systems. Ultrasound application in drug delivery is highly 
advantageous because it is non-invasive and has a good penetrating deep into the body. Moreover it 
can be focused and controlled by frequency, power, density, time of application and duty cycles.17 
Ultrasound mechanism is connected to the cavitation phenomena, which is activated by ultrasound. 
Cavitation is the alternating growth and shrinkage of microbubbles that means alternation of high and 
low pressure waves. When these microbubbles implode, generate local waves that perturb and can 
disrupt the polymeric shells of the capsules. Typical ultrasound stimuli-responsive polymeric systems 
are generally based on gels, polymeric micelles, LbL coated microbubbles. Moreover, cavitation and 
microbubble implosion can mediate enhancement of vessel permeability to facilitate the nanocarriers’ 
encapsulation. This process is known as “sonoporation”.19,25 An example of ultrasound stimuli-
responsive systems by Nelson et al. was based on micelles which released doxorubicin (Dox) upon 
application of low-frequency ultrasound in an in vivo rat model of a colon carcinoma. They 
demonstrated that ultrasound induced a selective release of doxorubicin at the tumor site providing a 
reduction of the tumor volume as compared to the noninsonated tumors.28  
 
1.3 The o-nitrobenzyl ether as photocleavable linker. 
The world of photo-cleavable linker and the research in this field have found a great interest in these 
years in particular when applied to drug delivery systems. Now, we wish to introduce the photo-
cleavable linker which has been adopted in this project, but before, by appropriate examples, we want 
to explain better the world of photo-trigger molecules and systems describing the variety of photo-
responsive linkers, their versatility, their fields of application and their advantages as shown in 
literatures.  
First of all, as just said previously, the use of an external stimulus on drug delivery systems brings 
benefits such as protection of the drugs until they enter into the desired site and reduction of side 
effects. Among the external stimuli, light is of particular interest for its clinical relevance and the 
advantage to ensure a spatio-temporal control that enhance efficiency and minimize toxicity. The 
light-tissue interactions are mainly scattering and absorption, whose attenuate surface power density 
of the light beam. The attenuation coefficient and the penetration depth of light are inversely 
proportional where the attenuation coefficient depend from the absorption and scattering coefficients, 
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i.e. from the light wavelength and the type of tissue. Using NIR, penetration depth of light is in the 
order of centimetre scale. The penetration depth decreases going towards visible and UV light.  
Phototoxicity to tissues is connected to photochemical reaction or photothermal effects which are 
involved by the emission phenomena that rise when a tissue is irradiated. The maximum permissible 
exposure (MPE) depends on wavelengths and irradiation time. In general, even a photon of light can 
carry out a reaction through photo-responsive nanoparticles. Example of these photochemical 
reactions are: photo-isomerization, photo-cleavage, photo-crosslinking (Figure 1.7). These 
photochemical reactions can only be initiated by UV/vis radiation because of their higher energy but 
suffers from disadvantages like lower penetrating power. While lower wavelength radiations in NIR 
region have deeper penetration capabilities but are not energetic enough to initiate the reaction. The 
use of two-photon absorption is a strategy to combine the deeper penetration power of NIR and the 
high energy of UV/vis radiation to trigger chemical reaction. Photo-responsive groups, such as o-
nitrobenzyl and coumarin, absorb two NIR photons which are converted in single UV/vis photons.29,30 
This could be a good opportunity since there are very few organic chromophores which absorb in 
NIR region, while the majority just responds to UV light.31  
 
 
Figure 1.7. Examples of photo-responsive groups used in photochemical reactions, such as photo-cleavage, photo-
isomerization, photo-induced rearrangement, and photo-crosslinking.29 
 
Yan et al. demonstrated the multiphoton effect of core-shell lanthanide-doped upconverting 
nanoparticles (UCNPs) in a photosensitive hybrid hydrogel of biomedical interest. The UV light 
generated by the UCNPs induces the photo-cleavage of a photolinker present in the structure of the 
hydrogel, the o-nitrobenzyl moieties.32,33 Another example of photodegradable hydrogels is formed 
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by the self-assembly of short peptides modified with a photo-responsive biaryl-substituted tetrazole 
moiety (Figure 1.8). This moiety, upon mild light irradiation, forms a fluorescent pyrazioline by a 
rapid intramolecular photoclick ligation. This photo intramolecular transformation, disturbing the 
system interaction, induces the disassembly of the hydrogel.34  
 
 
Figure 1.8. (A) Components of the photo-responsive hydrogel. (B) Photo-response mechanism.34 
 
Also inorganic materials are used for photo-based applications, such as titanium oxide nanotubes, 
calcium phosphosilicate, nanoscintillators, copper selenide nanoparticles and silica-cored gold 
nanoparticles.30 For example, a photo-responsive protein delivery system, studied by Luo and co-
workers, used TiO2 nanoparticles containing hydroxyl. They covalently attached hemoglobin onto 
the surface of TiO2 nanoparticles by 3,4-dihydroxyl benzoic acid (DB). Visible light triggered the 
controlled release of Hb by the cleavage of the coordination bonds between DB and TiO2 surfaces
24 
Another example of photo-responsive linker used in drug delivery system was the perylene-3-
ylmethanol (Figure 1.9). In biological studies, this linker contained in chlorambucil, nanoparticles 
exhibited good biocompatibility, cellular uptake and it was efficient in photo-responsive anticancer 
therapy. Perylene-3-ylmethyl is an efficient fluorescent photo-trigger for carboxylic acids and 
alcohols in aqueous media under visible light.35  
 
Figure 1.9. Photo-responsive nanoparticles containing perylene-chlorambucil moiety.35 
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In literature, they are also shown photo-responsive nano drug delivery system based on fluorescent 
carbon dots and a photo-responsive 7-methoxy quinoline moiety. In a work on HeLa cells, carbon 
dots were used for their fluorescence in vitro cellular imaging application, while quinolone for 
controlled photo-induced anticancer drug release upon both one-photon and two-photon excitation.36 
Some studies report examples of photo-responsive polymers introduced into nanocarriers. An 
examples is the bis(4-dimethylamino)phenylmethyl leucocyanide. Under UV irradiation it dissociates 
into ion pairs producing triphenyl methyl cations. The introduction of this photo-responsive linker in 
hydrogels brought to a swelling into the hydrogel via UV irradiation due to the formation of the 
cyanide ions after UV irradiation increasing the osmotic pressure within the gel.17 
A widely used photo-responsive linker for its photo-isomerization property is azobene. Its trans-cis 
photo-triggered transition opens the possibility of a controlled release of the molecules encapsulated 
in the nanocarrier that contains this photo-linker. Trans-cis isomerization is activated by UV 
irradiation while the return to trans form is originated by visible light irradiation or heating.37   
Azobene was used, for example, in UV-light responsive cross-linked polyamide nanocapsules 
obtained by O/W miniemulsion interfacial polycondensation. In this study, it was shown that the 
smaller the capsule size, the faster the achieved release. Moreover here, an azobenzene acyl chloride 
acted as co-surfactant and as crosslinking agent.1,38 In a study on hydrogel, Peng and coworkers 
attached azobenzene groups to dextran decorated with a cyclodextrin. Trans-azobenzene fit  into the 
cavities of the cyclodextrin but when the hydrogel was irradiated, cis-azobenzene did not fit into the 
cyclodextrin. This mechanism dissociated the cross-linking points and the encapsulated guest were 
released.5 Photo-isomerization property are typical of stilbene moieties too. In comparison with 
azobene, trans-cis photo-isomerization requires a shorter wavelength and cis form has a higher 
thermal stability. On the other hand, azosulfonate, diphenyliodonium-2-carboxylate, and 
pyrenylmethyl ester give photolysis and are applied in photo-responsive hydrogel systems. Coumarin, 
cinnamylidene acetate, nitrocinnamate, anthracene, and poly(cinnamic acid) group have been used as 
a reversible crosslinking point. They have been used for hydrogel formation by photo-dimerization 
as photo-reversible crosslinking points.37  
Among the myriad of photo-cleavable protecting groups which have been studied, the o-nitrobenzyl 
group is certainly the predominant one since it enables the caging of a wide range of functionalities, 
such as carboxy, amine, hydroxy, and thiol. Furthermore, the precise positioning of o-nitrobenzyl 
groups in polymer chains has allowed for the controlled alteration of polymer properties upon light 
stimulus.39 The o-nitrobenzyl moiety, variously functionalized, was studied in a lot of fields of 
applications. An interesting feature of o-nitrobenzyl, over its biocompatibility,37 is that its photo-
cleavage can be obtained either by one-photon absorption of UV light or via two-photon absorption 
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of near infrared.40 It has been employed in photo-responsive amphiphilic block copolymer (BCP) 
micelles,40,41 in photo-responsive hydrogel systems for biomedical applications,37 dendrons,42 
dendrimers,43 functionalized mesoporous silica nanospheres (MSNs),44 and so on. 
So the o-nitrobenzyl group is one of the most extremely studied photo-responsive linker because of 
its versatility of application, its biocompatibility, the possibility to modify its structure with desired 
functionalities thanks to its functional groups, its capacity to respond to UV by also two-photons 
irradiation and so the possibility to improve the depth of penetration in tissue applications. For all 
these properties, it is clear that it is not a case if it is the most studied photo-responsive linker, as 
emerged by literature studies. In this PhD project, as far as we know, for the first time, the o-
nitrobenzyl moiety has been employed in a LbL O/W nanoemulsion and not only as photo-trigger but 
also as component of a free initiator thiol-ene ‘click’ reaction. In our strategy, we started from a work 
on polymer-based hydrogels by DeForest et al., in which they studied a reversible strategy based on 
the combination of two orthogonal and biocompatible photoreactions. Visible light (λ=490–650 nm) 
and eosin Y as photoinitiator triggered the thiol-ene reaction involving the radical-mediated addition 
of a thiol to an alkene. Indeed UV light (λ=365 nm) was the trigger of the photoscission of the o-
nitrobenzyl ether, which gives a nitrous compound and an acid by-product. They synthesized a 
biological molecule containing both the thiol group (adding that function on a starting azide by 
reaction with a N-acetyl cysteine) for the thiol-ene reaction and the photo-labile o-nitrobenzyl moiety 
(Figure 1.10). In this way the thiol-ene and photo-cleavage reactions was used to attach and 
subsequently remove covalently bound bioepitopes in hydrogel networks, respectively. Because of 
these reactions are photo-mediated with different wavelengths, by light both the introduction and the 
removal of relevant biomolecules could be controlled in space and time, indipendently.45 
Furthermore, both the reactions could be initiated by multiphoton irradiation (λ=860 nm for addition, 
740 nm for cleavage). In this paper, DeForest et al. showed a useful chemistry performable in the 
presence of cells because the wavelengths, exposure times, and intensity of light are all 
cytocompatible.45 
 
Figure 1.10. The photoreversible o-nitrobenzyl ether patterning agent used by DeForest et al. 
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1.4 Nanotechnology for nutraceuticals.  
In this PhD project we focused on nutraceutical drugs encapsulated and stabilized in O/W 
nanoemulsions. In the simplest case, such nanoemulsion, possibly coated with chitosan, can be used 
as oral delivery system to prevent or support oncological patients during the clinical treatment. In this 
scenario, we studied lycopene and curcumin as cardio-protectors for chemotherapies. For this reason, 
starting from literature, we want to introduce the nutraceuticals world, its advantages in various 
therapeutic fields and its behaviour when associated with nanotechnologic systems, i.e. oral delivery 
systems.   
“Let food be your medicine and medicine be your food” asserted Hippocrates 2000 years ago. In 1989 
Dr Stephen DeFelice coined the term “Nutraceutical” combining the terms “Nutrition” and 
“Pharmaceutical”. Any substance (food or part of it) with medical or health benefits is considered a 
“nutraceutical” (Figure 1.11).46 So, nutraceuticals have been regarded as an emerging method for 
preventing chronic diseases. Moreover, being natural, most of the nutraceuticals exhibit relatively 
less toxicity and less secondary side effects than drugs used in similar pathological states.47   
  
 
Figure 1.11. Some food-derived bioactive compounds applied in nutraceutical treatments.48 
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The limit of a lot of nutraceuticals is their low bioavailability in vivo mainly caused by their lipophilic 
nature and thus low solubility. So they are poorly absorbed by human body. Moreover, when 
nutraceuticals arrive in the gastrointestinal (GI) tract, because of various physiochemical 
transformations, they may lose their bioactivities. Thus it is very interesting to combine nutraceutical 
drugs with oral delivery systems to improve nutraceuticals bioavailability of phytochemicals 
changing their pharmacokinetics and biodistribution.47,48,49,50 On the other hand, some delivery 
systems are modified to improve the intestinal absorption, for example chitosan is employed as a 
positively-charged muco-adhesive polymer which increases the absorption of lipophilic compounds, 
interacting in a specific manner with the intestinal membrane.47,51 
In literature nutraceuticals were encapsulated and studied in different nanocarriers, such as 
nanoemulsions,50 phospholipid based delivery systems, liposomes, phytosomes, solid lipid 
nanoparticles, self-emulsified drug delivery systems.47,52 
In delivery systems, different nutraceuticals with chemoprevention and anti-inflammatory properties, 
had been encapsulated, such as curcumin, green tea polyphenols, coenzyme Q, quercetin, 
thymoquinone, ajoene, allicin, allyl isothiocyanate, anethole, apigenin, capsaicin, carnosol, 
caryophyllene, cinnamaldehyde, diallyl sulphide eugenol, [6]-gingerol, humulene, kaempferol, 
limonene, myrcene, [6]-paradol, perillyl alcohol, phytic acid, piperine, sulforaphane, ursolic acid, 
zingerone and so on.46,49 Plant polyphenols (that is, curcumin, resveratrol, epigallocatechin gallate, 
and so on) and carotenoids (that is, lycopene, ß-carotene, lutein, zeaxanthin, and etc.), have been 
studied largely. In 2005, studying the polyphenol oral bioavailability, Manach and others showed that 
proanthocyanidins, galloylated tea catechins, curcumin, and the anthocyanins are the least absorbed 
pholyphenols. After that, oil-soluble lycopene, phytosterols, ω-3 fatty acids, coenzyme Q10, and so 
on were studied to improve their solubilities. Moreover, the improvement of oral bioavaibility by 
nanoemulsion was confirmed by dibenzoylmethane (DBM) nanoemulsion. DBM, a beta-diketone 
similar to curcumin, is found as a minor constituent in the root of licorice. It is a natural phytochemical 
with anticancer activities.50 Resveratrol (trans-3,4,5-trihydroxystilbene) is another example of natural 
polyphenolic compound. It is abundant in grapes, peanuts, red wine, and a variety of other food 
sources, and has been reported to have a lot of anticancer properties. However, it has low 
bioavailability, low water solubility, and instability. These limits have been overcame by active 
targeting of resveratrol on chitosan nanoparticles.49 Recently the interest in phenolic compounds in 
general, and flavonoids in particular, has increased for their use in treatment and prevention of cancer, 
cardiovascular disease and other pathological disorders.46 Quercetin (3,3’,4’,5,7-
pentahydroxyflavone) is a natural flavonoid and is a derivative of a flavone (2-phenylchromen-4-
one). It contains five hydroxyl groups, the reason for its biological activities and derivative 
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diversification. Mainly quercetin is found as glycosides in the edible parts of plants, in berries, tea 
leaves, onion, broccoli and other fruits and leafy vegetable, but is mostly extracted from Sophoro 
japonica L. Besides, quercetin is rich in red wine, black tea and other fruit juices. Quercetin is well 
known for possessing potent antioxidant activity with anticancer activities. However, its use is limited 
by its poor bioavailability, hydrophobic nature and low solubility. Thus, biodegradable and 
biocompatible carriers as delivery systems have been studied to enhance the therapeutic effect of 
quercetin. Examples of well-studied delivery systems used for quercetin are based on liposomes, 
PLGA, PLA, chitosan and silica, with good results both in vivo and in vitro studies.47,53  
In literature herbal drugs have become increasingly popular in particular in the treatment of liver 
diseases. Toxic chemicals (such as certain antibiotic, chemotherapeutic agents, paracetamol, carbon 
tetrachloride, thioacetamide etc., excessive alcohol consumption and microbes) have been studied as 
cause of liver cell injury. In these cases, synthetic drugs often damage more the liver. So formulations 
containing herbal drugs are becoming popular. For example, curcumin, from Curcuma longa, was 
studied also for its hepatoprotective activity.54  
As just said, curcumin has interesting anti-inflammatory as well as chemopreventive properties. 
However, its use in oral administration is limited by its low bioavailability because of its lipophilic 
nature and its poor stability in aqueous solutions. In our group, O/W nanoemulsions encapsulating 
curcumin have been proposed to improve curcumin bioavailability in oral delivery systems.55 In 2016, 
the behaviour of curcumin encapsulated in our O/W nanoemulsions, co-delivering curcumin and 
piperine (the alkaloid responsible for the pungency of black pepper and long pepper), has also been 
studied with the aim to improve the biodistribution of curcumin. In this study it was demonstrated an 
enhanced anti-inflammatory action of curcumin delivered in vivo by oral delivery.56 In a more recent 
study, we investigated the interaction of a similar nanocarrier, having just some chemical 
modifications in the polymer shell, with intestinal epithelial cells CaCo-2 in Transwell culture. The 
human CaCo-2 cells were used as a model that reproduces the intestinal barrier for in vitro prediction 
of drug performance. The results demonstrated that our nanocarriers could be used to obtain an 
efficient release of unstable and lipophilic drugs. Furthermore, we demonstrated the beneficial 
properties of curcumin in treatment and prevention of different inflammatory diseases.55 
In this PhD project, we focused our studies on anti-inflammatory and cardioprotection properties of 
natural drugs, such as curcumin and lycopene encapsulated in our chitosan coated O/W 
nanoemulsion. Moreover in this project, about curcumin we also studied its anti-inflammatory and 
anticancer properties on photo-responsive LbL O/W trilayer. About lycopene, it is a natural pigment 
extracted from tomatoes peers. Lycopene is a type of carotenoid,57 and among carotenoids, lycopene 
is the most potent antioxidant because of its high number of conjugated dienes.58 The anti-
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inflammatory and cardioprotective effects of lycopene are reported in literature.57 In an in vivo study 
on rats, it was demonstrated reduced myocardial injury by suppression of oxidative stress.58 
Combining the already cited advantages of nanotechnology formulations (bioavailability and 
prolonged circulation time) and natural lipophilic drugs leads to a new category of food supplements 
to support the oncology patient. Curcumin and lycopene are two of these drugs which can give cancer 
prevention, attack the inflammatory states and perform cardio-protection activities.59,60,61,62  
 
1.5 Ferric oxide nanocubes as contrast agents in MRI. 
In this PhD we also focused on diagnostic applications, in particular in Magnetic Resonance Imaging 
(MRI) of LbL O/W nanoemulsions encapsulating cubic iron oxide nanoparticles. As for the drugs, 
also in this case we engaged in the use of contrast agents that can be considered safe. So here we want 
to give an overview of MRI fields and its typical contrast agents, reported in literature. 
The nanoscale of LbL nanocarriers is the reason of their goodness diagnostic applications. Among 
the different imaging modalities, such as X-ray computed tomography (CT), positron emission 
tomography (PET), single photon emission computed tomography (SPECT), bioluminescence 
imaging (BLI), fluorescence imaging (FLI), and ultrasound imaging, MRI stands out for its safety 
and very high spatial resolution for soft tissue, giving not only anatomic but also important functional 
information. So it is a non-invasive powerful diagnostic technique in medical science, and in 
particular in cancer diagnosis. However, its sensitivity is lower than PET, SPECT, and optical 
imaging methods. On the other hand, image contrast can be improved by the introduction of contrast 
media. MRI contrast agents approved for clinical applications are gadolinium (Gd) or manganese 
(Mn) as paramagnetic molecules, and superparamagnetic iron oxide (SPIO) as nanoparticles. Their 
diagnostic capability can be enhanced when they are combined with advanced and multifunctional 
imaging probes. To this aim, a wide range of nanosystems have been used such as dendrimers, carbon 
nanotubes, fullerenes, viral capsids, liposomes and micelles. Among these nanosystems, LbL 
polyelectrolyte nanocarriers, encapsulating contrast agents, have shown great applications. For in vivo 
applications, their biocompatibility and stability are two important aspects. The biosafety mainly 
depends on the imaging component and capsule materials.63 As said previously, various 
polyelectrolytes are biocompatible and biodegradable polymers. However, some interesting contrast 
agents, such as gadolinium, can be toxic. Nanocarriers improve the circulation time of drugs/contrast 
agents and so their accumulation in the target site, limiting in this way the amount of contrast agent 
and therefore the toxicity. In this contest, PEGylation on LbL capsule surface is a simple method to 
preserve nanocarriers’ cargo from unspecific cellular uptake and leading to a prolonged blood 
circulation time.64,65  
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Magnetic contrast agents can be divided into two categories: paramagnetic and super-paramagnetic 
ones. They are characterized by either longitudinal or transverse proton relaxation time and thus give 
higher image contrast.64 The paramagnetic compounds are composed by metal ions with unpaired 
electrons (including lanthanides like gadolinium, Gd3+ or manganese Mn2+), and mainly reduce the 
longitudinal (T1) relaxation property. When the metal is chelated with ligands, such as diethylene 
triamine pentaacetic acid, DTPA, it is less toxic because the chelating ligand avoid the binding 
between the metal ion and the body. The super-paramagnetic magnetic nanoparticles (such as iron 
oxides) have a strong effect on the transversal (T2) relaxation properties. The super-paramagnetic 
nanoparticles have much higher magnetic moments, are non-toxic and rapidly cleared from the 
organism. So they are preferred to the Gd complexes as contrast agents. Moreover, in comparison 
with paramagnetic agents, which require the close contact between metal center and water molecules, 
super-paramagnetic agents do not necessarily need the direct contact.64 Among the different super-
paramagnetic contrast agents, such as magnetite, maghemite, cobalt ferrite, gadolinium ferrite, 
chromium dioxide, carbonyl iron, nickel, cobalt, neodymium–iron–boron or some other cobalt 
systems, magnetite is the favourite one. It has been well-studied and shows a very low toxicity. In 
fact, super-paramagnetic iron oxide nanoparticles are much safer than other ones, because the human 
body has a big iron pool and the degradation of those nanoparticles lead them in that iron pool to 
participate physiological iron homeostasis.64,65,66 So nanomedicine combined with magnetic iron 
oxide nanoparticles offer a lot of advantages such as easy and precise synthesis procedures, high 
magnetic response, tunable morphologies, enhancing patient safety and combining good magnetic 
properties and very reduced toxicity. Iron oxide nanoparticles can be a safer replacement to iodine or 
gadolinium tracers which are hazardous for patients. The US Food and Drug Administration (FDA) 
and the European Medicines Agency (EMA) have approved the medical use of some iron oxide 
nanoparticle formulations.67 An example of iron oxide nanoparticles application as MRI contrast 
agent is a work by Chertok et al. They studied the in vivo MRI detection of brain tumors in rats using 
iron oxide nanoparticles.  In accordance with other studies, their work show as magnetic nanoparticles 
can be retained at tumor sites applying a locally external magnetic field. Moreover since the strong 
T2 relaxation of the iron magnetic nanoparticles, they confirmed as MRI is non-invasive detection 
tool.68 Another example is a work by Prévotet et al. about super-paramagnetic iron oxide 
nanoparticles loaded in O/W nanoemulsions decorated with specific monoclonal antibody as contrast 
agents for atherosclerosis Magnetic particle imaging (MPI) and MRI. They results showed that their 
nanoemulsions could selectively image atherosclerosis. Moreover these nanoparticles were 
biocompatibility and biodegradability so able to use in in vivo applications.69  
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In 2016, our group published a work in which biocompatible, multifunctional and multicompartment 
nanocarriers consisted of an oil-core/hybrid polymer/silica-shell. To stabilize additionally our 
nanocapsules, the outer silica shell was coated with polyethyleneglycol (PEG). It is known that silica 
is one of the few inorganic materials recognized as ‘safe’ by the US FDA. In this work Nile Red (a 
lipophilic molecule) was encapsulated in those nanocapsules as drug model and CdSe (an inorganic 
nanoparticles), as a contrast agent model, with no variation in the expected size.70  
In 2017, we studied O/W nanoemulsion loaded with cobalt ferrite oxide (Co0.5Fe2.5O4) nanocubes (21 
nm) for photo-acoustic and magnetic resonance dual imaging in cancer therapy. We performed in 
vitro and in vivo studies. The proposed O/W systems showed no significant cytotoxicity and a high 
values of r2/r1, it could be use as T2 weighted image contrast agents. In this work we introduce the 
use of photo-acoustic, also called laser optoacoustic (LO) imaging, which is a new non-invasive and 
non-ionized diagnostic too, with high sensitivity and excellent resolution. In our nanocarriers, even 
if the cobalt, the concentration of the nanocubes was sufficiently low to avoid significant toxicity, but 
able to provide MRI and PA response.71  
Returning to the safer iron oxide nanoparticles and the said advantages brought by our O/W 
nanoemulsions, we studied photo-acoustic in vitro and MRI in vitro and in vivo responses of 
nanocubic iron oxide nanoparticles encapsulated in oil-core-PEG shell nanocarriers. This study had 
been object of this PhD work. In this way, we have surpassed the problem of toxicity connected to 
cobalt. Moreover, as iron oxide nanocubes are smaller than cobalt-ferrite ones, we were able to scale 
our nanoemulsions dimensions encouraging their internalization in the tumor tissue. 
  
1.6 Brief mention on nano-‘theranostic’ delivery systems.  
We have just discussed about the advantages given by engineered nanoparticles in therapeutic and 
diagnostic fields, such as enhanced permeation, specific release and enhanced medical imaging. 
Theranostics is the fusion of the words ‘therapy’ and ‘diagnosis’.30 ‘Theranostic’ nanoparticles 
combines therapeutic compounds and diagnostic agents in a single tool and so they have been 
particular interest in science research for their highly beneficial applications. The preparation of 
theranostic nanoparticles requires a multidisciplinary context of studies and investigation (Figure 
1.12).72 Theranostic nanoparticles give the possibility to develop more specific and individualized 
therapies for various diseases. Furthermore, the co-delivery of therapeutic and imaging functions 
permit to monitor the imaging also during the treatment.73 In cancer therapy, the research has a 
particular interest to implement theranostic nanoparticles with safer and more efficacious diagnostic 
and therapeutic agents.74,75 The use of the nanocarriers in theranostics could bring several advantages. 
The nano-size of the nanocarriers provides various advantages due to EPR effect first of all, for the 
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theranostic applications. So the nanocarriers can be localized in the cancer and inflammatory tissues. 
Moreover, the typical large surface area-volume ratio of the nanocarriers permit a higher loading 
capacity and the nanocarriers can be functionalized with multiple functionalities.77 As known, the 
nanoparticles’ surfaces can be modified to improve their biocompatibility and in the inner of the 
capsules, different drugs or contrast agents can be encapsulated (Figure 1.13). Thus for example, 
using super-paramagnetic iron oxide nanoparticles in a theranostic nanoparticles, we can not only use 
that in MRI for in vivo imaging but also manipulate the capsules by the iron oxide nanoparticles to 
carry drugs in the specific tissues by magnetic fields.72,73  
 
 
Figure 1.12. Schematic representation of the multidisciplinary research field of (nano)theranostics.76 
 
 
 
Figure 1.13.  Example of theranostic nanoparticles with different component to functionalize the surface. In the inner 
core, various compounds can be encapsulated such as nucleic acids, imaging contrast agents, drugs, and fluorescent 
material for different theranostic purposes.72 
 
For what said, theranostic nanocapsules are able to detect diseases and at the same time release the 
therapeutic drugs with a spatio-temporal control. In this context, LbL polyelectrolyte nanocapsules 
are particularly interesting because of the possibility to be engineered with different functionalities, 
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for their low cost, ease of preparation and versatility.1 Theranostic nanoparticles are becoming an 
important growing area of research. With an accurate choice of materials, these nanoparticles could 
provide less invasive tools for diagnostic and therapy, with more accuracy and safer for the patients.30  
 
1.7 Aim of the PhD project 
The following PhD project regards the field of the drug delivery systems. In particular, the aim of this 
project is the study of chemical modifications useful to activate photo-stimuli-responsive oil core 
polymer nanocapsules as theranostic delivery system. Mainly, we will focus the attention on layer by 
layer (LbL) polymer based nanocapsules loaded with natural drugs and safe contrast agents.  
In the tumor treatment context, our main purpose is the use of safe nanocarriers to reduce the side 
effects for the patient, improving the therapy efficacy and the bioavailability of the drugs. So in this 
PhD project we study systems which can enhance the clinical performance and the cancer detection 
exploring chemical modifications in the polymeric compositions and/or in the oil core formulations. 
To this aim we focused the attention on highly versatile nanocapsules built around an oil core and 
made of completely biocompatible natural polymers employable for therapeutic and diagnostic 
purposes. Chemical functionalization of nanoemulsions’ shells is studied to engineer a photo-
responsive nanocarrier with spatio-temporal control in the release of the drug.  
In Chapter 2 a LbL O/W cross-linked photo-responsive nanoemulsion, loaded with a natural drug, 
curcumin, is explained. As just demonstrated in our group, it is possible to functionalize the polymers 
deposited on the oil core, such as glycol chitosan and heparin, with a thiol moiety and an allylic 
moiety respectively, and then create a covalent bond between the polymeric shells via a biocompatible 
photoinitatior free thiol-ene ‘click’ reaction, to improve the nanosystem’s stability.15 Starting from 
this strategy to obtain a stable cross-linked LbL systems, we introduced a photolabile chemical linker, 
based on a modified N-acetyl cysteine-o-nitrobenzyl moiety,45 between the polymeric materials of 
LbL. Functionalized the glycol chitosan with this thiol-photo-responsive moiety and the heparin with 
an allyl one, we were able to perform the cross-linkage and to stabilize our LbL O/W nanoemulsion 
multilayer shell by the photoinitiator free thiol-ene ‘click’ reaction. Interestingly, the photo-
responsive linker gave us the possibility to trigger a controlled destabilization of the nanocarriers to 
release the drug by single or multi-photon UV light (365 nm or 740 nm). After the chemical 
modifications of the nanocarriers and its characterizations in terms of stability and conditions of 
release, we performed biological studies of uptake and cell viability on melanoma cells.  
In Chapter 3 it is reported a recent published article which is part of this PhD project. It regards an 
oral delivery application of our nanoemulsions encapsulating nutraceutical drugs, such as curcumin 
and lycopeneand the study of their cardioprotection and anti-inflammatory effects. These properties 
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have been assessed by in vitro tests performed on cardiomyoblasts (H9C2 cells) in presence of 
doxorubicin.  
In Chapter 4 we report another possibility concerning the modification of the oil core formulation of 
the nanoemulsions, using an inorganic compound, in particular cubic iron oxide nanoparticles as 
contrast agents. We prepared oil-core-PEG shell nanocarriers encapsulating nanocubic iron oxide 
nanoparticles to study how these systems respond to in vitro photoacoustic and in vitro and in vivo 
magnetic resonance imaging.   
Final conclusion and future perspectives are presented and discussed in Chapter 5. Each part of this 
work can be seen distinctly or in a more general point of view. In this case, we can think to engineer 
a photo-responsive LbL O/W nanoemulsion co-loaded with natural drugs and safe contrast agents to 
employ as theranostic nanocapsules. 
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Abstract  
In the cancer therapy, stimuli-responsive drug delivery systems are of particular interest, managing 
to reduce the collateral effects in the healthy tissues and improving the selectivity of the drugs in the 
cancer ones. Here we report the strategy of preparation of a photo-responsive cross-linked trilayer 
deposited onto an oil-in-water (O/W) nanoemulsion via Layer-by-Layer (LbL) technique. Our 
systems is made of completely biocompatible materials such as soybean oil as core, egg lecithin as 
surfactant and polymeric shells of glycol chitosan and heparin. The oil core can be empty or loaded 
with curcumin as nature based drug. The cross-linkage of the trilayer is performed via a photoinitiator 
free thiol-ene ‘click’ reaction. In particular we introduce an o-nitrobenzyl group functionalized with 
a thiol moiety which can perform both the thiol-ene ‘click’ reaction and the reaction of cleavage for 
the controlled release of drug at specific wavelengths. So, we showed the preparation and 
characterization of a photo-responsive natural nanocarrier stable in physiological conditions thanks 
to the thiol-ene cross-linkage. The performance of the system are also studied in biological 
environment on melanoma cells (A375.S2 cell lines). The results promise for possible future 
applications in the treatment of skin tumors or in surgery applications considering the penetration 
limitation of the light stimulus.   
 
2.1 Introduction 
Nanomaterials are born from the fusion between nanotechnology and biomedicine and have various 
advantages compared to traditional therapies (such as targeted delivery, controlled drug release and 
improvement of cell barrier crossing).1,2 Among the diverse nanocarriers for cancer drug delivery 
studied in the last decades, a particular interest is recognized to Layer-by-Layer (LbL) polymeric 
nanocapsules, based mainly on electrostatic interaction between the polymers, for the precision of the 
final particles, their high versatility and the possibility to encapsulate different drugs and release them 
in different manners.2,3,4 From 2014, our team developed biodegradable O/W nanoemulsions (size < 
200 nm),5 specific for hydrophobics drugs, coated with biodegradable polyelectrolytes via LbL 
technique, with high monodispersity and stability over time.6,7 Because of the weakness of the 
electrostatic interaction, in 2016 we developed a photoinitiation free thiol-ene ‘click’ reactions, 
providing a completely non-cytotoxic final product, to improve the stability of our O/W 
nanoemulsion by cross-linkage, e.g. a covalent bond, between the polymeric shells.8,9  
In cancer therapy, for their easy preparation and versatility,10,11 LbL nanocarriers are interesting 
platforms to reduce the toxicity of the drugs and improve the selectivity towards the tumor. In 
particular, the differences between normal and pathological tissues are the start point for the design 
of stimuli-responsive nanocarriers, that can attack cancer cells without damaging healthy ones.12 It is 
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known that there are two types of stimuli for drug’s release: endogenous (e.g., pH, enzymes, redox 
potential, glucose concentration, ions) or exogenous stimuli (temperature, magnetic fields, electrical 
fields, ultrasound and light). The choice of release mechanism is connected to the desired 
application.2,5,13  
Particularly within this project, we focused on light as stimuli source. It is a particularly interesting 
stimulus for its advantages of not to be invasive and to permit a spatio-temporal control in the 
release.14   Moreover, the light is strongly absorbed by tissue and can be focused on microscopic spot, 
determining a controlled opening of the individual capsules. Additionally, light helps to improve the 
therapeutic benefit and minimize the toxicity, because the active drug is delivered and released in the 
proximity of the affected tissues. Finally, radiation of UV, near IR and IR frequency are tissue 
compatible, and so show a quite good biocompatibility in specific conditions.4,13,15 
Light has been strongly studied in literature introducing photo-responsive molecules in the structure 
of different nanocarries. Such as o-nitrobenzyl moieties,16,17 biaryl-substituted tetrazole moiety,18 
perylene-3-ylmethanol,19 azobene,4,13,20,21 stilbene, azosulfonate, diphenyliodonium-2-carboxylate, 
pyrenylmethyl ester, coumarin, cinnamylidene acetate, nitrocinnamate, anthracene, poly(cinnamic 
acid),20 7-methoxy quinolone22 in hydrogels,4,16,17,18,20,23 carbon dots,22 inorganic materials,24 O/W 
mini-emulsions.13,21 For a lot of photochemical reaction near infrared (NIR) light is not sufficient but 
its penetration depth is higher than UV/vis. However, on the other hand, also a single UV/vis photon, 
manages to achieve a lot of reaction widely applied in photo-responsive nanoparticles. The use of 
two-photon absorption is a strategy to combine the deeper penetration of NIR and the UV/vis 
triggered chemical reactions.24,25 So this could be a good strategy but there are very few organic 
chromophores which absorb in NIR region, while the majority responds to UV light.26  
In particular, the o-nitrobenzyl group has been our choice and it has been introduced as a photo-
responsive linker in the multilayer shell of our O/W nanoemulsions. This because the o-nitrobenzyl 
group has a chemical structure which can be functionalized in the desired manner easy,27 it is 
biocompatible,20 and another important characteristic is that its photo-cleavage can be obtained either 
by one-photon absorption of UV light or via two-photon absorption of NIR, improving the depth of 
penetration in tissue application.28 This photo-cleavable group had been used in a lot of photo-
responsive systems such as micelles,28,29 hydrogel,20 dendrons,30 dendrimers,31 functionalized 
mesoporous silica nanospheres,32 and so on. 
In this work, we report an O/W core - LbL trilayer shell, which is exposed twice to the light stimulus. 
Indeed, at the beginning the trilayer is stabilized by a photoinitiator free thiol-ene ‘click’ reaction and 
then it is destabilized by an appropriate wavelength, and both of them involve the o-nitrobenzyl group. 
In this work, we synthetized an o-nithobenzyl group with some modification of a strategy shown in 
34 
 
literature.33 In particular, we introduce a thiol group via a N-acetyl cysteine on the o-nitrobenzyl 
group and then by a coupling reaction we prepare a glycol chitosan functionalized with this photo-
linker. The polymers of the shell are deposited alternately to form a trilayer multishell and are 
functionalized with the thiolated o-nitrobenzyl group and an allyl group respectively. The nanocarrier 
is then stabilized by the photoinitiator free thiol-ene ‘click’ reactions to improve its stability in 
physiological conditions. On the other hand, using UV light at 365 nm we induce the photo-cleavage 
of the o-nitrobenzyl moiety and the controlled release of the drugs. Such systems is explored in 
melanoma’s cellular vitality tests. The possibility to use two-photons mechanism instead of UV 
thanks to the o-nitrobenzyl group, makes our final photo-responsive system a potentially powerful 
instrument for the treatment of skin tumors or in the treatment of cancer residual cells during surgery.  
 
2.2 Material and Methods 
Soybean oil (density at 20 °C of 0.922 g mL-1) and surfactant Lipoid E80 (egg lecithin powder 80-
85% enriched with phosphatidylcholine and 7–9.5% content in phosphatidylethanolamine) were 
purchased from Lipoid GmbH and used without further purification. For preparation of all 
nanoemulsions and solutions, Millipore Milli-Q water was used. Curcumin (from Curcuma longa 
Turmeric, powder), heparin sodium salt (from porcine intestinal mucosa), allylamine, 1-
hydroxybenzotriazole hydrate (HOBt), 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide 
hydrochloride (EDC), 5,5’-dithiobis(2-nitrobenzoicacid) (DTNB, also known as Ellman’s reagent), 
Fluorescein5(6)-isothiocyanate (FITC), Rhodamine B isothiocyanate (RhodB), sodium chloride, N-
acetyl-L-cysteine (NAC), Tris(2-carboxyethyl)phosphine hydrochloride (TCEP), Ethyl 4-
bromobutyrate, 4-[4-(1-Hydroxyethyl)-2-methoxy-5-nitrophenoxy]butyric acid (Hydroxyethyl 
photolinker), sodium azide, sodium sulfate, anhydrous pyridine, magnesium sulfate, N,N′-
Dicyclohexylcarbodiimide (DCC), N,N′-Diisopropylcarbodiimide (DIC), 4-
(Dimethylamino)pyridine (DMAP), anhydrous pyridine, N,N-Diisopropylethylamine (DiPEA), 
triphenylphosphine, sodium bicarbonate, celite, acetic acid, methanol, sodium hydroxide, 
hydrochloric acid, deuterium oxide (D2O), Deuterochloroform (CDCl3), trifluoroacetic acid (TFA), 
anhydrous and not dimethyl sulfoxide (DMSO), anhydrous and not dichloromethane (DCM), acetone, 
diethyl ether, anhydrous and not tetrahydrofuran (THF), hexanes, ethyl acetate were purchased from 
Sigma-Aldrich. Glycol chitosan (GC) was purchased from Wako Chemicals. Carboxyl latex beads 
(4% w/v, 0.1 μm) was purchased from Invitrogen. Dialysis membranes were purchased from 
Spectrum Laboratories Inc. PBS tablets (1x) was purchased from MP Biomedicals. 
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Oil in water nano-emulsion. 
As previously described,6 a 20 wt % oil in water pre-emulsion was prepared. A 5.8 g of Lipoid E 80 
was dissolved in 24 mL of soy-bean oil at 60 °C and then added dropwise to the aqueous phase (Milli-
Q water) and mixed using the immersion sonicator (Ultrasonic Processor VCX500 Sonic and 
Materials). The pre-emulsion so obtained, was then homogenized at 2000 bar by a high-pressure 
homogenizer (110P series microfluidizer) to obtain the final nanoemulsion. The nanoemulsion could 
be loaded with curcumin by dissolving the drug in the oil phase in the pre-emulsion step, after lecithin 
(100 mg of curcumin in the oil phase for 15 minutes at 60°C) or with FITC (0.75mg/mL) dissolved 
in 4 mL of ethanol added always in the pre-emulsion step and drying the ethanol from the mixture 
with mild heating. 
 
Modification of glycol chitosan with rhodamine B isothiocyanate. 
Glycol chitosan (100mg, 0.5 mmol) was dissolved in 10 mL of a 0.1M acetic acid solution. After 
complete dissolution, a solution of RhodB (5.0 mg in 500 μL of DMSO) was added dropwise. The 
reaction proceeded overnight at room temperature, protected by light. Sample was then dialyzed 
(dialysis tubing of 3.5 kDa) against water more times for a couple of days to remove no reacted dye. 
Finally, the purified product was freeze-dried for 24 h. The degree of functionalization was 
determined with 1H NMR spectra and it resulted less than 1%.   
 
Modification of heparin with fluorescein isothiocyanate. 
As mentioned in a literature procedure,34 FITC (6.4 mg) was conjugated with heparin (20 mg), both 
in the case of pure or allylated heparinin sodium bicarbonate buffer (pH 8.5) for 4-6 h at 25°C. 
Heparin-FITC was precipitated by ethanol. The original protocol was modified adding same 
centrifugation steps to wash the polymer faster. Three centrifuges (10000 rpm, 10 min, 4°C) were 
performed, replacing the surfactant with ethanol each time. Then, the polymer was dissolved in water 
and dialyzed (dialysis tubing of 3.5 kDa) against water for 3 days. The degree of functionalization 
was determined with 1H NMR spectra and it resulted less than 1%.   
 
Modification of glycol chitosan with N-acetylcysteine. 
In a flask, 0.5 mmol of glycol chitosan (Mv = 205.21 kDa), in some cases just modified with a dye, 
were dissolved in 10 ml of Milli-Q water acidified at pH 5-6. In a different beaker, 1 mmol of N-
acetylcysteine was dissolved in DMSO with the minimum volume required. Then, we added 1 mmol 
of EDC and 1 mmol of HOBt to NAC solution and we left under stirring for 15 min. The pH was at 
5-6. Then, to the solution of GC, we added dropwise the solution of the activated NAC, checking that 
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pH is between 5 and 6 and, if necessary, fixing it, recheck it in the first hour of reaction. We let it 
react overnight at room temperature. After that, pH reaction solution was adjusted at 4. A 0.5 M TCEP 
(1.5 mmol) water solution was added to the reaction flask and pH was maintained at a value of 4. The 
reactions proceeded at room temperature for 1 h. The product was then purified by dialysis (dialysis 
tubing of 3.5 kDa) four times against water acidified with HCl at pH 4. Each dialysis lasted 2 h or 
more. The whole purification process ended in two days maximum. Finally, the purified product was 
freeze-dried for 24 h (Freeze Dryer CHRIST Alpha 1–4 LSC).  
The Ellman’s test,35,36,37 a colorimetric assay, was used to determine the free thiols in the polymer. 
To estimate the molar extinction coefficient (ε) of TNB2- it was performed a calibration curve with 
standard solutions of NAC. For the functionalized glycol chitosan, 0.4 mg of polymer was dissolved 
in 0.5 mL of acetic acid 0.1M and mixed with a solution of 0.2 mg/mL DTNB in a phosphate buffer 
at pH 8.03. The sample was stored in the dark at 25 °C under stirring for 2 h. Then, the absorbance 
of TNB2- was registered at 412 nm using a Varian Cary Scan 100 Spectrophotometer.8  
 
Modification of heparin with allylamine. 
Heparin was modified with allylamine as showed in a previous study.8 In the general procedure, the 
reaction was in water at pH 6.8, for 6 h and at room temperature. The molar ratio between the reagents 
was heparin/allylamine/HOBt/EDC = 1/10/4/4. Sample was then dialyzed (dialysis tubing of 3.5 kDa) 
against 1% w/v NaCl, 0.75% w/v NaCl, 0.5% w/v NaCl, 0.25% w/v NaCl and four times against 
water. Each dialysis lasted 2 h or more. The whole purification process ended in two days maximum. 
Finally, the purified product was freeze-dried for 24 h. The degree of functionalization (80%) was 
determined with 1H NMR spectra. 
 
Synthesis and characterization of the photocleavable linker: the thiol modified o-nitrobenzyl group  
The synthesis of azide-funzionalized photodegradable precursor (PLazide) was reported in 
literature.33 Briefly, after azidification and deprotection of ethyl-4-bromobutyrate to obtain 4-
azidobutanoic acid, it was converted in its anhydride. Then, the anhydride was reacted with 4-[4-(1-
Hydroxyethyl)-2-methoxy-5-nitrophenoxy]butanoic acid (Hydroxyethyl photolinker). The final 
product (PLazide) was checked by LC/MS and 1H NMR. LC/MS (ESI): C17H21N4O8
- [M-1H]-, 
calculated 409, found 409. 1H NMR (600MHz, CDCl3,δ: 7.58 (s, 1H), 6.99 (s, 1H), 6.48 (q, 1H), 4.13 
(t, 2H), 3.96 (s, 3H), 3.38 (t, 2H), 2.6 (t, 2H), 2.48 (t, 2H), 2.19 (m, 2H), 1.92 (m, 2H), 1.62 (d, 3H). 
The pure product (PL azide) was reducted to PL amine. The started PLazide (0.1 mmol) and 
triphenylphosphine (1.5 x) were dissolved in tetrahydrofuran (THF, 2 mL), and then water was added 
to the mixture (v/v 2:1, THF:H2O). The reaction was stirred for 3 h at room temperature. To obtain 
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the complete hydrolysis of PL iminophosphorane intermediate, an excess of a 1 M HCl solution (120 
mL) was added to the mixture.38 The reaction was stirred overnight at room temperature. The reaction 
run was checked by LC/MS (ESI): C17H23N2O8
+ [M-1H]+, calculated 385, found 385. At the end, the 
crude mixture was concentrated via rotary evaporation. The general procedure for the coupling of N-
acetyl-L-cysteine and the PLamine was kept by a previous work39, with same modifications in molar 
ratio between reagents and starting from an activated amine, without purification but pushing the 
reaction until completion.The PLamine intermediate (0.1 mmol) was dissolved with dry THF (5 mL) 
and activated with N,N-diisoproprylethylamine (DiPEA, 3 x), stirring under argon for 30 min. On the 
other hand, NAC (1.2 x) was co-evaporated twice with THF (2 mL) under reduced pressure and then 
was dissolved in dry THF (2 mL). To this solution HOBt (1.2 x) previously dissolved in dry THF (1 
mL) was added, and this mixture was stirred for 10 min at 0°C. Then, DIC (1.2 x) was added and the 
mixture was stirred for other 30 min at 0°C. The mixture of PLamine and DiPEA was added to the 
NAC mixture. The reaction was stirred under argon overnight and the temperature was increased to 
room temperature within 30 min. The reaction run was checked by LC/MS (ESI): C22H31N3O10S
- [M-
1H]-, calculated 528, found 528. At the end, the final PLNAC (shown in Figure 2.1 that shown the 
general chemical strategy) was concentrated via rotary evaporation. 1H-1H 2D-TOCSY NMR 
characterization in CDCl3 was performed (see Results and Discussion). 
 
 
Figure 2.1. Chemical strategy to obtain the photodegradable o-nitrobenzyl ether containing a thiol moiety (PLNAC) 
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Modification of glycol chitosan with photoresponsive linker (PLNAC). 
This protocol is as the modification of glycol chitosan with NAC. In fact, it performs the same 
coupling reaction. So in a flask, 0.05 mmol of glycol chitosan (Mw = 205.21 kDa), in case just 
modified with a dye, were dissolved in 1 mL of Milli-Q water acidified at pH 5-6. In a different 
beaker, 0.1 mmol of phoresponsive linker was dissolved in DMSO with the minimum volume 
required. Then, we added 0.1 mmol of EDC and 0.1 mmol of HOBt to the photolinker solution and 
we left under stirring for 15 min. The pH was at 5-6. Then, to the solution of GC, we added drop by 
drop the solution of the activated PLNAC checking that pH is between 5 and 6 and, if necessary, fix 
it, monitoring it in the first hour of reaction. Then, we let it react overnight at room temperature. After 
that, pH reaction solution was adjusted at 4. A 70mM TCEP (0.15 mmol) water solution was added 
to the reaction flask and pH was maintained at a value of 4. The reactions proceeded at room 
temperature for 1 h. The product was then purified by dialysis (dialysis tubing of 3.5 kDa) four times 
against water acidified with HCl at pH 4. Each dialysis lasted 2 h or more. The whole purification 
process ended in two days maximum. Finally, the purified product was freeze-dried for 24 h. The 
successful functionalization was determined with 1H-1H 2D-TOCSY NMR characterization. Free 
thiols were determined using the Ellman’s test colorimetric assay. To estimate the molar extinction 
coefficient (ε) of TNB2-, it was performed a calibration curve with standard solutions of PLNAC. For 
the functionalized glycol chitosan, 0.4 mg was dissolved in 0.5 mL of acetic acid 0.1 M/acetone with 
a volume ratio of 2.125 and mixed with a solution of 0.2 mg/mL DTNB in a phosphate buffer at pH 
8.03. The sample was stored in the dark at 25 °C under stirring for 2 h. Then absorbance of TNB2- 
was registered at 405 nm using a Varian Cary Scan 100 Spectrophotometer.8  
 
Ellman’s test for molar extinction coefficient (ɛ) determination.  
The calibration curves for Ellman’s test were obtained according to a previous protocol,8 with some 
modification for PLNAC in terms of solubility. Briefly, for glycol chitosan with NAC and with 
PLNAC, the calibration curves for Ellman’s tests were obtained using NAC and PLNAC as standard, 
respectively. NAC was dissolved in acetic acid 0.1 M at different concentrations, while PLNAC in 
acetic acid and acetone (volume ratio: 2.125) to optimize its dissolution. Then, to 0.5 mL of each 
standard, 3.5 mL of a solution of 0.2 mg/mL DTNB in 0.5 M buffer phosphate at pH 8.03 were added. 
The final pH is 7-8, a value necessary for the essay. The baseline was registered at t = 0 to subtract 
the absorbance due to DTNB at 412 nm for NAC and at 405 nm for PLNAC. In fact, in PLNAC case, 
the DTNB solution for the baseline measurement was obtained using the appropriate acetic 
acid/acetone solution in accordance with the same PLNAC solution standards’ conditions. Then, 
standards were stored in the dark at 25 °C under stirring for 2 h. Finally, for each standard the 
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absorbance and the TNB2- values at 412 nm for NAC and at 405 nm for PLNAC were measured. The 
absorbance values were fitted to obtain the calibration curves (each measurement was in triplicate).  
 
Solution nuclear magnetic resonance spectroscopy. 
For 1D 1H NMR experiments, we used an Agilent 600 MHz spectrometer equipped with a DD2 
console and an OneNMR HX probe. GC based samples were prepared at 10 mg/mL in deuterium 
oxide, containing 1% (v/v) of TFA. Heparin based samples were prepared at 10 mg/mL in deuterium 
oxide. NMR spectra were recorded with a total of 64 transients and a PRESAT sequence was used to 
saturate the water residual peak. Spectra analysis was performed using VNMRJ 4.0 software. For 
PLNAC and GC-PLNAC characterizations we performed a 1H-1H 2D-TOCSY (TOtal Correlated 
SpectroscopY) experiments. 
 
LbL deposition of polymers on polystyrene carboxylated nanoparticles.  
We also performed LbL technique around carboxyl latex beads (PS NPs, 0.5% w/v) as in a previous 
study.8 Briefly, monolayer was obtained adding a water suspension (pH 4) of PS NPs (0.5% w/v), 
under vigorous stirring for 15 min, to a solution of GC (0.04% w/v) in water at pH 4. The volume 
ratio between water suspension of PS NPs (0.5% w/v) and solution of GC (0.04% w/v) is 1:2. Then, 
a water solution of heparin (0.128% w/v) at pH 4 was added to an equal volume of monolayer coated 
nanoparticles suspension (0.16% w/v PS NPs; 0.0256% w/v GC) under vigorous stirring for 15 min. 
At the end, a trilayer was performed by addiction to a water solution of GC (0.064% w/v) at pH 4, of 
an equal volume of bilayer-coated nanoparticles suspension (0.08% w/v PSNPs; 0.0128% w/v GC; 
0.064% w/v Hep) under vigorous stirring for 15 min. The same procedure was followed with 
functionalized polymers, such as GC-NAC, GC-PLNAC and Hep-all. 
 
LbL deposition of polymers on oil in water nanoemulsion.  
A water solution of nanoemulsion (5 wt%) was added to a solution of GC (0.015% w/v) in water at 
pH 4 under vigorous stirring for 15 min. The volume ratio between the solutions was respectively 
1:4. Then, a water solution of heparin (0.0276% w/v) was added to an equal volume of monolayer 
coated nanoemulsion suspension (1 wt% oil, 0.012% w/v GC) under vigorous stirring for 15 min. To 
obtain the final trilayer, the bilayer-coated nanoemulsion suspension (0.5 wt% oil, 0.006% w/v GC, 
0.0138% w/v Hep) was added to an equal volume of a water solution of GC (0.0276% w/v) at pH 4 
under vigorous stirring for 15 min. The same procedure was followed with functionalized polymers, 
such as GC-NAC, GC-PLNAC and Hep-all. 
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Particle size and Z-potential measurements. 
We characterized the suspensions using a laser dynamic light scattering (DLS) instrument (λ = 632.8 
nm), detecting angle of 173°. All the samples were diluted to a droplet concentration of 0.025 wt% 
by using Milli-Q water acidified at pH 4 for monolayer and trilayer supensions, and Milli-Q water 
for emulsions and bilayer suspensions. The calculations of the particle size distribution was 
performed using a default refractive index ratio (1.59) and 5 runs for each measurement (1 run lasting 
100 s). A particle electrophoresis instrument (Zetasizer zs nano series ZEN 3600, Malvern 
Instruments Ltd., Malvern, U.K.) was used for the Z-potential determinations. Samples were diluted 
as for the particle size analysis. The Z-potential analysis was carried out by setting 50 runs for each 
measurement.  
 
Photoinitiator free thiol-ene ‘click’ reaction and photocleavage of the multilayer conditions. 
The suspensions of PS NPs or O/W nano-emulsions coated with polymer multilayer were irradiated 
with UV light (λ=254 nm) for 1.5 h to perform the photoinitiator free thiol-ene ‘click’ reaction. As 
light source a UV Hand Lamp Spectroline® E-Series UV lamp (output 6 W, wavelength 254 and 365 
nm) was used. The light source was at 3 cm distance. A water bath was used to avoid overheating of 
the solution. Photoreaction was conducted without a photoinitiator.8 For the photo-cleavage we used 
a High Intensity Lamp Blak-Ray®UV (Ultraviolet Lamp with Spot Bulb, output 100 W, wavelength 
365 nm) and an ice bath was used to avoid overheating of the solution.  
 
Modified Ellman’s test. 
To determine the reduction of free thiols after irradiation to perform the thiol-ene ‘click’ reaction 
(corresponding to the degree of cross-linkage), in accordance to a previous method,8 we adopted it 
with some modifications in employed solvents and volume of sample. 4 mL of PS NPs coated with a 
bilayer were concentrated by ultracentrifuge (13,000 rpm, 20 min, 4◦C), dissolved in 1.1mL of 0.1M 
acetic acid and sonicated (10 min, 40 MHz, 50% of power, 4◦C). Half volume was stored at room 
temperature for 1.5 h in presence of natural light and atmospheric oxygen, while half volume was 
irradiated. Then, 0.34 mL of each sample were added to 0.16 mL of acetone and 3.5 mL of a solution 
containing the Ellman’s reagent. After 2 h, each sample was centrifuged (13000 rpm, 15 min) and 
supernatant was collected for UV measurement. 
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Stability tests on cross-linked O/W trilayer. 
In accordance with previous results,8 we analysed by DLS particle size variations, two systems 
prepared by LbL depositions of functionalized and non-functionalized polymers on PS NPs as 
template, before thiol-ene ‘click’ reaction, after it and then in PBS 10 mM pH 7.4. 
Moreover, such systems were monitored over time to evaluate their stability in PBS 10mM pH 7.4. 
The systems’ stability over time was indirectly determined by DLS particle size variations.  
 
Cryo-TEM Characterization of LbL cross-linked O/W trilayer based on GCPLNAC.  
By cryo-TEM we observed the morphology of the LbL cross-linked photo-responsive O/W trilayer. 
For the preparation of the frozen-hydated sample the plunge freezing method was performed. Briefly 
a drop of 3 μL of the trilayer were put on a previously glow-discharged 200 mesh holey carbon grids 
(Ted Pella, USA) after the grid was inserted in the chamber of a FEI Vitrobot Mark IV (FEI company, 
the Netherlands) at 4°C and 90% of humidity. The droplet of sample was blotted with filter paper for 
1 s, (blot force 1, drain time 0,5 s) and then the grid was plunged into the liquid propane. The grid 
was then stored in liquid nitrogen in a grid box until it was finally transferred to a cryo-specimen 626 
holder (Gatan, Inc., USA) and loaded into the cryo-transmission electron microscope for imaging. To 
obtain the image of the nanoparticles we used a Tecnai G2 20, a cryo-tomo transmission electron 
microscope (FEI company, the Netherland) equipped with LaB6 emitter (acceleration voltage of 200 
kV) and recorded at with a 2 k × 2 k CCD-Eagle 2HS camera. The Frozen-hydrated sample is 
radiation-sensitive material so to avoid damaging, the observation was carried out in Low Dose Mode. 
 
Confocal analysis of oil core - cross-linked LbL trilayer shell based on GCPLNAC. 
The cross-linked trilayer built onto the O/W nanoemulsion containing the photo-linker (25μL in 1mL 
PBS 10mM pH 7.4) and the last layer labelled with RhodB was put (50μL) on a coverglass for 10 
min to allow it to adhere to the surface. After that, the solution droplet is removed from the coverglass 
which is covered with a microscope slide, in a central region where we had loaded 10 μL of PBS 
10mM pH 7.4. Images of the sample were captured with a Leica TCS SP5 Laser Confocal Scanning 
microscope (Leica-Microsystems, Mannheim, Germany) with a Plan Apo 100x/1.4 oil immersion 
objective using a 543nm HeNe excitation laser and detecting 560-610nm emission. Images were 
acquired with a field of view 77.5 x 77.5 μm for a pixel size of 76 x 76 nm. Images were visualized 
by LAS-AF software (Leica-Microsystems, Mannheim, Germany).  
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Tests of photocleavage on cross-linked trilayer 
Before starting the photocleavage tests of our cross-linked photo-responsive trilayers, we checked if 
the thiol-ene ‘click’ conditions (254 nm for 1.5 h) could damage the photodegradable unit of the 
linker (PL azide) and also we checked its rupture in the photocleavage conditions (365 nm), as just 
demonstrated in a previous work.33 We compared 1H NMR spectra in CDCl3 of untreated PLazide, a 
PLazide first irradiated at ‘click’ reaction conditions and then at 365 nm for 30 min. 
The destabilization of the cross-linked trilayer containing the photolinker and built on O/W 
nanoemulsion was evaluated starting from the trilayer 0.25 wt% oil, 0.003% w/v GCPLNAC, 
0.0069% w/v Hep-all, 0.0138% w/v GCPLNAC, dissolved in PBS 10mM pH 7.4, as ‘simil’ 
physiological medium. In particular, 25 μL of that system were put in 1 mL PBS and then this solution 
was irradiated with High Intensity Lamp Blak-Ray®UV as explained above. The times of exposition 
were 2 h in steps of 30 min and 10 min of rest between the different steps. We used an ice bath to 
avoid overheating and refilled it after each step of rest. The destabilization was monitored by DLS 
particle size variations of the same sample in analysis. To confirm the results the same tests were 
performed on a cross-linked trilayer with a linker no light sensitive and based on O/W nanoemulsion. 
So the system was the trilayer 0.25 wt% oil, 0.003% w/v GCNAC, 0.0069% w/v Hep-all, 0.0138% 
w/v GCNAC.  
 
FRET analysis for photocleavage detection.  
Another approach to detect photocleavage was based on using fluorescence lifetime analysis on cross-
linked trilayers containing the photolinker and built on O/W NE as mentioned above but with Hepall-
FITC and GCPLNAC-RhodB as second and third polymers. Specifically, it was exploited the FRET 
(Fluorescence Resonance Energy Transfer) occurrence between the two polymer-labelling 
fluorophores, where FITC is the donor and RhodB is the acceptor, which is known to produce 
variations of donor lifetime on the basis of the distance between them.40 A comparison of lifetimes 
and FRET efficiencies was performed on the same cross-linked trilayer in PBS solutions in two 
different conditions: irradiated with 365 nm wavelength as explained above for 1.5 h (in steps of 30 
min, 10 min of rest and ice bath for temperature control) and non-irradiated. Samples loading on 
coverglass was the same described in “Confocal analysis” section. For further control, the same FRET 
analysis in the same conditions was performed on cross-linked trilayer with a linker non light 
sensitive, so with GCNAC as first layer, and Hepall-FITC and GCNAC-RhodB as second and third 
polymers. FITC reference lifetime was measured on a GC-HepallFITC polymers deposition on 
coverglass.  
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A laser scanning confocal microscope TCS SP5 SMD (Leica Microsystems, Germany) equipped with 
a Chameleon Ultra II 80MHz pulsed NIR laser (Coherent Inc., US) that was the laser source used for 
performing FLIM (Fluorescence Lifetime Imaging) experiments, was used. An HCX IRAPO L 
25x/0.95 water immersion objective was used for all the experiments exciting FITC donor at 740 nm 
and detecting emission at 500-530 nm whereas RhodB acceptor was excited at 840 nm and its 
emission was detected at 560-610 nm. LAS-AF software was used for exporting pre-histogrammed 
FLIM data that were then elaborated by the FLIM fit software 5.1.1,40 for calculating lifetime values. 
To evaluate the lifetime (τ) of the FITC donor we adopted a method of LbL polymer layers deposition 
on coverglass, reported in literature41 but with some modifications, in particular in the choice of the 
solvents, in accordance with our purpose, so we prepared a bilayer of GC and Hepall-FITC. Briefly, 
we used a coverglass (14 mm) as substrates to build the bilayer films. We diluted GC 1%w/v and 
Hepall-FITC 1%w/v to 0.1%w/v in the respective solvents (acid water pH 4 for GC and milliq water 
for Hep). LbL deposition started with GC 0.1%w/v (200 μL for 20 min of deposition). Then, we 
removed the polymer solution from the coverglass and continued with a washing step (200 μL of acid 
water pH 4 for 10 min). Then, also this solvent was removed and we started with the second polymer 
film (200 μL of Hepall-FITC 0.1%w/v for 20 min), and continued as for the first layer but using for 
the washing step, Milli Qwater. Before putting the coverglass on the microscope slide, we repeated 
another washing with abundant water to a complete removal of polymer residues and to obtain a good 
deposition and imaging of the LbL thin films.  
 
Cell viability. 
The cytotoxicity effects of nutraceuticals-loaded nanoemulsions was studied on human skin 
melanoma cell line A375.S2 (ATCC® CRL-1872™), obtained from American Type Culture 
Collection (Manassas, VA, USA),  looking at their mitochondrial dehydrogenase activity by means 
of a modified MTT [3-(4,5-dimethyldiazol-2-yl)-2,5- diphenyltetrazoliumbromide] method 
according to the manufacturer’s instructions (Dojindo Molecular Technologies Inc., Rockville, MD).                                                                                                                                                           
A375.S2 cells were grown in Dulbecco modified Eagle’s medium (DMEM) with 10% (V/V) heat 
inactivated FBS, penicillin G (100 U/mL), and streptomycin (100 mg/mL) in 96-well plates at a 
density of 10000 cells per well at 37°C in a humidified 5% CO2 atmosphere. After 24 h of appropriate 
growth we tested the following solutions in full medium and added them to the cells after washing 
with PBS: Photo-responsive cross-linked trylayer on nanoemulsions (all loaded with curcumin ranged 
from 0,05 up to 5 µg/mL) were pre-incubated for 2 or 4 or 6 h with melanoma cells; after, cells were 
washed (or not washed) slowly with PBS, irradiated with UV for 3 min under sterile conditions (under 
biological cappa) and allowed to grow at standard conditions for 24 or 72 h. We decided to irradiate 
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cells only for 3 min with UV because of the biological safety of this irradiation time (data not shown); 
in fact irradiating cells (with or without incubated curcumin ) with UV for 3 min cell viability did not 
change and did not change also the biological activity of curcumin so on the basis of these data we 
are sure that the biological effects observed in this study were due to the effects of UV on the 
nanocarriers structure or interactions with intracellular microenvironment making curcumin 
potentially more bioavailable in the cell cytoplasm. Moreover, at the end of the incubation period, the 
cells were washed three times with PBS at pH 7.4 and incubated with 100 μL of a MTT solution (0.5 
mg/mL in cell culture medium) for 4 h at 37 °C. The absorbance readings were acquired at a 
wavelength of 450 nm with the Tecan Infinite M200 plate-reader using I-control software. The 
relative cell viability (%) was calculated by the formula [A]test/[A]control×100, where “[A]test” is the 
absorbance of the test sample, and “[A]control” is the absorbance of the control cells incubated solely 
within culture medium. After evaluating cell cytotoxicity, the total protein content was measured by 
using the Micro BCA protein assay kit (Pierce). Briefly, the cells were washed with ice-cold PBS, 
and incubated for 15 min in 150 μL cell lysis buffer (0.5% v/v Triton X-100 in PBS), to which 150 
μL of Micro BCA protein assay kit reagent (prepared following the instructions of the manufacturer) 
were added. The absorbance at 562 nm was finally measured on a plate reader. The cytotoxicity 
measurements were then normalized by the amount of total protein content in each well. 
 
Cellular uptake quantification.   
A375.S2 cells were grown in Dulbecco modified Eagle’s medium (DMEM) with 10% (V/V) heat 
inactivated FBS, penicillin G (100 U/mL), and streptomycin (100 mg/mL) at 37 °C in a humidified 
5% CO2 atmosphere. For uptake experiments, 5x10
3 cells/well were seeded in 24-well plate and 
allowed to grow for 24 h. The medium was then replaced with 0.1 mL of a solution based on 
fluorescent photo-responsive cross-linked or non-functionalized trylayer nanoemulsions dissolved in 
culture medium and allowed to incubate for a time comprised between 0.5 and 24 h. Cells were then 
washed twice with PBS (pH 7.4) and after specified time intervals, the experiments were terminated 
by removing the supernatant, washing the cells three times with 10 mM PBS and lysing the cells with 
0.1 mL of 0.5% Triton X-100 in 0.2 N NaOH. The membrane-bound and internalized fluorescent 
nanoemulsions were quantified by analyzing the fluorescence of the cell lysate (λexc = 485 nm, λem = 
535 nm), employing a calibration with 0,001-5% oil of fluorescent nanoemulsions dispersed in a cell 
lysate solution (106 untreated cells dissolved in 1 mL of the Triton X-100/0.2 N NaOH solution). 
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2.3 Results and discussions 
 
The first part of the results and discussion regard the chemical modification and characterization of 
the polymers used then it follows a part regarding the stability of the multilayer shell cross-linkage 
and finally a part regarding the assessment of photo-responsive activity of the nanocarrier. 
 
1H-1H 2D-TOCSY NMR characterization of PLNAC and GCPLNAC. 
PLNAC was prepared according to the procedure reported in the ‘Materials and Methods’ section. 
PLNAC was different from PLN3 for the presence of NAC exclusively. In fact, from 
1H-1H 2D-
TOCSY spectra (PLNAC in CDCl3, Figure 2.2) we observed that the group of peaks at 4.11 ppm, 
2.53 ppm, 2.15 ppm can be assigned to -OCH2CH2CH2COOH group and the chemical shifts are not 
different from those attributed to the same group in PLN3. Instead, the group of peaks at 3.65 ppm, 
1.50 ppm and 1.42 ppm can be assigned to –CH2CH2CH2- group linked to the amidic bond. In fact, 
in this case there is a shift of the signal because of the substitution of the azide with a different bond, 
the amidic bond which links the –CH2CH2CH2- group to the NAC. Finally, the group of peaks at 3.75 
ppm and 1.84 ppm can be assigned to the –CH-CH2- in the NAC. 
After a coupling reaction between glycol chitosan and PLNAC, the GC-PLNAC polymer was 
characterized by 1H-1H 2D-TOCSY NMR analysis (Figure 2.3). In this case, as described above, the 
polymer was dissolved in deuterium oxide, containing 1% (v/v) of TFA, so it is obviously to observe 
different chemical shifts for the groups of PLNAC just analysed. However, PLNAC is clearly 
recognizable by the peaks at 3.15 ppm, 2.30 ppm, 1.72 ppm (–CH2CH2CH2- group) and the peaks at 
4.11 ppm, 2.49 ppm, 2.06 ppm (-OCH2CH2CH2COOH group). The group of peaks between 3.4-3.9 
ppm can be attributed to the proton in position 2, 3, 4, 5 and 6 of chitosan glucosamine units. Other 
signals are covered by polymer’s ones. 
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Figure 2.2. 1H-1H 2D-TOCSY spectra of PLNAC (on left) in CDCl3. 
 
 
 
 
Figure 2.3. 1H-1H 2D-TOCSY spectra of GCPLNAC (on left GC structure) in D2O/TFA 1% (v/v). 
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Ellman’s test calibration curves and free thiols in glycol chitosan with NAC and PLNAC. 
As said in Materials and Methods, we measured the absorbance and the TNB2- values at 412 nm for 
NAC and 405 nm for PLNAC. Then, these values were fitted to obtain the calibration curves (each 
measurement was in triplicate, Figures 2.4 and 2.5).  For NAC the ɛ value of TNB2- at 412 nm was 
1.3664∙104 M-1 cm-1. For PLNAC the ɛ value of TNB2- at 405 nm was 1.9646∙104 M-1 cm-1. Starting 
from these values of ɛ, we calculated the degree of free thiol in GCPLNAC and GCNAC as explained 
in Materials and Method, and in both cases the polymers showed ~ 6% of free thiols. 
 
 
Figure 2.4. Calibration curve to determinate molar extinction coefficient for Ellman’s test of GCPLNAC. 
 
 
 
 
Figure 2.5. Calibration curve to determinate molar extinction coefficient for Ellman’s test of GCNAC. 
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Ellman’s test to demonstrate the cross-linkage on a bilayer on PS NPs with functionalized 
polymers. 
In a previous work by our team,8 we had already demonstrated that with NAC and allyl modified 
polymers, a covalent cross linkage among successive layers could be performed by a thiol-ene 
photoinitiatior free reaction at room temperature in the presence of oxygen. In that study, we started 
from a bilayer of N-acetylcystein glycol chitosan and allylated heparin on PS NPs deposited via LbL. 
Then, a modified Ellman’s test was performed before and after irradiation determining the relative 
reduction of free thiol groups corresponding to the amount of thio-ether bonds formed. Thanks to 
their rigidity and therefore their ability to be separated by centrifuge, PS NPs were chosen as template 
instead of O/W nanoemulsion for that characterization study.  
In this study, we had repeated this test with the same purpose to demonstrate the cross-linkage 
between the shells through the reduction of the free thiol groups. However, in this case the system is 
different because for the bilayer preparation on PS NPs we have used the synthetized photo-linker 
conjugated on glycol chitosan. In particular, the test was performed both on irradiated (90 min at 254 
nm), i.e. crosslinked, and non-irradiated, i.e. non-crosslinked bilayer systems. The experimental 
conditions are reported in Materials and Methods. By TNB2- UV analysis, we observe the expected 
reduction of free thiol (red lines in the Figure 2.6) demonstrating, also in this study, cross-linkage in 
absence of photoinitiator. 
 
 
 
Figure 2.6. Schematic representation of the modified Ellman’s test on crosslinked (red) and non-crosslinked PS NPs 
bilayer. The relative reduction of free thiols indicates the formation of the thioether. The tests were repeated three times.  
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Cross-linkage stability tests. 
In accordance with previous results,8 we prepared via LbL two trilayer systems with functionalized 
and non-functionalized polymers on PS NPs as template. Both of them were investigated by DLS 
analysis. In both cases (see Figure 2.7), we have the confirmation that irradiating at 254 nm for 90 
min (photoinitiator free thiol-ene ‘click’ reaction conditions), with an ice bath to control the 
overheating, the stability of the systems is preserved. While a media change, using PBS 10 mM pH 
7.4, after irradiation at 254 nm, brings to a destabilization of the non-functionalized systems. On the 
other hand, a functionalized and so cross-linked system, retains its integrity also in PBS even if we 
observe a slight swelling probably connected to weaker interactions when PS NPs are used as 
template.  
 
 
Figure 2.7. Comparison of size measurements between non-functionalized polymers system and functionalized and cross-
linked polymers systems sample: blue, samples dispersed in water at pH 4 before 254 nm; orange, samples dispersed in 
in water at pH 4 after 254 nm for 90 min; grey, samples after 254 nm for 90 min dispersed in 10 mM phosphate buffer 
solution at pH 7.4. Error bars indicate the standard deviations.  
 
DLS stability tests on cross-linked O/W trilayer. 
As previously described, to perform the stability and cleavage tests of the final system we used cross-
linked trilayer built on O/W NE, leaving the PS NPs, which were only a model template. Indeed, the 
cross-linked trilayer built on O/W nanoemulsion is the real drug delivery system developed in this 
project.  
Normal and cross-linked trilayer based on O/W nano-emulsions containing GCPLNAC as first and 
third shell, were monitored over 20 days to evaluate their stability in PBS 10 mM pH 7.4.  
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Table 2.1. Average DLS particle size data of non-crosslinked and crosslinked O/W GCPLNAC trilayers. 
 
day non-crosslinked (nm) crosslinked (nm) 
0 111,9 ±  2,6 106,2 ± 2,3 
3 115,8 ± 1,2 109,0 ± 2,7 
7 116,7 ± 0,9 109,3 ± 1,5 
14 128,4 ± 3,0 110,0 ± 1,6 
20 130,2 ± 1,3 111,1 ± 3,5 
 
As shown in Table 2.1, DLS particle size analysis of the non-crosslinked and crosslinked systems 
show a swelling of the non-crosslinked one over the days but the crosslinked systems preserve their 
size. This is an indirect demonstration of the higher stability provided by the cross-linkage to the 
nanocarrier. It has to be noted that physiological environment is more complex than PBS providing 
many more mechanisms of degradations that can destroy a multi-layer in absence of a chemical cross-
linkage.  
 
Results of cryo-TEM characterization of LbL cross-linked O/W trilayer based on GCPLNAC.  
 
 
Figure 2.8. Cryo-TEM image of an example of LbL O/W cross-linked photo-responsive trilayer. 
 
Cryo-TEM characterization of the LbL cross-linked photo-responsive trilayer (Figure 2.8) shows the 
uniform morphology of the systems and the accordance with DLS size measurements. Cryo electron 
microscopy gives the possibility to preserve the native state of the samples by rapid freezing of 
suspensions. This process is known as vitrification. Cryo-TEM images were collected to investigate 
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the shape and the distributions of the LbL cross-linked photo-responsive trilayer. In all images 
obtained, sample is always embedded in a solid matrix, to give the possibility to have a good 
characterization of a soft nanocarrier like the oil core based one exploited in this project. As shown 
in the image (Figure 2.8) LbL cross-linked photo-responsive trilayers are spherical with a uniform 
morphology in the size range of ∼ 50–200 nm. These values agreed with the LbL cross-linked photo-
responsive trilayer size data obtained by DLS.   
 
Photocleavage conditions for photolinker. 
As mentioned above, glycol chitosan was modified introducing a thiol moiety via a coupling reaction 
with PLNAC. Moreover thanks to this chitosan functionalization, it was possible to obtain a cross-
linked LbL system with a photoinitiator free thiol-ene ‘click’ reaction between the thiol moiety on 
glycol chitosan and the double bond on the allylated heparin. Therefore, photolabile linker was 
inserted between the polymers of the LbL, and tested at 365 nm in terms of ability to be cleaved 
irreversibly, thus, resulting in the destabilization of the multilayer and the release of the drug. As 
explained in Materials and Methods, before starting the photocleavage tests of our cross-linked photo-
responsive trilayers, by 1H NMR analysis we checked the behaviour of the photodegradable unit of 
the linker (PLazide) in the cross-linkage (photoinitiator free thiol-ene ‘click’ reaction, 254 nm 1.5 h) 
and photocleavage (365 nm) conditions. The mechanism of photocleavage is shown in Figure 2.9 and 
was demonstrated in a previous work.33 So to verify PLazide integrity at 254 nm, i.e. in the 
photoinitiator free thiol-ene ‘click’ reaction conditions, we compared 1H NMR spectra in CDCl3 of 
untreated PLazide, a PLazide first irradiated at ‘click’ reaction conditions and then at 365 nm for 30 
min. For simplicity of explanation, we report the superimposed spectra of the linker treated at the two 
wavelengths (Figure 2.10). In the conditions of the ‘click’ reaction, the linker shows only a slight 
rupture (not more than 20%, red line). That is, this spectrum is practically identical to that of untreated 
PLazide. At 365 nm (blue line) instead, it is possible to see a shift of all signals, the break is 80% in 
30 min. In particular, considering the products of the scission reaction, the characteristic peaks of the 
rupture are highlighted in the spectrum. 
 
 
Figure 2.9. Photocleavage mechanism of PLazide. 
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Figure 2.10. 1H NMR of PLazide: red line, PLazide at 254nm for 90 min; blue line, PLazide at 365 nm for 30 min. 
 
Results of photocleavage on cross-linked trilayer. 
As described above, we had evaluated the effect of the irradiation at 365 nm on the cross-linked 
trilayer composed by GCPLNAC, Hepall, GCPLNAC (25 μL in 1 mL PBS 10mM pH 7.4). We 
irradiated at 365 nm for 2 h in steps of 30 min and 10 min of rest and we observed a swelling of the 
trilayer (Figure 2.11). We selected this strategy of irradiation because in preliminary experiments 
(data no shown) we noticed that a combination of irradiation and rest steps, improve the swelling of 
the nanocapsules. Very probably, we observe only a swelling, because despite the photo-linker 
cleavage, the electrostatic interactions among the polymeric shells and oil core tend to preserve in 
part the system’s integrity. However, the cross-linkage and the next photo-swelling permit a 
controlled release of the capsules (as shown in the biological study). Moreover, this test shows that 
the irradiation of the system in step of 30 min and 10 min of rest brings to a more marked swelling in 
1.5 hours. For this reason, we choose this time and method of irradiation for our next investigation 
and characterization.  
The same experiment of irradiation at 365 nm was performed on a cross-linked O/W trilayer 
composed by GCNAC, Hepall, GCNAC. In this case, no variation can be observed on the capsules 
after irradiation. This result confirms that the swelling of cross-linked GCPLNAC trilayer is 
connected to the cleavage of the photo-linker. Indeed, in the same system but with GCNAC, meaning 
a polymer with no any photo-cleavable linker, the irradiation does not bring any destabilization 
(Figure 2.12).  
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Figure 2.11. Cross-linked trilayer composed by GCPLNAC irradiated for 2h in steps of 30 min and 10 min of rest. 
 
 
 
 
 
Figure 2.12. Comparison between irradiated cross-linked trilayer for 2h in steps of 30 min and 10 min of rest.  
Blue bars: GCPLNAC trilayer – Orange bars: GCNAC trilayer. 
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Confocal characterization and FRET analysis for photocleavage detection in LbL cross-linked 
trilayer based on GCPLNAC built on O/W nanoemulsions. 
As described in Materials and Methods, we used confocal analysis to acquire an image of the 
distribution of the cross-linked trilayer containing the photo-linker built on the O/W nanoemulsion 
and diluted in PBS 10 mM pH 7.4. Clearly, the image (Figure 2.13) shows the accordance with our 
expectations: uniform distribution and good deposition.  
 
 
Figure 2.13.Confocal analysis of cross-linked O/W trilayer containing the photo-linker dispersion in PBS and with the 
last layer labelled with rhodamine B.  
 
In Figure 2.13, we show an image of our cross-linked photo-responsive trilayer diluted in PBS 10 
mM pH 7.4, with the last layer labelled with RhodB. However, we have abandoned the confocal 
analysis for the study of photo-cleavage at 365 nm of the irradiated and non-irradiated cross-linked 
trilayers, photo-responsive and not. In fact, having verified from the DLS data that 365 nm exposure 
involved a swelling with a dimensional increase of much less than 200 nm, this was expected to be 
not appreciable with the optical microscopy. Therefore, we switched to FRET analysis to confirm the 
swelling observed by DLS after 365 nm irradiation in the photo-responsive cross-linked trilayer 
respect to no-photo-responsive one.  
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Figure 2.14. % FRET Efficiency (donor FITC/ acceptor RhodB) - Condition of irradiation: Cross-linked trilayers were in 
PBS 10 mM pH 7.4. Irradiated for 1.5 h in steps of 30 min and 10 min of rest at 365 nm in an ice bath. 
 
Table 2.2. % Averages of FRET Efficiency of the photo-responsive and no-photo-responsive LbL cross-linked trilayers 
based on GCPLNAC and GCNAC: before and after 365 nm irradiation. 
 
FRET Efficiency (%) 
sample % EFRET % st.dev. 
irradiated GCLINKER 18 2 
irradiated GCNAC 25 1 
no-irradiated GCLINKER 32 5 
no-irradiated GCNAC 33 2 
 
The FRET efficiency was calculated by the following equation:  
EFRET = (donor - donor-acceptor)/donor 
where the reference donor is that of FITC on allylated heparine in the absence of RhodB and therefore 
of any FRET.  τdonor was evaluated by polymers deposition on coverglass as described in Materials 
and Methods and was 3.56ns. While τdonor-acceptor was that of the tested samples. As shown in the 
Figure 2.14, after 1.5 h of 365 nm irradiation the cross-linked photo-responsive trilayer based on GC-
PLNAC in PBS 10 mM pH 7.4 showed a significant decrease of FRET efficiency, which was 
calculated respect to the non-irradiated sample. This result is in agreement with the swelling of the 
nanocapsules seen by DLS analysis, and can be explained by the cleavage of the photolinker. 
Conversely, the cross-linked non-photo-responsive trilayer based on GCNAC upon the same 
treatments showed only a weak decrease of the FRET efficiency (see Table 2.2). This result far from 
being in contrast with the DLS measurements where the non-photo-responsive systems was shown 
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stable in the irradiation’s conditions, could be explained by an expected sensitivity of donor acceptor 
pair to a photochemical effect of UV irradiation at 365 nm able to change the lifetime of the donor 
even if the donor-acceptor distance remains the same as expected in the non-swelling case. 
 
Cellular uptake quantification and cell viability studies.  
As previously reported,42 the cellular uptake of fluorescent nanocarriers is time-dependent. Here, after 
2 h of incubation, approximately 30–35% of photo-responsive cross-linked and non-functionalized 
trilayer nanoemulsion were internalized or adhered to the membrane of A375.S2 cells (Figure 2.15). 
After 6 h of incubation, around 70-75% of both the systems were internalized and started a quite-
plateaux curve (Figure 2.15). This is the reason why we decided to adopt 6 h of internalization as the 
superior limit in our cellular experiments when to start with UV stimulation.   
 
 
Figure 2.15: Melanoma cellular uptake of photo-responsive cross-linked and non-functionalized trilayer nanoemlsions 
incubated from 0,5 up to 24 h.  
 
On the other hand, focusing on our photo-responsive cross-linked trilayer having the oil core loaded 
with curcumin, the cytotoxicity measurements are in accordance with the fact that in 6 h of pre-
incubation before UV irradiation (365 nm) there is a complete internalization. In fact, in Figure 2.16 
and 2.17 we compare the photo-responsive cross-linked trilayer loaded with curcumin at different 
time of pre-incubation (2 h, 4 h, 6 h) with melanoma cells and we compared washed or no-washed 
conditions after this pre-incubation time and UV exposure in terms of cell viability at 24 and 72 h. In 
both cases, we observe that for 2 h or 4 h of pre-incubation, the washed systems are less toxic than 
no-washed ones, while for 6 h of pre-incubation, there are not differences between washed and no 
washed conditions, so the washing step does not change the cellular results, both for 24 or 72 h of 
culture. Therefore, we can be sure that in 6 h of pre-incubation, there is the maximum internalization.  
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Figure 2.16. Growth condition: 24 h. Photo-responsive cross-linked trilayer loaded with curcumin (range of curcumin 
concentrations from 0.05 to 5 μg/mL) for different times of pre-incubation, washed or no-washed, then expose to UV.  
 
 
Figure 2.17. Growth condition: 72 h. Photo-responsive cross-linked trilayer loaded with curcumin (range of curcumin 
concentrations from 0.05 to 5 μg/mL) for different times of pre-incubation, washed or no-washed, then expose to UV.  
 
For what we have just said above, the next presented results are referred to 6 h of pre-incubation time. 
Curcumin and photo-linker effect of the photo-responsive cross-linked trilayer on human skin 
melanoma cell line A375.S2 are promising. Indeed, first of all, for both 24 h or 72 h of culture 
conditions, we observe that a photo-responsive cross-linked trilayer no-loaded (blue lines in Figure 
2.18 and 2.19) , also irradiated, does not show cytotoxicity. Therefore, in all the other cases, the 
observed cellular mortality is connected to the release of the drug while the nanocarriers is not toxic 
by itself.  Furthermore, we could appreciate the photo-linker effect on curcumin action, observing 
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that the photo-responsive cross-linked trilayer when irradiated showed a cellular viability much lower 
than the same system (washed or not washed) but not photo-stimulated (violet curve in Figure 2.18 
and 2.19). The only difference in the two cases was the absence or presence, respectively, of the UV 
irradiation. This is a nice demonstration of the goodness of our photo-responsive cross-linked trilayer.  
 
 
Figure 2.18. Viability of A375.S2 cell after 24h of exposure to 37°C as a function of curcumin concentration (μg/mL). 
Growth conditions: 24h.  
 
 
Figure 2.19. Viability of A375.S2 cell after 24h of exposure to 37°C as a function of curcumin concentration (μg/mL). 
Growth conditions: 72h.  
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2.4 Conclusions  
In this work, we showed the preparation of a photo-responsive cross-linked LbL multilayer built on 
O/W nanoemulsion made of biocompatible materials. The introduction of a thiol functionalized o-
nitrobenzyl group on glycol chitosan, opportunely characterized, allowed us to prepare a cross-linked 
trilayer using the alternated depositions of that polymer and allylated heparin via LbL technique and 
a photoinitiator free thiol-ene ‘click’ reaction, obtaining stable nanocapsules in physiological 
conditions. On the other hand, the same thiol functionalized o-nitrobenzyl group allowed us to induce 
a controlled photo-cleavage of the nanocarrier at 365 nm, demonstrated by different characterization 
techniques. The goodness of our systems was also assessed by biological tests on melanoma cell 
models using curcumin as drug. Therefore, we provide a strategy to prepare biocompatible photo-
responsive oil core based nanocapsules with possible use as controlled drug delivery systems. In 
particular, they may be used in the therapy of skin tumors or in the treatment of tumor tissues during 
surgery applications. Future in vivo studies could be another confirmation of the interesting 
applications of this new system.  
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Abstract 
Doxorubicin is a highly active antineoplastic agent, but its clinical use is limited because of its 
cardiotoxicity. Although nutraceuticals endowed with anti-inflammatory properties exert 
cardioprotective activity, their bioavailability and stability are inconsistent. In an attempt to address 
this issue, we evaluated whether bioavailable nanoemulsions loaded with nutraceuticals (curcumin 
and fresh and dry tomato extracts rich in lycopene) protect cardiomyoblasts (H9C2 cells) from 
doxorubicin-induced toxicity. Nanoemulsions were produced with a high-pressure homogenizer. 
H9C2 cells were incubated with nanoemulsions loaded with different nutraceuticals alone or in 
combination with doxorubicin. Cell viability was evaluated with a modified MTT method. The levels 
of the lipid peroxidation products malondialdehyde (MDA) and 4-hydroxy-2-butanone (4-HNA), and 
of the cardiotoxic-related interleukins IL-6, IL-8, IL-1β and IL-10, tumor necrosis factor-alpha (TNF-
α), and nitric oxide were analyzed in cardiomyoblasts. The hydrodynamic size of nanoemulsions was 
around 100 nm. Cell viability enhancement was 35–40% higher in cardiomyoblasts treated with 
nanoemulsion + doxorubicin than in cardiomyoblasts treated with doxorubicin alone. Nanoemulsions 
also protected against oxidative stress as witnessed by a reduction of MDA and 4-HNA. Notably, 
nanoemulsions inhibited the release of IL-6, IL-8, IL-1β, TNF-α and nitric oxide by around 35–40% 
and increased IL-10 production by 25–27% versus cells not treated with emulsions. Of the 
nutraceuticals evaluated, lycopene-rich nanoemulsions had the best cardioprotective profile. In 
conclusion, nanoemulsions loaded with the nutraceuticals described herein protect against 
cardiotoxicity, by reducing inflammation and lipid oxidative stress. These results set the stage for 
studies in preclinical models. 
 
3.1 Introduction 
Doxorubicin is a cytotoxic antibiotic that is used to treat leukemia and lymphoma, as well as breast, 
lung, and other solid tumors. However, its clinical use is limited because of its irreversible 
cardiotoxicity that can lead to heart failure in a dose-dependent manner.1-3 The mechanism of 
doxorubicin-induced cardiotoxicity is based on the generation of free radicals and reactive oxygen 
species that attach to membrane lipids and proteins thereby generating toxic products.4,5 Doxorubicin 
stimulates overproduction of reactive oxygen species and impairs cardiac cell function.2 It induces 
cardiotoxicity also by producing the pro-inflammatory interleukins IL-8 and IL-6.6 Natural products 
endowed with antioxidant activity, namely, survivin, sesamol and herbaleonurin, decrease or prevent 
doxorubicin-induced damage.7 The natural antioxidants vitamin E and catalase, and the synthetic 
antioxidants 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone) are used to treat cardiac hypertrophy. 
The mechanism of action of nutraceuticals is based on the reduction of oxidative stress, 
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cardiovascular risk factors such as Metabolic Syndrome8,9 but their therapeutic potential in cardiology 
remains unknown.10,11 Lycopene is a potent dietary carotenoid antioxidant thanks to its many 
conjugated double bonds12 and it has the strongest singlet oxygen-quenching ability of all dietary 
carotenoids.13 The relationship between lycopene and cardiovascular disease has been examined in 
several epidemiological studies.5 The few studies conducted so far regarding the effect of lycopene 
or tomato extract on doxorubicin-induced cardiotoxicity showed some protective effects, but more 
studies are needed to evaluate their potential as cardioprotectors under doxorubicin treatment.14 
Curcumin is the main active ingredient of the turmeric spice Curcuma longa; it has several 
pharmacological and biological properties being an antioxidant, anticancer, anti-inflammatory and 
antiviral agent.12 Curcumin induces apoptosis, via deactivation of NF-kB and its regulated gene 
products, and it also suppresses inflammatory cytokines such as interleukins (IL-1, -1β, -6, and -8), 
TNF-α, and COX-2.15 In studies comparing free and nano encapsulated curcumin, the bioavailability 
and effect of curcumin were greatly increased in terms of anti-inflammatory action.16,17 The 
mechanism of action of these nutraceuticals are based on cell cycle regulation, tyrosine kinase 
modulation18 inhibition of cytokine and interleukin secretion, and AMPK-Sclerosis Tuberous 
Complex (TSC) activation with consequent AKT-mTOR axis inhibition.19 However, the clinical use 
of these nutraceuticals is limited by their low oral bioavailability due to oxidation in biological 
environments, which results in a low accumulation in the cell cytoplasm.20 Given these limitations, 
the aim of this study was to encapsulate such nutraceuticals in nanocarriers able to protect them from 
oxidative and enzymatic environmentsin order to achieve a more specific and controlled release. We 
also investigated the pathways involved in cardioprotection by analyzing the anti-inflammatory and 
anti-oxidant effects of the nanocarriers based on IL-1β, IL-8, IL-6 and malondialdehyde (MDA)/4-
HNA cellular secretion under pro-inflammatory conditions.  
The proposed strategy of cardioprotection could be of translational importance in cardioncology 
considering the crucial role of the heart and vascular microenvironments in the etiology of 
cardiotoxicity. 
 
3.2 Materials and Methods 
Synthesis and Characterization of Nanoemulsions. Materials: Both soybean oil (density at 20 °C of 
0.922 g mL-1) and surfactant Lipoid E80 (egg lecithin powder 80–85% enriched with phosphatidyl 
choline (PC) and 7–9.5% content in phosphatidylethanolamine (PE)) were purchased from Lipoid 
GmbH and used without further purification. Millipore Milli-Q water was used for the preparation of 
all nanoemulsions and solutions. Chitosan (CT, LMW 90–150 kDa, DDA 75–85%) was purchased 
from Sigma Aldrich (Milan, Italy). Chitosan was soluble in acidic conditions due to the protonation 
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of its amine moieties21 and was used without further purification; Fluorescein isothiocyanate (FITC, 
M.W. = 389.38 g mol-1) was also purchased from Sigma Aldrich and used without further purification. 
Curcumin (from Curcuma longa Turmeric, powder, M.W. = 368.38 g mol-1) was again purchased 
from Sigma-Aldrich and used with no further purification. 
 
Preparation of Nanoemulsions. 
Nanoemulsions were prepared following a previously developed protocol22 which can also be adapted 
to the encapsulation of contrasting agents.23 Briefly, first the oil phase was prepared by adding the 
surfactant to the soybean oil and mixed at 60 °C under gentle stirring. Then, the oil phase was added 
drop wise to the water phase (Milli-Q water) and mixed using the immersion sonicator (Ultrasonic 
Processor VCX500 Sonic and Materials) until there was a suitable dissolution. The pre-emulsions 
were finally passed at 2000 bar through the high-pressure valve homogenizer (Microfluidics 
M110PS) for the first three individual cycles to greatly reduce the initial size, then the reservoir was 
continuously refilled for 200 steps. This method was used for the preparation of all oil-in-water 
nanoemulsions at 20 wt% of oil concentration. In particular, 5.8 g of surfactant were dissolved in 24 
mL of oil. In the case of curcumin, 100 mg of drug were added to 24 mL of the oil phase dissolving 
the surfactant, and mixing at 60 °C under gentle stirring. Instead, in the case of tomato peel extracts, 
5.8 g of surfactant were dissolved in 24 mL of oil already containing the biomolecule always mixing 
at 60 °C under gentle stirring. In fact, in the case of tomato peel extracts, in one option, ~800 g of 
fresh tomato peels were processed overnight with ~1.5 L of soy-bean oil in the Naviglio extractor 
which is a type of solid-liquid extractor.24 This method has already been used to extract pure lycopene 
by using an alcoholic extraction.25 In this case, for the first time we extracted the bioactive compounds 
from the tomato peels by using a vegetable oil as solvent that is then used for the preparation of the 
nanoemulsion. In a second option, the same amount of fresh tomato peels was first lyophilized and 
then processed by using the same procedure as for the fresh tomato peels. Fluorescent nanoemulsions 
were obtained by mixing 4 mL of ethanol solution of FITC (0.75 mg/mL) to the soybean oil during 
the emulsion preparation and drying the ethanol from the mixture with mild heating. The final 
concentration of FITC in the 10 wt% emulsion is 125 μg/mL. Then, 0.1 M acetic acid solution of 
chitosan (0.125 wt%) was prepared. Each nanoemulsion (freshTom-Ne, dryTom-Ne, curc-Ne and 
FITC-Ne) 20 wt% oil was added to the chitosan solution quickly under vigorous stirring and kept 
under stirring for 15 min to allow uniform chitosan deposition. Final concentrations of oil and 
chitosan were 10 and 0.1 wt%, respectively, while the pH of the final secondary nanoemulsions was 
4. These nanoemulsions were re-dispersed using the method reported previously26 and stored at room 
temperature. The nutraceutical-loaded nanoemulsions tested in this study are listed in Table 3.1. 
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Table 3.1. The nutraceutical-loaded and fluorescent nanoemulsions 
 
 
LC/MS Analysis for Lycopene Measurement. 
HPLC-grade acetonitrile, methanol, dichloromethane, n-hexane and lycopene analytical standard 
were purchased from Sigma (St. Louis, MO, USA). The assay was performed according to the 
procedure described by Kozukue and Friedman (2003) slightly modified.27 HPLC analysis was 
performed on a Jasco Extrema LC-4000 system (Jasco Inc., Easton, MD, USA) equipped with photo 
diode-array detector and autosampler. Data were acquired and analyses were performed using JASCO 
ChromNAV (version 2.02.04). Samples were analyzed on a Gemini C18 column (250 x 4.6 mm, 5 
μm, Phenomenex) and lycopene was detected at 450 nm. The column was eluted at a flow rate of 
1mL/min with a two-solvent system, namely, (A) acetonitrile, (B) n-
hexane/dichloromethane/methanol (1:1:1) with 82–76% A for the first 10 min, then in 2 min 58% A, 
in 6 min 40% A, and finally returned to 82% A in 5 min. This was followed by isocratic elution for 2 
min. Calibration curve was performed with lycopene samples prepared freshly on a daily basis. The 
retention time of lycopene was 15 min. Each analysis was performed in triplicate. Lycopene standard 
was diluted to obtain the following ppm concentrations: 1, 5, 25, 50 and 100. A good linear fit range 
was found, the regression equation and correlation coefficient were respectively: y = 11660x + 
776.75, R = 0.9998. 
 
Cell Viability. 
To evaluate the cardioprotective effects of nutraceutical-loaded nanoemulsions on H9c2 
cardiomyoblasts (American Type Culture Collection, Manassas, VA, USA), we measured the 
mitochondrial dehydrogenase activity of these cells using a modified MTT [3-(4,5-dimethyldiazol-2- 
yl)-2,5-diphenyltetrazoliumbromide] procedure according to the manufacturer’s instructions 
(Dojindo Molecular Technologies Inc., Rockville, MD, USA). H9c2 cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) with 10% (v/v) heat inactivated fetal bovine serum, penicillin G 
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(100 U/mL), and streptomycin (100 mg/mL) in 96-well plates at a density of 10,000 cells per well at 
37 °C in a humidified 5% CO2 atmosphere. After 24 h of growth, we divided cells into the following 
groups: doxorubicin at 20 μM; nutraceutical-loaded nanoemulsions in the uncoated form: dryTom-
Ne, freshTom-Ne, curc-Ne and in the chitosan-coated formulations, designated dryTom-Ne-CT, 
freshTom-Ne-CT, curc-Ne-CT (all at concentrations ranging from 0.5 to 5% w/v of oil) all tested in 
combination with 20 μM doxorubicin. We decided to use only this Doxorubicin concentration 
referring to several works, related to cardioprotection, in the literature.2,3 Moreover, we tested and 
compared the effects of Enalapril, a common inhibitor of angiotensin-converting enzyme at 10, 25 
and 50 μM as reported elsewhere28 and Carvedilol at 1, 5 and 10 μM29 both co-incubated with 20 μM 
doxorubicin. Carvedilol is a nonselective beta blocker/alpha-1 blocker used to treat mild-to-severe 
congestive heart failure and left ventricular dysfunction after a heart attack. In all experiments, cells 
were incubated for 24 h under standard conditions. Cells were then washed three times with PBS at 
pH 7.4 and incubated with 100 μL of an MTT solution (0.5 mg/mL in cell culture medium) for 4 h at 
37 °C. Absorbance readings were acquired at a wavelength of 450 nm with the Tecan Infinite M200 
plate-reader (Tecan Life Sciences Home, Männedorf, Switzerland) using I-control software. Relative 
cell viability (%) was calculated with the following formula [A]test/[A]control x 100, where “[A]test” is 
the absorbance of the test sample, and “[A]control” is the absorbance of the control cells incubated 
solely in culture medium. After the evaluation of cell cytotoxicity, we measured the total protein 
content using the Pierce Micro BCA protein assay kit (Thermo Fisher, Milan, Italy). Briefly, the cells 
were washed with ice-cold PBS, and incubated for 15 min in 150 μL cell lysis buffer (0.5% v/v Triton 
X-100 in PBS) that included 150 μL of the Micro BCA protein assay kit reagent (prepared according 
to the manufacturer’s instructions). Absorbance at 562 nm was measured on a plate reader. 
Cytotoxicity measurements were normalized by the amount of total protein content in each well. 
 
Cellular Uptake Studies. 
Uptake Quantification. H9c2 cardiomyoblasts were grown in DMEM with 10% (v/v) heat inactivated 
FBS, penicillin G (100 U/mL), and streptomycin (100 mg/mL) at 37 °C in a humidified 5% CO2 
atmosphere. For uptake experiments, 5 x 103 cells/well were seeded in a 24-well plate and allowed 
to grow for 24 h. The medium was then replaced with 0.1 mL of a 0.5% oil solution of fluorescent 
uncoated and chitosan-coated nanoemulsions in culture medium and incubated for between 0.5 and 
24 h. Cells were then washed twice with PBS (pH 7.4) and after specified time intervals, the 
experiments were terminated by removing the supernatant, washing the cells three times with 10 mM 
PBS and lysing the cells with 0.1 mL of 0.5% Triton X-100 in 0.2 N NaOH. The membrane-bound 
and internalized fluorescent nanoemulsions were quantified by analyzing the fluorescence of the cell 
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lysate (λexc = 485 nm, λem = 535 nm), using a calibration curve with 0.001 up 5% oil of fluorescent 
nanoemulsions dispersed in a cell lysate solution (106 untreated cells dissolved in 1 mL of the Triton 
X-100/0.2 N NaOH solution). 
 
Mechanistic Studies. To determine the mechanism underlying nanoemulsion internalization in H9c2 
cells, we investigated the effects of following treatment: bafilomycin A1 (that inhibits endosomal 
acidification by inhibiting membrane ATPases, that also affects the budding of endosomal carrier 
vesicles from early endosomes, filipin (an inhibitor of caveolae-mediated endocytosis), nocodazol 
(that inhibits membrane ruffling and active [vesicular] transport by disrupting cytoplasmic 
microtubules), cytochalasin D (a well-known inhibitor of membrane ruffling and active [vesicular] 
transport that acts by disrupting actin fibers), hypertonic sucrose and potassium-free buffer (that 
inhibit the clathrin-mediated uptake with lower and higher selectivity, respectively), and sodium azide 
(that reduces active transport by inhibiting cellular respiration).In the case of fluorescent 
nanoemulsions, cellular uptake experiments were conducted after 4 h of incubation in the presence 
of these inhibitors, specifically: 0.45 M sucrose, 0.1mg/mL cytochalasin D, 1 mg /mL nocodazole, 
0.1 mg/mL filipin and 2 x 10-7 M bafilomycin A1. In separate experiments, cancer cells were 
preincubated with 10-2 M of the metabolic inhibitor sodium azide for 30 min before the uptake of 
uncoated and chitosan-coated nanoemulsions and during uptake to evaluate the energy dependence 
of the process. With the exception of sodium azide and sucrose, which were dissolved directly in the 
culture medium, stock solutions of the other effectors were prepared in DMSO then diluted with 
culture medium to the proper concentration. H9c2cells were pre-incubated at 4 °C for 30 min with 
inhibitors then at 37 °C for 4 h as reported elsewhere.30 Instead, to study the effect of intracellular 
potassium depletion, cardiomyocytes were rinsed twice and incubated with a potassium-free buffer 
solution with the following substances: 0.14 M NaCl, 0.02 M of MES buffer, 10-3 M of CaCl2 and 1 
mg/mL of glucose pH 7.4 for 30 min before uptake experiments were performed in the same medium, 
as reported in literature.31 
 
Cellular Antioxidant Activity Following Oxygen Radical Generator Exposure. Cellular uptake of 
nanoemulsionsin H9c2 cells after oxygen radical generator exposure was measured as reported 
elsewhere.32 In brief, H9c2cellswere incubated with 50 μL of 2,2’-Azobis(2-methylpropionamidine) 
dihydrochloride (AAPH) 4 μM for 10 min to simulate oxidative stress. Cells were then washed three 
times with PBS and then treated with nutraceutical-loaded nanoemulsions at oil concentrations 
ranging from 0.5 to 5% w/v of oil for 10, 20, 45, or 60 min. Gallic Acid (at 25, 50 and 100 μM), a 
common antioxidant, was used as positive control. Subsequently, samples were washed twice and 
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sonicated at 10% amplitude with energy of 20 W/cm2 for 5 min to lyse cardiomyoblasts by sonicator 
(Sonics, Vibra Cell, Newtown, CT, USA). After sonication, samples were centrifuged for 30 min at 
2700x g. The supernantant was then removed as the lysate fraction. Three different plates per 
compound were run for lysate fractions. 
 
Detection of Intracellular Reactive Oxygen Species. The formation of intracellular reactive oxygen 
species was evaluated using a conventional fluorescent probe, called DCFH-DA, as described 
elsewhere.33 Briefly, H9c2 cells were grown in DMEM with 10% (v/v) heat-inactivated FBS, 
penicillin G (100 U/mL) and streptomycin (100 mg/mL) at 37 °C in a humidified 5% CO2 atmosphere. 
Subsequently, 5 x 103 cells/well were seeded in a 24-well plate and allowed to grow for 24 h. After 
washing twice with PBS, cells were pretreated or not with all nutraceutical-loaded nanoemulsions at 
oil concentrations ranging from 0.5 to 5% w/v of oil for 4 h; pretreatment also with gallic acid (at 25, 
50 and 100 μM) was used as positive control. After pretreatments, cells were then incubated with 5 
μM DCFH-DA in PBS for 30 min. After the DCFH-DA removal, cells were stimulated with 40 ng/mL 
of lipopolysaccharide (LPS) or doxorubicin at 50 nM for 12 h. Cell fluorescence was measured using 
a microplate spectrofluorometer (xMark Microplate, Spectrofluorometer Biorad, Milan, Italy). 
Intracellular antioxidant activity was expressed as percentage of control cells. 
 
Lipid Peroxidation Studies. To study the protective effects of nutraceutical-loaded nanoemulsions at 
the membrane level of cardiomyoblasts, H9c2 cells were grown in DMEM with 10% (v/v) heat 
inactivated FBS, penicillin G (100 U/mL), and streptomycin (100 mg/mL) at 37 °C in a humidified 
5% CO2 atmosphere. Subsequently, 5 x 10
3 cells/well were seeded in a 24-well plate and allowed to 
grow for 24 h. Briefly, H9c2 cells were treated with doxorubicin (50 nM) or LPS (40 ng/mL) for 6 h 
or pretreated for 4 h with all nutraceutical-loaded nanoemulsions at oil concentrations ranging from 
0.5 to 5% w/v or with gallic acid (at 25, 50 and 100 μM) as positive control. Then, cells from each 
group were washed three times with cold PBS, harvested with 0.25% trypsin, and centrifuged at 
1000x g for 10 min. The supernatant was discarded and the cell pellet sonicated in cold PBS. After 
centrifugation (800x g, 5 min), the supernatant was immediately evaluated for MDA and 4-
HNAcommercial kits with a spectrophotometer according to the manufacturer’s protocols (Sigma 
Aldrich, Milan, Italy). We measured the protein content of the cell homogenates using the Micro 
BCA protein assay kit (Pierce, Thermo Fisher, Milan, Italy) according to kit instructions. 
 
Measurement of Nitric Oxide. To evaluate the effects of nutraceutical-loaded nanoemulsions on the 
release of nitric oxide from H9c2 cells we analyzed the release of nitrite, a stable product of nitric 
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oxide in aqueous medium, using the Griess Reagent System (Promega, Madison, WI, USA) as 
described elsewhere.18 Briefly, H9c2 cardiomyoblasts were grown in DMEM with 10% (v/v) heat 
inactivated FBS, penicillin G (100 U/mL), and streptomycin (100 mg/mL) at 37 °C in a humidified 
5% CO2 atmosphere. Subsequently, 5 x 10
3 cells/well were seeded in a 24-well plate and allowed to 
grow for 24 h. Cells were treated with doxorubicin (50 nM) or LPS (40 ng/mL) for 6h or pretreated 
for 4 h with all nutraceutical-loaded nanoemulsions at oil concentrations ranging from 0.5 to 5% w/v. 
Also, in this case, pre-incubation with gallic acid (at 25, 50 and 100 μM), a common antioxidant, was 
used as positive control. The culture medium was then mixed with an equal volume of sulfanilamide 
solution (1% v/v in 5% v/v phosphoric acid) and of N-1-naphtylethylenediamine dihydrochloride 
solution (0.1% v/v in water). Absorbance was measured at 540 nm with a spectrophotometer (xMark 
Microplate, Spectrofluorometer Biorad, Milan, Italy). Nitrite concentrations were determined from a 
calibration curve of standard 0.1 M sodium nitrite concentrations from 0.5 to 50 μM against 
absorbance. 
 
Intracellular Calcium Level. Doxorubicin-induced cardiotoxicity is also accompanied by an increase 
in intracellular calcium levels. Dysregulation of intracellular calcium concentrations is both a result 
and a cause of the generation of radical oxygen species. Doxorubicin induces the release of calcium 
from the sarcoplasmic reticulum by increasing the probability that the channel adopts the open state. 
An increase in intracellular calcium is not the only cause of mitochondrial calcium dysregulation, in 
fact, doxorubicin affects mitochondrial calcium transport thereby contributing to the increase in 
intracellular calcium levels. To monitor the intracellular calcium in H9c2 cardiomyoblasts, we used 
the fluorescence dye Fluo-3 AM, following the manufacturer’s protocol. Briefly, H9c2 cells were 
treated with doxorubicin (50 nM) or LPS (40 ng/mL) for 6h or pretreated for 4h with each of the 
nutraceutical-loaded nanoemulsions at oil concentrations ranging from 0.5 to 5% w/v. After 
incubation, H9c2 cardiomyoblasts were loaded with 5 μM Fluo-3 AM at 37 °C for 30 min in the dark, 
and then washed three times with PBS to remove excess dye. The fluorescence intensity of Fluo-3 
chelated with calcium was recorded on a microplate spectrofluorometer (xMark Microplate, 
Spectrofluorometer Biorad, Milan, Italy) at excitation and emission wavelengths of 488 and 525 nm, 
respectively.  
 
Anti-Inflammatory Studies. The expression of IL-6, IL-8, IL-1β, IL-10, and tumor necrosis factor-
alpha (TNF-α) in cardiomyoblasts was evaluated with ELISA, as described elsewhere.34 Briefly, 
H9c2 cells were grown in DMEM with 10% (v/v) heat inactivated FBS, penicillin G (100 U/mL), 
and streptomycin (100 mg/mL) at 37 °C in a humidified 5% CO2 atmosphere. After incubation for 
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24h and starvation in serum-free medium for 2.5 h, cardiomyoblasts were treated or not with the 
nutraceutical-loaded nanoemulsions at oil concentrations ranging from 0.5 to 5% w/v for 4h before 
exposure to LPS (40 ng/mL) for 12 h to stimulate inflammation. Subsequently, culture supernatants 
were collected, centrifuged to pellet any detached cells, and measured using TNF-α, IL-1β, IL-6, IL-
8 and IL-10 ELISA kits according to the manufacturer’s instructions (Sigma Aldrich, Milan, Italy). 
The sensitivity of this method was below 10 (pg/mL), and the assay accurately detected cytokines in 
the range of 1–32,000 pg/mL.  
 
Statistical Analysis. Differences between the experimental groups were identified with a one-way 
analysis of variance and subsequently with Turkey’s multiple comparison test in Sigma Plot Software 
(Sigma, San Jose, CA, USA). p < 0.05 was the lowest acceptable threshold for significance. 
 
3.3 Results. 
Synthesis and Chemical-Physical Characterization of Nutraceutical-Loaded Nanocarriers. 
Oil in water nanoemulsions in their uncoated and chitosan-coated form were produced as previously 
described.23 In particular, among different possible sizes of the nanoemulsions that can be tuned with 
the amount of surfactant, namely egg lecithin, we chose to work with the smallest possible. Indeed, 
we have already demonstrated the importance of scaling down the size in terms of bioavailability 
once in vivo. Regarding curcumin, we reproduced the uncoated and chitosan-coated oil in water 
nanoemulsion that we previously used to evaluate their cardio-protective properties.16 Then, given 
the well-known cardio-protective properties of lycopene, we started from tomato peel that is 
notoriously rich in lycopene and we applied the Naviglio solid-liquid extraction method by directly 
immersing tomato peel in the oil phase. After enriching the oil with the active principles contained in 
tomato peel, we used it to prepare the uncoated and chitosan-coated form of the oil in water 
nanoemulsion by applying the same procedure described above. In one extraction procedure, we used 
wet tomato peels directly as obtained from a tomato company (Pietro Grimaldisrl, Sant’Egidio del 
Monte Albino SA, Italy), and in another we lyophilized the tomato peels before extraction. In the 
latter case, we used an amount of peel corresponding to the starting amount of wet tomato peels. For 
the overall uptake study, we also used oil in water nanoemulsions again uncoated and coated with 
chitosan by repeating the procedure previously reported. Together with the nutraceutical 
encapsulating nanoemulsions we also used an FITC-loaded nanoemulsion for uptake studies. The 
dimensional characterization of the nanocarriers used in this study is reported in Table 3.2, together 
with the z-pot of the all systems. Thanks to the surface charge and to the narrow size distribution, the 
systems are stable for several months especially in the coated forms, as reported elsewhere.21,26 As an 
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example, the uncoated and coated nanoemulsions richest in lycopene were characterized by cryo-
TEM as reported in Figure 3.1. It is clear from the morphological analysis the level of monodispersion 
of the uncoated and coated carrier and the sizes are in agreement with the DLS analysis. 
 
Table 3.2. Physical–chemical characteristics of nanocarriers used in this study: hydrodynamic size, polydispersity index 
and z-potential. 
 
 
 
Figure 3.1. Cryo-TEM projection images of dryTom-Ne (left) and dryTom-Ne-CT (right). 
 
Measurement of Lycopene Content in Tomato Peel Extracts. 
The amount of lycopene in the two samples was measured using a previously reported LC/MS method 
slightly modified.25 Quantitative measurements were obtained on the basis of a calibration curve 
established with commercial lycopene standard samples as reported in the materials and methods 
section. The lycopene content was significantly lower in “fresh tomato extract” than in “dry tomato 
extract” (0.007 mg/mL ± 0.0005, versus 0.029 mg/mL ± 0.001). A representative chromatogram of 
the two samples is depicted in Figure 3.2. This is due to the fact that the presence of water in fresh 
products makes the extraction of lipophilic compounds more difficult using this method. Based on 
this information, for all subsequent studies, it is important to specify that the nanoemulsions are based 
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on fresh tomato extract at 0.5%, 1% and 5% of oil contain, respectively, 0.035, 0.07 and 0.35 μg of 
lycopene/mL of solution. Moreover, nanoemulsions must be based on dry tomato extract at 0.5%, 1% 
and 5% of oil contain, respectively, 0.145, 0.29 and 1.45 μg of lycopene/mL of solution. 
 
 
Figure 3.2. Representative chromatograms for the samples “dry tomato extract” (left) and “fresh tomato extract” (right). 
Lycopene is peak n. 5. 
 
Cell Viability. 
As shown in Figure 3, doxorubicin treatment for 24 h decreased cardiomyoblasts viability by more 
than 80% but co-incubated with all the nanoemulsions used resulted in concentration-dependent 
cardioprotective effects. Chitosan-coated forms of nanoemulsions had the best cardioprotective 
properties, probably due to a better cellular uptake on cardiomyoblasts (Figure 3.3A). Overall cell 
viability was 5-20% higher in cells treated with chitosan-coated nanoemulsions than in unpretreated 
cells. Moreover, lycopene-rich nanoemulsions (dry-Tom-Ne) had better cardioprotective properties 
than did fresh-Tom-Ne-treated and curc-Ne-treated cardiomyoblasts. In fact, the viability of 
cardiomyoblasts treated with uncoated and chitosan-coated dryTom-Ne at 5% oil was about 45% and 
60% higher, respectively versus doxorubicin-treated cells. To determine the translational potential of 
these nanoemulsions in cardioprotection during doxorubicin treatment, we compared the effects of 
Enalapril and Carvedilol (Figure 3.3B–D) as common drugs used in cardio-oncology; interestingly, 
the best nanoemulsion formulation at the higher concentration tested seems to be 30% and 35% more 
effective, compared to Enalapril and Carvedilol at very high concentration such as 50 and 100 μM 
respectively (p < 0.001 for both). 
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Figure 3.3. Cell viability in function of the concentration of nutraceutical-loaded uncoated and chitosan-coated 
nanoemulsions all tested at concentrations from 0.5 to 5% v/v of oil tested combined with doxorubicin at 20 μM. (A). 
The viability of cardiomyoblasts incubated with doxorubicin (at 20 μM) in association with Enalapril at 10, 25 and 50 
μM and Carvedilol at 1, 5 and 10 μM. (B). Difference in the percentage of cell viability versus control, between (C) 
Enalapril and (D) Carvedilol and the best nanoemulsion (dryTom-Ne-CT) at different concentrations * p < 0.001; ** p < 
0.05; ns: not significant. 
 
Uptake Quantification and Mechanistic Studies. 
As we previously reported,18 the cellular uptake of fluorescent nanocarriers is time-dependent. In the 
present study, after 2 h of incubation, approximately 30–35% of chitosan-coated nanoemulsions were 
internalized or adhered to the membrane of H9c2 cells (Figure 3.4). The uptake of uncoated 
nanoemulsions at 24 h of incubation was invariably less than 30–35% that of chitosan-coated 
emulsion, which corroborates the effects on cell viability described previously. After 24 h of 
incubation, around 90% of chitosan-coated nanoemulsions were internalized in cardiomyoblasts 
(Figure 3.4). Having established that nanocarriers are able to internalize in H9c2 cells, we 
complemented this study by analyzing the mechanism of cell uptake using a small library of inhibitors 
of general active transport processes, endosomal acidification, caveolae-mediated endocytosis, 
membrane ruffling and vesicular transport microtubules and actin fibers.35 Thus, we evaluated the 
effects of these inhibitors on the internalization of fluorescent nanocarriers in cells. As shown in 
Figure 3.4, the nanocarriers were highly sensitive to all these factors. In detail, sodium azide inhibited 
endocytosis by 55–60% and cytochalasin by 35–40%. Nocodazole did not have any significant effect 
on H9c2, which is in line with the energy-dependent nature of the nanocarrier internalization and the 
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involvement of stress fibers, but not of microtubules. Filipin did not significantly inhibit cellular 
internalization thereby excluding a caveolae-mediated endocytic mechanism of nanoemulsions 
uptake. Bafilomycin A1 significantly reduced endocytosis by 50%. Although hypertonic sucrose is 
known to inhibit also macropinocytic and caveolar uptake, the more clathrin-selective potassium-free 
buffer had the same inhibitory effect, indicating the clathrin-dependent endocytosis is the most likely 
internalization mechanism.36 It seems that uncoated and chitosan-coated nanoemulsions have the 
same mechanism of endocytosis, however, chitosan-coated nanoemulsions are clearly more sensitive 
to the inhibitors than uncoated nanoemulsions, which indicates a clathrin-dependent endocytosis. 
 
 
Figure 3.4. Left, overall cellular uptake quantification of H9c2 cells (at a density of 5 x 103 cells/well) from 0.5 up to 24 
h of contact with fluorescent nanocarriers at 1% v/v oil. Right, effect of different inhibitors on the internalization of 
fluorescent nanocarriers (1% v/v oil) in H9c2 cells after 4 h of incubation. The data are normalized against their controls. 
 
Cellular Antioxidant Activity after Oxygen Radical Generator Exposure. 
As shown in Figure 3.5A, the mean antioxidant capacity differed significantly between the lysates of 
cells treated with chitosan-coated nanocarrier sand those of uncoated nanocarriers. Specifically, 
treatment of H9c2 cells with dryTom-Ne exerted antioxidant activity in a concentration-dependent 
manner with a mean of 12,323 (±998), 20,233 (±956), 30,122 (±1023) TE/L/10 cells for 0.5%, 1% 
and 5% of oil, respectively. The chitosan-coated emulsion had similar behavior with even higher 
antioxidant activity than uncoated nanocarriers with a mean of 15,456 (±744), 27,233 (±535) and 
38,344 (±898) TE/L/10 cells for 0.5%, 1% and 5% of oil, respectively. The antioxidant properties of 
dryTom-Ne were 10–13% higher than curc-Ne, and around 40% higher than freshTom-Ne. Gallic 
acid, a common antioxidant used as positive control, as reported in Figure 3.5B has a slight 
antioxidant property compared to nanoemulsions a mean of 10,245 (±886), 14,563 (±978) and 19,856 
(±1023) TE/L/10 cells for 25, 50 and 100 μM, respectively. 
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Figure 3.5. Mean antioxidant values (±SEM) of H9c2 cell lysates (TE/L/106 cells). Antioxidant values of cell lysates after 
challenge with 50 mL of AAPH (4 mM) for 10 min and recovery with PBS (control) or chitosan-coated or uncoated 
nutraceutical-loaded nanoemulsions (A) or gallic acid (B) at 25, 50 and 100 μM. * p < 0.001; ** p < 0.05. 
 
Detection of Intracellular Reactive Oxygen Species. 
The H9c2 cell lysate fraction served as a model to measure the antioxidative effect of nutraceutical-
loaded nanocarriers under pro-inflammatory conditions induced by lipopolysaccharides (LPS) and 
doxorubicin (Figure 3.6). As reported elsewhere,37 intracellular ROS production was higher in LPS-
treated H9c2 cells due to the stimulation of the TLR4—NADPH oxidase 1 (NOX1) pathway. 
Treatment of cardiomyoblasts with LPS and doxorubicin increased the antioxidant properties by 50% 
and 55–60%, respectively, versus the control (Figure 3.6A). Incubation with nutraceutical-loaded 
nanocarriers invariably decreased oxidative status at all concentrations tested but not in a statistically 
significant manner at 0.5% oil, compared to untreated cells. Chitosan-coated dryTom-Ne, namely 
dryTom-Ne-CT, had the best antioxidant activity. Indeed, it reduced oxidative stress by 45–50%, 
similar to control cells, and by 45% similar to LPS- and doxorubicin-treated cells. In LPS-treated 
cells, the antioxidant activity of dryTom-Ne was 35% and 25% higher than that of freshTom-Ne and 
curc-Ne, respectively (p < 0.001). As shown in Figure 3.6B,D, Gallic acid used as positive control, 
had antioxidant effects both in LPS (Figure 3.6B) and Doxorubicin (Figure 3.6D) treated cells with a 
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reduction of oxidative stress of around 26% and 21% at 100 μM, respectively, compared to untreated 
cells (p < 0.001 for both). 
 
 
Figure 3.6. Detection of intracellular reactive oxygen species by fluorescence (a.u) in the H9c2 cell line (5000 cells/well). 
Cells were pretreated or not with uncoated and chitosan-coated nutraceutical-loaded nanoemulsions for 4 h before 
stimulation with 40 ng/mL of lipopolysaccharide (LPS) (A) or 50 nM of doxorubicin (C) for 24 h. Gallic acid was also 
exposed to cardiomyoblasts as positive control before stimulation with LPS (B) or doxorubicin (D). * p < 0.001; ** p < 
0.05. 
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Lipid Peroxidation Studies.  
As reported in Figure 3.7, nutraceutical-loaded nanocarriers significantly decreased the production of 
MDA and 4HNA by cardiomyoblasts under pro-inflammatory conditions (LPS) and chemotherapy 
(doxorubicin). Inhibition of lipid peroxidation is a cardioprotective strategy used to increase vascular 
and cardiac cell viability during anthracycline therapies. Specifically, curcumin-loaded nanocarriers, 
chitosan coated, at 5% oil reduced the formation of MDA and 4HNA by 31%and 23%, respectively 
versus LPS-treated cells (p < 0.001); dryTom-Ne had better lipid-antioxidant properties than the other 
nutraceuticals with reductions (at 5% oil) of MDA and 4HNA of 37.5% and 57%, respectively versus 
LPS-treated cells (p < 0.001). The same applies to doxorubicin-treated cells, which indicates that the 
same mechanism of action counteracts lipid peroxidation synthesis in the two nutraceuticals. As 
positive control, we analyzed effects of gallic acid as common antioxidant at the same conditions 
tested with nanoemulsions and, as reported in Figure 3.7E–H, at 100 μM, it reduced MDA and 4HNA 
production of around 26% and 21% in LPS treated cells and of 20% and 28%, respectively, in 
doxorubicin treated cells. However, based on all results obtained, chitosan-coated lycopene-enriched 
nutraceuticals, namely dryTom-Ne-CT, had the best biological properties of all the nutraceuticals 
evaluated thereby corroborating the results of the cell viability, antioxidant and cellular uptake 
studies. 
 
Measurement of Nitric Oxide. 
Nitric oxide initiates lipid peroxidation and, by interacting with superoxide anion, produces 
peroxynitrite which is implicated in atherosclerosis.38 Peroxynitrites trigger lipid peroxidation, 
protein oxidation, nitration and activation of matrix metalloproteinases.39 Under pro-inflammatory 
conditions and chemotherapy, cardiomyoblasts can produce NO. As shown in Figure 3.8A,B, H9c2 
cells increase NO production under pro-inflammatory conditions and chemotherapy. Treatment with 
nutraceutical-loaded nanocarriers significantly inhibited NO production at all tested concentrations 
with inhibition percentages reaching 93% (very near to baseline concentrations) in the case of curc-
Ne-CT and dryTom-Ne-CT at the maximum tested concentration (5% of oil). As shown in Figure 
3.8, there was no significant difference between curcumin-loaded and high lycopene concentration 
nanoemulsions, for both uncoated and chitosan coated nanoemulsions, which suggests that the same 
mechanism of action underlies the NO inhibition of these bioactives. Also, in this experiment, the 
chitosan-coated nanoemulsions were more effective than the uncoated ones. As positive control, 
gallic acid at the maximum concentration tested (100 μM) inhibit of around 33 and 42% NO 
production under LPS and Doxorubicin exposure, respectively, compared to unpretreated cells. 
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Calcium Levels. 
To determine the intracellular calcium level in cardiomyoblasts during LPS or doxorubicin treatments 
and the biological effects of nutraceuticals-loaded nanoemulsions, we used the fluorescence probe 
Fluo-3 AM as reported elsewhere,40 LPS and DOXO treatment dramatically increased intracellular 
calcium levels in cardiomyoblasts compared to control cells (p < 0.001) for both. DryTom-Ne-CT 
treatment dose-dependently attenuated the overload of intracellular calcium in cardiomyoblastsas 
witnessed by the reduced fluorescence intensities of 8%, 19% and 55.6% at 0.5%, 1% and 5% (p < 
0.001) compared to cells treated with LPS alone (Figure 3.9A). Similar behavior was seen for DOXO 
exposed cardiomyoblasts; specifically, dryTom-Ne-CT decreased calcium overload in H9c2 cells of 
0.6%, 17% and 52% at 0.5%, 1% and 5% (p < 0.001) compared to only DOXO treated cells (Figure 
3.9B). These results suggested that nutraceuticals-loaded nanoemulsions were able to reduce the 
overload of intracellular calcium in H9c2 cells induced by LPS and DOXO treatments. 
 
Anti-Inflammatory Studies. 
Given the anti-inflammatory activity of nutraceuticals, we investigated how nutraceuticals affect      
IL-8, IL-6, IL-1β, IL-10 and TNF-α production in cardiomyoblasts under pro-inflammatory 
conditions. As shown Figure 8, LPS at a dose of 40 ng/mL significantly stimulated the production of 
all interleukins analyzed versus untreated cells due to their binding with Toll Like Receptor type 4 
(TLR4) expressed on the membrane of cardiomyoblasts leads to up-regulation of interleukins mRNA 
expression and their secretion. Pretreatment with all nutraceutical-loaded nanocarriers significantly 
decreased the level of all molecules analyzed (Figure 3.10). Specifically, dryTom-Ne-CTat 5% oil 
decreased the levels of IL-8, IL-6, IL1β and TNFα, by 58%, 64%, 67% and 65% respectively, versus 
LPS-treated cardiomyoblasts (p < 0.001). These effects are very similar to those observed for 
curcumin-loaded nanoemulsions (chitosan coated) thereby indicating very strong anti-inflammatory 
effects. Lastly, IL-10, dryTom-Ne and curc-Ne stimulated the release of IL-10 from cells under pro-
inflammatory conditions. 
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Figure 3.7. Cellular quantification of malondialdehyde (MDA) and 4HNA production under pro-inflammatory conditions 
and doxorubicin exposure. MDA and 4HNA (nmol/mL) production by cardiomyoblasts treated with LPS (A,B) and 
doxorubicin (C,D) alone or combined with uncoated or chitosan-coated nutraceutical-loaded nanocarriers at 
concentrations ranging from 0.5 to 5% oil. At the same condition, as positive control, we tested also the effects of gallic 
acid at 25, 50 and 100 μM (E,F) for LPS treatments; (G,H) for doxorubicin treatments). * p < 0.001; ** p < 0.05; ns: not 
significant. 
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Figure 3.8. Measurement of nitric oxide (NO) production expressed as nitric oxide concentration (μM) in H9c2 cells 
(5000 cells/well). Cells were pretreated or not with uncoated and chitosan-coated nutraceutical-loaded nanoemulsions at 
0.5%, 1% and 5% of oil 4 h before stimulation with 40 ng/mL of LPS (A) or 50 nM of DOXO, (B) for 24 h. Pretreatments 
were also performed by incubating cells with gallic acid, as positive control, for both LPS (C) and DOXO (D) treatments.  
* p < 0.001; ** p < 0.05; ns: not significant. 
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Figure 3.9. Intracellular calcium fluorescence staining in H9c2 cells (expressed as fluorescence intensity a.u). Cells were 
pretreated or not with uncoated and chitosan-coated nutraceutical-loaded nanoemulsions at 0.5%, 1% and 5% of oil for 
4h before stimulation with 40 ng/mL of LPS (A) or 50 nM of DOXO, (B) for 24 h. * p < 0.001; ** p < 0.05; ns: not 
significant. 
 
 
 
Figure 3.10. Anti-inflammatory effects of nutraceutical-loaded nanoemulsionson IL-8 (A), IL-6 (B), IL-1β (C), TNF-α 
(D) and IL-10 (E) production of cardiomyoblasts (at a density of 1.2 x 105 cells/well). Cells were treated or not with 0.1 
mL of a 0.5%, 1% and 5% of oil of chitosan-coated and uncoated nanoemulsions for 5 h before exposure to 
lipopolysaccharides (40 ng/mL) for 12 h. * p < 0.001, ** p < 0.05; ns: not significant. 
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3.4 Discussion 
Anthracyclines are powerful drugs used to treat a multitude of neoplasms; however, cardiotoxicity, 
which generally results from ROS overproduction, lipid peroxidation and mitochondrial damage, 
compromises their clinical applications. The heart and vascular microenvironments play key 
pathological roles in the etiology of cardiovascular disease related to some anticancer drugs and to 
radiotherapy. These recent observations are of extreme interest in cardioncology because several 
interleukins, cytokines, growth factors and hormones are crucial for cardiomyocyte survival. 
Specifically, IL-6 is a cytokine derived from T lymphocytes, macrophages and adipocytes, and acts 
via its membrane-bound or soluble receptor, stimulating C-reactive protein, fibrinogen hepatic 
synthesis, and joint inflammation and accelerating atherosclerosis processes. High IL-6 
concentrations have been associated with an increased relative risk of myocardial infarction in healthy 
men. Moreover, IL-6 and its receptor levels have an early peak in the acute phase of myocardial 
infarction, probably due to plaque instability.41 Moreover, recent clinical evidence supports the 
potential role of IL-8 in atherosclerosis, both as a marker or as a potential therapeutic target. In the 
field of interventional cardiology, it was suggested that increased serum levels of IL-8 after 
percutaneous coronary intervention could predict the development of heart failure in patients with 
acute myocardial infarction.42 Another interleukin of interest in cardioncology is Interleukin-1 (IL-1) 
that plays an important role in the development and progression of coronary atherosclerosis and 
congestive heart failure. Moreover, IL-1 receptor antagonists exerted cardioprotective effects in rat 
myocardial ischemia-reperfusion injury and mouse viral myocarditis. Interestingly, doxorubicin 
treatment leads to overproduction of IL-1β in cardiac tissue, which suggests that this interleukin is 
involved in doxorubicin-related cardiotoxicity and apoptosis induction also by overloading calcium 
in cardiac cells. Moreover, IL-1 in association with nitric oxide (in the field of the NO-IL1β axis) can 
induce neonatal cardiac myocyte apoptosis even at very low concentrations.43 
Under pro-inflammatory conditions such as LPS exposure, fibroblasts, monocytes, macrophages and 
cardiomyocytes secrete TNF-α.44 Toll-like receptor 4 (TLR4), which is the main target of LPS, is 
expressed throughout the body including cardiomyocytes, and it is involved in the etiology of several 
cardiovascular diseases; for example, cardiac dysfunctions were frequently observed in patients with 
sepsis and also in animals injected with LPS.45 These findings suggest that, the heart 
microenvironment, seen as the inflammation-interleukin-NO-ROS axis, could play a key role in the 
pathogenesis of cardiotoxicity. Consequently, new cardioprotective strategies that act on this network 
could optimize heart protection in patients undergoing cancer treatments. Nutraceuticals are natural 
bioactives that exert anti-inflammatory activities. Lycopene is a promising cardioprotective anti-
inflammatory molecule that acts on the AMPK-mTOR pathway and exerts anti-atherosclerosis and 
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anti-myocarditis effects.46 Lycopene, a naturally occurring hydrocarbon carotenoid found in red food 
such as tomatoes, pink guavas and watermelons has attracted considerable clinical attention as a 
potential chemopreventive agent against cardiovascular disease.47 Interestingly, lycopene regulates 
Mg2+-ATPase and maintains the Mg2+ balance during some anticancer therapies.48 In addition, 
lycopene exerted heart-protective effects and improved cardiac function in preclinical models.49 
Curcumin suppresses the inflammatory cytokines IL-1,-1β, -6, and -8, TNF-α, and COX-2.16 It was 
recently demonstrated that curcumin decreased several markers of doxorubicin-related cardiotoxicity 
in preclinical models, however its biological activities are limited by its reduced bioavailability.12 
Consequently, new formulations are required to optimize bioavailability of cardioprotective 
nutraceuticals during doxoribincin treatment. Biodegradable nanocarriers are promising 
pharmacological tools to increase in vivo accumulation of drugs and/or chemo-sensitizing agents in 
cancer therapy both by oral or by intravenous injection as we have recently shown with similar 
nanocarriers.16,23 
Here we show that the nanoemulsions loaded with both curcumin and lycopene (derived from fresh 
or dry tomato extract) exert multiple molecular mechanisms of cardioprotection during doxorubicin 
treatment. The anti-inflammatory activities of the nanocarriers described herein hold potential in 
terms of modulating the heart microenvironment thereby providing insights for further preclinical 
studies, also in combination with other cardiotoxic anticancer drugs, namely anti-VEGF therapy and 
immunotherapies. Such studies could be valuable especially given the crucial role of interleukins in 
the pathogenesis of cardiac toxicity.  
The results of this study demonstrate the cardioprotective effects of nanoemulsions loaded with 
nutraceuticals with abilities of cellular internalization with actin and ATP-dependent mechanism of 
uptake. However, we recognize that one limitation of our study is the use of only one type of 
cardiomyocyte and further investigations are required to explore the biological effects of 
nutraceutical-loaded nanoemulsions also in endothelial cells as well as in the co-culture of endothelial 
and adult cardiomyocytes. Preclinical studies are currently underway in our group to evaluate 
modification of left ventricular ejection fraction and factional shortening upon administration of 
nanocarriers during doxorubicin treatment, by using conventional murine models of cardiotoxicity 
often used by our research group.50 
 
3.5 Conclusions 
Doxorubicin-induced cardiotoxicity remains a major concern for patients receiving chemotherapy. 
There is great interest in identifying compounds and developing drugs aimed at reducing oxidative 
stress and lipid peroxidation as well as inhibiting the secretion of interleukin from cardiac cells. This 
85 
 
study shows that nutraceutical-loaded nanocarriers exert cardioprotective effects. Of particular 
translational interest are their effects on interleukins especially on IL1-β, considering its prognostic 
role in cardiology and its correlation with an increased relative risk of cardiovascular disease.48 
Nutraceuticals loaded in nanocarriers could be considered an emerging strategy with which to elicit 
cardioprotection from chemotherapies. 
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Abstract 
Oil-in-water emulsions represent a promising carrier for in vivo imaging because of the possibility to 
convey poorly water-soluble species. To promote accumulation at the tumor site and prolong 
circulation time, reduction of carrier size and surface PEGylation play a fundamental role. In this 
work a novel, simple method to design an oil-core/PEG-shell nanocarrier is reported. A PEG-shell is 
grown around a monodisperse oil-in-water nano-emulsion with a one-pot method, using the radical 
polymerization of poly(ethylene glycol)diacrylate. PEG polymerization was triggered by UV, thus 
obtaining a PEG-shell with tunable thickness. This core-shell nano-system combines the eluding 
feature of the PEG with the ability to confine and preserve high payloads of lipophilic species in the 
oil core. Indeed, the core was successfully loaded with a lipophilic contrast agent, namely super 
paramagnetic iron oxide nano-cubes. Interestingly, it was demonstrated an in vitro and an in vivo 
MRI response of the nanocapsules. Additionally, when the nano-system loaded with nanocubes was 
mixed with a fluorescent contrast agent, Indo-cyanine green, a synergic photo-acoustic effect was 
observed. Moreover, viability and cellular uptake studies showed no significant cell cytotoxicity. 
These results, together with the choice of low cost materials and the scale up production, make this 
nanocarrier a potential platform for in vivo imaging. 
 
4.1 Introduction 
Nanoparticles (NPs), with dimensions below 100 nm1 and in contrast to macroscopic materials, have 
a high ratio of surface to volume and the way in which they interact with matter is unique. As 
consequence, several nanoparticle formulations have found remarkable applications in biophysical 
studies, biological sensing, imaging, medical diagnostic, and cancer therapy.2 NPs have high payload 
efficiency, stability, and signal enhancement. Moreover, due to their dimensions – larger than 
molecules and smaller than cells and tissues – they possess advantageous features compared to other 
therapies and imaging agents. For example, NPs show an enhanced permeability to cancer tissue than 
in healthy tissue, since they exploit the difference in capillary structure between these tissues.3   
Despite these advantages, their application may be limited by their inadequate clearance 
characteristics. Indeed, small NPs can be rapidly removed by the vascular system, while large NPs 
can accumulate and be retained in the body for long time, also thanks to their high stability.4,5 
Recently, we proposed the use of nano-emulsions as a vehicle for magnetic cobalt-ferrite NPs as 
imaging contrast agents.6 The nano-emulsions developed by us possess some pharmaceutical and 
clinical advantages, such as easy of manufacture, scalable production, good biocompatibility, 
biodegradability, reasonable stability and the possibility to incorporate hydrophobic drugs and 
inorganic NPs.7,8  
91 
 
In general, the ability to extend the circulation times in blood depends largely on the carrier size and 
the physicochemical properties of the surface.9 Modifying the surface with a hydrophilic polymer 
such as poly(ethylene glycol) (PEG) is widely used - as a strategy to alter protein absorption and 
prolong circulation time with consequent enhanced accumulation at the tumor site.10 The mechanisms 
of preventing opsonization by PEG – and subsequent excretion by reticuloendothelial system (RES) 
– include the shielding of the surface, the increased surface hydrophilicity and the enhanced repulsive 
interaction between polymer-coated nanocarriers and blood component.11 More recently, Schöttler et 
al.12 demonstrated that, in addition to reducing protein adsorption, PEG – and poly(ethyl ethylene 
phosphate) (PEEP) – can modify the composition of proteins that surround nano-particles (protein 
corona), and the presence of specific proteins is required to prevent non-specific cellular uptake. As 
a protecting polymer, PEG provides a very attractive combination of properties: excellent solubility 
in aqueous solutions, high flexibility of its polymer chain, very low toxicity, immunogenicity, and 
antigenicity, lack of accumulation in the RES cells, minimum influence on specific biological 
properties of modified pharmaceuticals.11,13  
In light of these observations, in this work we propose a novel synthetic strategy to prepare oil core 
– PEG shell nanocarriers (PEG-NE). Compared to other procedures widely proposed,14-18 our strategy 
results simple to be performed and low cost. It consists of a photo-activated radical polymerization 
of poly(ethylene glycol) diacrylate (PEGDA), directly performed on the oil-water interface. The PEG 
shell was functionalized with a methacrylate dye (Rhodamine B), thus demonstrating that the outer 
surface can be further modified to accomplish to other functions such as optical imaging. 
Furthermore, the oil core - of 100 nm - was loaded with cubic iron oxide nanoparticles (IONC, 14 
nm). Compared with cubic cobalt ferrite nanocubes,19 used in a previous work, IONCs have higher 
biocompatibility and also result exploitable for both magnetic resonance imaging (MRI) and photo-
acoustic imaging (PAI). In vitro PA tests, cell viability and uptake studies were also performed to 
evaluate the biocompatibility and the potentiality of this PEG-NE as diagnostic tool for imaging. 
 
4.2 Results and Discussion 
Nanocarrier design and physico-chemical characterization.  
The presented nanocarrier is a core-shell system consisting of an oil-core and a PEG-shell. We chose 
a monodisperse oil-in-water (O/W) emulsion as the morphology-casting template to obtain the final 
nano-capsules. We used highly monodisperse O/W nano-emulsions with droplet size of around 90–
110 nm, a polydispersity index (PDI) <0.1 and a ζ-potential <−30 mV, as measured by DLS. The size 
of the starting nano-emulsion is crucial since the final capsule should be small enough to pass through 
the human capillaries and, in particular, to exploit the difference in capillary structure between healthy 
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and tumor tissues (EPR effect). This difference allows to discriminate against healthy and tumor 
tissues with a favourable drug accumulation at the tumor site – thus obtaining the passive targeting.3,20  
To provide a PEGylated shell a simple, one-pot synthesis has been designed. This strategy relies on 
a different approach with respect to the ones proposed in literature to obtain PEGylated nano-
emulsions.14 PEGylation typically involves chemical attachment of PEG chains onto individual lipid 
monomers which are subsequently incorporated into the carrier systems.15 The resulting PEGylated 
lipid based nano-system has a hydrophobic lipid structure camouflaged by an outer PEG region. The 
most common strategy to cover the surface with PEG is to use a PEG-modified surfactant. 
Distearoylphosphatidylethanolamine (DSPE)-PEG, at defined PEG chain lengths and structure, have 
been used to prepare and investigate PEG-coated nano-emulsions;16,17 and modified DSPE-PEGs 
have also been used to further functionalize the outer surface for active targeting.18 However, this 
approach is not fully convincing because of the use of such PEG-surfactant species that are costly – 
even more if they are designed to add target moieties – and because the coverage of PEG layer on 
particle surface is very critical: the length of the PEG chains, the PEG amount and the overall surface 
composition must be finely balanced to obtain suitable PEG coated nano-emulsions.17  
Conversely, in our procedure a photo-activated polymerization is performed directly at the oil-water 
interface of the nano-emulsion to create a solid PEG shell. The sequence of mixing of the reactants 
and the intervals between each step have been set to obtain with any certainty the shell around the 
oil-core. Indeed, as depicted in Figure 4.1, a saturated water solution of Darocur 1173 is firstly added 
to the nano-emulsions suspension to allow the absorption of the photoinitiator on the oil surface. In 
this way, it is possible to guide the following PEG polymerization selectively at the oil-water 
interface. Darocur 1173 is a hydroxyphenilketone used to generate free radical species.  
 
 
Figure 4.1. Schematic synthesis protocol of a core/shell type nanocarrier with a lipophilic core and a PEGylated shell. 
The photoinitiator, adsorbed on the oil nano-emulsion at the interface with water, allows to activate and guide the shell 
growth on the oil template. 
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The UV photo-cleavage of this molecule generates a benzoyl radical and a α-hydroxyalkyl radical, 
both of which are able to react with the acrylate double bond (Figure 4.2A).21 The addition of the 
photoinitiator solution to the O/W nanoemulsion, together with the following addition of the water 
solution of PEGDA700, does not affect the size distribution of the nano-emulsion, as verified through 
DLS measurements (see Supporting Information, Tables S1). Once added photoinitiator and 
monomer, the radical polymerization (Figure 4.2B) was triggered with a UV irradiation (365 nm, 20 
minutes).  
 
 
Figure 4.2. A) Photocleavage of hydroxyphenylketone with the production of two radical species, a benzoyl radical and 
a α-hydroxyalkyl radical; B) the free radical obtained from the cleavage of the photoinitiator initiate the polymerization 
of PEGDA forming a polymer network. 
 
The irradiation does not determine any immediate increase in the particle size, but it starts the 
polymerization. In fact, by following the evolution of the size with the time, it is noteworthy that the 
size increases gradually (Figure 4.3), suggesting that the polymerization goes on until all the 
monomers of PEGDA in solution are consumed. A fine tuning of the shell thickness is obtained, as 
confirmed by the following observations. Firstly, the increase of the particle size has been tracked for 
several days and it can be noticed that size increases up to a plateau, but PDI is still rather below a 
value of 0.1. In a second test, we followed the same protocol but taking care to avoid any interaction 
of the system with the ambient light: once the UV irradiation has been performed no increase of the 
particle size is detected (see Figure S1 in the Supporting Information). In another case the 
polymerization is stopped by dialyzing the sample and, again, no increase of the particle size is 
detected (see Figure S1 in the Supporting Information). We decided to use the dialysis as a 
purification step of the standard procedure since it enables to stop the polymerization at the desired 
shell thickness and to remove the excess of unreacted species, which can have toxic effects. Of course, 
an alternative procedure with a prolonged use of the UV irradiation could have been designed – thus 
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obtaining the same shell growth in a shorter time – but such an intensive irradiation may affect the 
food grade materials of the oil-core22 and especially it can lead to the degradation of light sensitive 
molecules.23 In the proposed procedure the polymerization is stopped before the size growth reaches 
the plateau, as smaller PEG-nanoparticles begin to form spontaneously (see Figure 4.4D and 
Supporting Information, Figures S4). 
 
 
Figure 4.3. Particle size growth as function of the time. Error bars are derived from standard deviation over 3 sample 
preparations. 
 
PEG-NE were further characterized by Electron and Confocal Microscopy. In particular, the 
morphological analysis was performed using TEM. For PEG-NE with only 1 day of reaction time, 
the shell was very thin and the only way to obtain micrographs was by Cryo-TEM. However, the 
observation was rather difficult as the nano-capsules are composed of low-contrast materials and, as 
shown in Figure 4.4A, the micrograph of PEG-NE with 1-day reaction time displayed the presence 
of a nanocarrier with narrow distribution but a core-shell system was not yet appreciable. Instead, for 
sample obtained after a longer reaction time, traditional TEM could be carried out and an OsO4 
staining could be performed obtaining a better image contrast. The Figure 4.4B depicts a TEM image 
of PEG-NE after 5 days of reaction time. The aggregation is only due to the drying process, as 
confirmed from cryo-TEM analysis (Figure 4.4A and C). Finally, for very long reaction times, like 
30 days, the shell structure could be clearly seen by traditional TEM and a mutation from a smoother 
to a fuzzy surface can be appreciate (Figure 4.4D and Inlet).   
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Figure 4.4. Micrographs of PEG-NE at different reaction times: A) Cryo-TEM micrograph after one day of 
polymerization; B) TEM micrograph after 5 days of polymerization, sample stained with OsO4 vapours; C) Cryo-TEM 
micrograph after 5 days of polymerization; D) TEM micrograph after 30 days of polymerization, sample stained with 
OsO4 vapours. In the inlet of Figure D, it can be better appreciated the irregular surface of the shell after long shell 
growth. Images and inlet scale bars are 200 nm and 50 nm, respectively. 
 
For fluorescent analysis both the core and the shell of PEG-NE were marked with a fluorescent dye. 
In detail, the inner oil-core was loaded with FITC (Supporting Information, Figure S5). As described 
in previous works, the liquid template can encapsulate dyes (e.g. nile red24 and fluorescein7) or 
contrast agents (e.g. iron oxide NPs and CdSe QDs24,25), thus suggesting a possible multi-imaging of 
the final nanocarrier. On the other side, the outer shell was conjugated with Rhodamine B (Figure 
4.5) by simply adding a methacrylate derivative of the dye during the shell growth. The shell 
modification did not bring any noticeable change in size or aggregation (see Supporting Information, 
Table S2) showing further possibility to add a contrasting functionality to the system. Moreover, this 
approach represents a very simple method to functionalize the outer PEGylated surface and, therefore, 
may be further exploited to add bioactive molecules for active targeting.26 
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Figure 4.5. Confocal image of nano-capsules labelled with Rhodamine B on the outer PEGylated shell. Scale bar 5 μm. 
 
Cell viability and cellular uptake studies. 
As clearly shown in Figure 4.6A-D, confocal images depict a time dependent overall uptake of 
fluorescent PEG-NE, obtained by loading FITC in the oil core, in human breast cancer cells with a 
peripheral localization after 0.5 h of incubation and a more central accumulation after 24 h (Figure 
4.6, D). Therefore, in summary, PEG-NE seems to localize mainly on the cell membrane and in the 
juxtamembrane region (Figure 4.6A and 4.6B) at short time of incubation. A quantitative uptake of 
the fluorescent PEG-NEs was performed by fluorescence analysis. As reported in Figure 4.6E, a great 
cellular accumulation of the proposed nanocarrier can be noticed.  
To understand how the proposed nanocapsules can have an impact on the biocompatibility of the 
resulting nano-system, PEG-NE@IONC (i.e. PEG-NE loaded with IONC) were tested in terms of 
cytotoxicity on human breast cancer cells. As shown in Figure 4.7, even after 24 h of contact with 
cells, the PEG-NE@IONC did not show any significant decrease in cell viability.  
Additionally, cellular uptake studies of PEG-NE@IONC, (see Figure S4 C and D for TEM 
characterization) were also performed to qualitatively asses the presence of the iron. In more detail, 
intracellular iron was detected by means of Prussian blue staining, while cells nuclei were 
counterstained using Nuclear Fast Red. As can be seen in Figure 4.8, blue spots were observed in the 
majority of cells and seemed to be localized around the cell membrane and throughout the cytoplasm, 
indicating a significant cellular uptake of the IONCs. We did not observe any blue staining of the 
control cells (image not shown).  All these considerations remark the ability of this PEG-NE as a 
potential bio-safe nanocarrier for cancer imaging.  
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Figure 4.6. Cellular images by Confocal Laser Scanning Microscope of MCF-7 cells (5000 cells/well) after 0.5 h (A), 4 
h (B), 8 h (C) and 24 h (D) of incubation with fluorescent PEG-NE at 0.05% of oil. Green signal: fluorescent PEG-NE; 
Red signal: cellular membrane labelled with concanavalin A tetramethylrhodamine conjugate; Blue signal: nucleus 
labelled with TO-PRO 3 Iodide. Scale bar: 50 µm. E) Overall cellular uptake quantification of MCF-7 cells (5x103 
cells/well) from 0.5 up to 24 h of contact with fluorescent PEG-NE at 0.05 % of oil. 
 
 
 
Figure 4.7. MCF-7 cell viability (± SEM) performed by modified MTT method as in function of the time (from 2 up to 
24h of incubation time) and concentration of PEG-NE@IONC (from 0.001 up to 0.05 % of oil). 
  
98 
 
                     
Figure 4.8. Prussian blue staining of MCF-7 cells after 30 min (A), 4 h (B), 8 h (C) and 24 h (D) of exposure to PEG-
NE@IONC. Scale bar 100 μm. 
 
Photo-acoustic and MRI analysis. 
Photoacoustic imaging is a new diagnostic tool with non-invasive and non-ionizing properties which 
provides high sensitivity, and excellent resolution typical of acoustic methods.27 It is based on the 
generation of acoustic waves by the absorption of electromagnetic energy, thus overcoming the 
limited spatial resolution of the conventional optical imaging of soft tissues.28 To accentuate the 
image contrast, a contrast agent material (with an organic or inorganic nature) can be administered to 
a patient. Herein, we used oil nanodroplets to convey lipophilic inorganic nanoparticles acting as 
contrast agents and a PEG shell for its antifouling properties.  
In vitro tests were performed to determine the variation of the intensity values of the photo-acoustic 
signal as a function of the excitation wavelengths of the laser beam (Figure 4.9). Each trend of the 
curves was calculated according to the ROI outlined in the area of analysis and by identifying the 
region where the photo-acoustic signal was significant and perceivable. Each curve is expressed as 
the average of five measurements, performed at different points of the sample tube. For all curves, 
the standard error of the mean (SEM), expressed as a percentage, ranged from 8% to 10%. The results 
evidence that the stock PEG-NE@IONC and the corresponding samples diluted in PBS showed a 
good photo-acoustic signal intensity, as expected (Figure S6, Supporting Information). On the 
contrary, the photoacoustic signal of the sample resulted to be sensibly attenuated after dilution with 
the blood (Figure 4.9A). To confirm this, it is possible to use the Spectragryph 1.1 software to make 
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a spectral addition of different components, thus predicting and taking into account the effect of blood 
dilution (Figure 4.9B). These results seem to prevent a photoacoustic application of pristine PEG-
NE@IONC since the signal derived from IONC should not be detectable at the concentration used 
for the experiments. However, by adding a fluorescent contrast agent, namely the ICG, at a 
concentration which is not detectable alone, we observed an interesting synergic effect. In fact, as 
shown in Figure 4.9A and B, we observed an increase in the photo-acoustic intensity above the blood 
spectrum (both for OXY and DEOXY components), especially in the high frequency of range from 
680 to 760 nm, which cannot be merely attributed to the sum of the contributions from PEG-
NE@IONC and ICG.  
 
 
Figure 4.9. PA in vitro study of PEG-NE@IONC. A) PA average intensity as a function of the wavelength for blood (red 
line), PEG-NE@IONC+blood (blue line), ICG+blood (violet line) and PEG-NE@IONC+ICG+blood (green line). B) 
Combined spectral analysis: PA spectra obtained by ICG plus PEG-NE@IONC (cyan line) – its trend is comparable with 
PEG-NE@IONC+ICG+blood in the spectrum (A). SEM = 9.5%, n = 5.  Additional spectra are calculated with 
SpectraGryph software. 
 
This synergic behaviour may be due to an accumulation of ICG onto the surface of the PEG-
NE@IONC that enhances the ICG response, as it was also reported in the case of single walled carbon 
nanotubes.29. No variation of the in vitro detected signal was registered upon multiple stimulation 
cycles confirming the stability of the proposed nano-system combined with ICG (data not shown).  
Additionally, PEG-NE@IONC showed a relevant magnetic response thus confirming a possible dual 
imaging, Figure 4.10. In particular, water solutions of PEG coated nanoemulsion doped with iron 
oxide nanocubes were diluted in a range of concentration from 0.039 mM to 0.00162 mM in Fe. The 
highest concentration of 0.039 mM was obtained by concentrating three times the initial solution of 
PEG coated nanoemulsion, on a permanent neodymium magnet with an overnight exposure.  
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Figure 4.10. Inverse relaxation time T2, as a function of different Fe concentrations containing in PEG-NCs and under 
different magnetic field. 
 
The solution of PEG coated nano-emulsion, not doped with magnetic nanocubes (as control), was 
diluted using the same dilution factor of the nanocubes containing solution. The longitudinal (T1) and 
transverse (T2) relaxation times were measured at 40 °C using a Minispec spectrometer (Bruker, 
Germany) mq 20 (0.5 T), mq 40 (1 T) and mq 60 (1.5 T). T2 relaxation time was measured using a 
Carr–Purcell Meiboom Gill (CPMG) spin–echo pulse sequence with 5000 data points with inter echo 
time of 0.5 ms. The relaxivities r2 was determined by the following equation:  
 
1
𝑇2
=  
1
𝑇2 (𝐻2𝑂)
+ 𝑟2 𝐶𝐹𝑒 
 
where CFe is the concentration of Fe, T2(H2O) the relaxation time of pure water and T2 the measured 
value of relaxation time of the solution. Data are reported in Fig. 4.10. The slope of the best fitting 
straight lines represents the transversal relaxivity r2 of PEG coated nanoemulsion doped with iron 
oxide nanocubes at the different magnetic fields. The values of r2 are comparable to those reported 
for other iron-oxide based contrast agents.30 For control, transversal relaxation times have been also 
measured for the PEG coated nanoemulsion not doped with magnetic nanocubes. As expected, 
undoped nanoemulsions did not affected the water relaxation time (data not shown). Finally, within 
the experimental error, no significant change has been detected in the longitudinal relaxation time T1. 
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Consequently, further investigations have been conducted in vivo by performing an in vivo MRI 
detection of PEG-NE@IONC after intratumoral injection.  
Representative coronal T2-weighted images of tumor mass before and after intratumoral injections 
of 200 µL (11% w/v of oil in water emulsion containing iron nanocubes at concentration of ~20 
ng/mL corresponding to ~ 0.4 μmol of Fe) of PEG-NE@IONIC are shown in Figure 4.11. In vivo 
MR images revealed that PEG-NE@IONIC nanoparticles were clearly detectable in the tumor tissue: 
post-contrast MR images showed areas of strong signal drop as expected for a T2 relaxing contrast 
agent. Areas of signal drop were detected in both the subcutaneous region (asterisks in Fig. 4.11, 
frames c, d) and within the tumor tissue (arrows in Fig. 4.11, frames c, d). Histological examination 
of tumor mass confirmed the presence of iron. Prussian Blue staining showed several blue-stained 
areas at the periphery of the tumor tissue (asterisks in Fig. 4.11, frame e) and inside the tissue (arrows 
in Fig. 4.11, frame f) corresponding to the signal drop areas detected in MRI. 
 
 
Figure 4.11. Consecutive T2W MRI slices acquired in vivo before (a-b) and after (c-d) intratumor injection of PEG-
NE@IONIC; the presence of PEG-NE@IONIC is clearly detectable in slices acquired after the injection of the contrast 
agent as hypointense areas (frames c-d, asterisks and arrows). The tumor mass was excised for histological examination 
with Prussian Blue staining; representative histological slices from the excised tumor tissue with Prussian blue stained 
are reported in frames e-f: blue stained areas at tumor periphery (e, asterisk) and inside the tumor tissue (f, arrows) 
confirmed the presence of iron (magnification ×10, scale bar 50 μm).  
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4.3 Conclusions 
Nano-emulsions represent a promising system for drug delivery and diagnostic, because of their 
ability to convey lipophilic compounds. In this work, oil-core/PEG-shell nano-capsules with a narrow 
size distribution have been successfully prepared. The synthetic strategy is based on a one-pot process 
in which a PEG shell is grown directly at the oil nano-droplet interface, exploiting the radical 
polymerization of poly(ethylene glycol) diacrylate. This core-shell nano-system retains an average 
size ranging from 100 to 200 nm, as a result of the polymerization time, but the increase in size does 
not affect the narrow size distribution. Moreover, a lipophilic contrast agent (IONC) has been 
preloaded in the oil core with no effects in the average size. Then, in vitro and in vivo MRI analysis 
have also assessed the possible use of PEG-NE for this kind of imaging. Additionally, thanks to the 
presence of this contrast agent it was demonstrated a relevant in vitro photoacoustic response with a 
synergistic mechanism when combined with a water-soluble contrasting agent, namely ICG. 
Therefore, we believe that PEG-NE represents an innovative, easy, low cost and green nanocarrier 
and that has the potentiality to be used as powerful tool for diagnostic. 
 
4.4 Materials and Methods 
Soy-bean oil (density at 20 °C of 0.922 g mL−1), and Lipoid E80 Lecithin (egg lecithin powder 80–
85% enriched with phosphatidylcholine (PC) and 7–9.5% content in phosphatidylethanolamine (PE) 
as per the manufacturer’s specifications), were both purchased from Lipoid and used without further 
purification. Poly(ethylene glycol) diacrylate (PEGDA, 700 MW) and Fluorescein 5(6)-
isothiocyanate (FITC) were purchased from Sigma Aldrich. Crosslinking reagent Darocur 1173 was 
purchased from Ciba. The dye Methacryloxyethyl thiocarbonyl rhodamine B was obtained from 
Polyscience Inc. Paclitaxel was purchased from Discovery Fine Chemicals Ltd. 
 
Nanocarrier synthesis. Nano-emulsions were prepared through a three-step process, as already 
described.8 Briefly, the initial step involved the preparation of a homogeneous oil phase by simply 
adding a certain amount of surfactant (Lipoid E 80, Lecithin (2.4g)) to a predetermined volume of 
soy-bean oil (20 mL) at 60 °C followed by sonication for a few minutes to homogenize and mix. In 
the second step a pre-emulsion was prepared by a step-by-step addition of the as-prepared oil phase 
to a weighed amount of aqueous phase (Milli-Q water), so as to obtain a final concentration of 20 
wt% in the oil phase. The mixture was thoroughly mixed using an immersion sonicator for a few 
minutes in a beaker. A low temperature was maintained throughout the process by keeping this 
assembly inside a larger beaker containing ice in the form of a continuous ice jacket. Finally, in the 
third step the pre-emulsions were passed at 2000 bar through a high-pressure homogenizer 
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(Microfluidics M110PS) with a combination of individual cycles and continuous steps until minimum 
size and PDI were reached. For dye loading, 5 mL of an ethanol solution (Fluorescein 0.6% w/v in 
ethanol) were added to the oil phase before the pre-emulsion preparation step and the alcoholic 
solvent was evaporated at 60 °C for 30 minutes. Similarly, to prepare PEG-NE@IONC, 0.42 mL of 
IONC suspension in toluene (2.137 g/L of Fe) were added to the oil phase (20 mL) before the pre-
emulsion preparation step and the aromatic solvent was evaporated at 60 °C for 90 minutes. 
PEGylate shell was prepared through a simple procedure (see Figure 4.1). A saturated water solution 
of photoinitiator was prepared by adding 20 μL of Darocur to 1 mL of MilliQ water, mixing 
thoroughly (Vortex) and allowing the phase separation to occur. Equal volumes (500 μL) of 
photoinitiator supernatant solution and O/W nano-emulsion (5 wt%) were mixed (Vortex) and the 
resulting suspension was stored for 15 minutes. A water solution of PEGDA (3% w/v, 500 μL) was 
added to the suspension and mixed thoroughly (Vortex). After further 15 minutes of storage, the final 
suspension was irradiated with an UV source (Blak-Ray® Lamp with an intensity long-wave - 365nm 
– ultraviolet light) for 20 minutes at 5 cm distance. The resulting nano-capsules suspension was stored 
without any shielding for the ambient light. The photo-polymerization proceed till a dialysis against 
water was performed. 
 
Synthesis of cubic iron oxide nanoparticles. Iron oxide nano-cubes (IONC) with edge size length of 
14±2 nm were prepared accordingly to a procedure developed by the authors and previously 
reported.19,31 Briefly, iron (III) acetylacetonate (Acros 99.9%, 0.353 g, 1 mmol) Decanoic Acid 
(Acros, 1.03 g, 6 mmol) Dibenzyl ether (Acros, 15 mL) and Squalane (Alfa Aesar, 10 mL) were 
mixed together in a three-neck flask of 100 mL, equipped with a water cooled Allhin condenser. The 
synthesis was conducted under nitrogen gas. After degassing the mixture at 65 °C for 120 minutes 
(29 x10-3 mbar), the mixture was heated-up from 65 to 200 °C in 40 minutes and kept at this 
temperature for 2.5 hours. The temperature was further increased at 305 °C at a heat rate of 7°C/min 
and maintained at this temperature for 1 hour. After cooling, 10 mL of Chloroform were added to the 
crude of the reaction and the content was transferred in 3 falcon tubes of 50 mL in volume. To each 
falcon, acetone was added to a final volume of 50 mL. The tubes were centrifuged at 4000 rpm for 
20 minutes. The supernatant was replaced with 5 mL chloroform for each falcon tube. After 
sonication, the sample was fully dispersed and the washing step with acetone was repeated two more 
time. As last step, the sample was re-dispersed in 10 mL toluene, ready to be used. 
 
Particle Size and ζ-Potential measurements. Suspensions were characterized using a laser dynamic 
light scattering (DLS) instrument (Zetasizer zs nano series ZEN 3600, Malvern Instruments Ltd., 
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Malvern, U.K., λ = 632.8 nm). All the samples were diluted up to a droplet concentration of 
approximately 0.025 wt% by using Milli-Q water. A detecting angle of 173° was used. A default 
refractive index ratio (1.5900) and 5 runs for each measurement (1 run lasting 100 s) were used in the 
calculations of the particle size distribution. ζ -potential analysis was carried out by setting 50 runs 
for each measurement. 
 
Electron microscopy characterizations. Samples for TEM characterization were previously exposed 
for not less than 4 h to the vapour of an OsO4 solution (1% w/v in water) as an oil core dopant that 
enhances the contrast of the images and confers robustness to the nano-capsules. About 5 μL of the 
sample was spread on a 200-mesh copper grid with carbon membrane (TED Pella, USA). After 
carefully removing the excess of solution the grids were left to dry overnight.  
Frozen hydrated samples for Cryo-TEM characterizations were prepared by applying a 3 µL aliquot 
to a 200-mesh holey carbon grids (Ted Pella, USA). Each grid was blotted for 1.5 s in a chamber at 
4 °C and 90% humidity using a FEI Vitrobot Mark IV (FEI company, the Netherlands) and then 
immersed into nitrogen cooled liquid ethane. The particles were imaged using a Tecnai G2 F20 
transmission electron microscope (FEI company, the Netherland) and recorded at low dose with a       
2 k × 2 k Ultrascan (Gatan, USA) CCD camera TEM and Cryo-TEM images were obtained using a 
TECNAI 20 G2: FEI Company (CRYO-TEM-TOMOGRAPHY, Eindhoven) equipped with a 
Schottky field emission gun operating at an acceleration voltage of 200 kV. TEM image were recorder 
with a camera Eagle 2HS; Cryo-TEM images were recorded with a Ultrascan (Gatan, USA) CCD 
camera; camera exposure time: 1 s; size 2048 × 2048. 
 
Confocal and STED Microscopy. For Confocal Laser Scanning Microscope studies we followed the 
same procedure followed by our research work7  MCF-7 cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (Gibco) containing 10% v/v FBS, 1% v/v Pen-Strep at 37 °C in a humidified 5% 
CO2 atmosphere. After, 5x10
3 cells/well were seeded in a 24-well plate and allowed to grow for          
24 h. For imaging studies, the medium was then replaced with fluorescent PEG-NE (at 0.05 % of oil) 
suspension in culture medium and incubated for 0.5, 4h, 8h and 24 h. After incubation time, cancer 
cells were thoroughly rinsed three times with PBS and fixed with a 2.5% glutaraldehyde in PBS for 
20 min. Membrane staining was obtained by using Concanavalin A Tetramethylrhodamine Conjugate 
(Invitrogen, Life Technology) at a final concentration of 100 μg/mL. After washing in PBS, cells 
were blocked with 1% BSA in PBS for 20 min and washed three times with PBS. Using a Confocal 
Microscope (C1 Nikon) equipped with a EZ-C1 Software for data acquisition and 60x or 100x oil 
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immersion objective, the fluorescent PEG-NE was imaged through excitation/emission at 492/518 
nm for, and the cell membrane with excitation/emission at 555/580 nm. 
For STED/confocal analysis of fluorescent PEG-NE, a FC3510 dish was first washed with ethanol 
and dried. Then 200 μL of an aqueous solution of Poly-L-lysine (0.1 wt%, from Sigma Aldrich) were 
added in order to positively charge the dish surface. After 10 minutes, the dish was washed replacing 
the poly-lysine solution twice with 120 μL of water and then 120 μL of the sample (diluted 1:20 with 
water) were poured onto it. The excess of PEG-NE that not adhere to the glass surface was washed 
out replacing the solution twice with 120 μL of water and in the end with 120 μL of 5% (w/v) DABCO 
antifade solution (from Sigma Aldrich), taking care to left the central part of the dish always full of 
water. DABCO antifade was needed to reduce the bleaching effects on the dyes. Laser sources of 488 
and 543 nm were used to excite the oil core with FITC from one side and PEG-shell with rhodamine 
B from the other side. The samples were imaged with a Leica TCS STED-CW microscope (Leica-
Microsystems, Mannheim, Germany). 
 
In Vitro cytotoxicity tests. Cytotoxicity of nanoemulsions was evaluated on hormone dependent 
human breast cancer cell line MCF-7 looking at their mitochondrial dehydrogenase activity by means 
of a modified MTT [3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyltetrazolium bromide] method 
according to the manufacturer’s instructions (Dojindo Molecular Technologies Inc., Rockville, MD). 
Breast cancer cells were seeded in 96-well plates at a density of 10000 cells per well in Dulbecco’s 
Modified Eagle’s Medium (Gibco) containing 10% v/v FBS, 1% v/v Pen-Strep at 37°C in a 
humidified 5% CO2 atmosphere. After 24 h of appropriate growth, we tested PEG-NE at different 
concentration ranged from 0.001 up to 0.05 % w/v of oil in full medium and added them to the cells 
after washing them with PBS. Cells were then incubated from 2 up to 24 h under standard conditions. 
At the end of the incubation period MCF-7 cells were washed three times with PBS at pH 7.4 and 
incubated with 100 μL of a MTT solution (0.5 mg/L in cell culture medium) for 4 h at 37°C. The 
absorbance readings were acquired at a wavelength of 450 nm with the Tecan Infinite M200 plate-
reader using I-control software. The relative cell viability (%) was calculated by the formula 
[A]test/[A]control×100, where “[A]test” is the absorbance of the test sample, and “[A]control” is the 
absorbance of the control cells incubated solely within culture medium. After evaluating cell 
cytotoxicity, the total protein content was measured by using the Micro BCA protein assay kit 
(Pierce). Briefly, cells were washed with ice-cold PBS, and incubated for 15 min in 150 μL cell lysis 
buffer (0.5% v/v Triton X-100 in PBS), to which 150 μL of Micro BCA protein assay kit reagent 
(prepared following the instructions of the manufacturer) were added. The absorbance at 562 nm was 
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finally measured on a plate reader. The cytotoxicity measurements were then normalized by the 
amount of total protein content in each well. 
 
Cellular uptake. MCF-7 human breast cancer cells were grown in Dulbecco’s Modified Eagle’s 
Medium (Gibco) containing 10% v/v FBS, 1% v/v Pen-Strep at 37 °C in a humidified 5% CO2 
atmosphere. For cellular uptake experiments, 5x103 cells/well were seeded in 24-well plate and 
allowed to grow for 24h. The medium was then replaced with 0.1 mL of a fluorescent PEG-NE (at 
0.05 % w/v of oil) suspension and allowed to incubate for a time comprised between 0.5 and 24 h. 
Cells were then washed twice with PBS (pH 7.4), and after specified time intervals, the experiments 
were terminated by removing the supernatant, washing the cells three times with 10 mM PBS and 
lysing the cells with 0.1 ml of 0.5 % Triton X-100 in 0.2 N NaOH. The membrane-bound and 
internalized PEG-NE were quantified by analyzing the fluorescence of the cell lysate (λexc = 485 nm, 
λem = 535 nm), employing a calibration with 0.001 – 0.05 % of oil related on PEG-NE dispersed in a 
cell lysate solution (106 untreated cells dissolved in 1 mL of the Triton X-100/0.2 N NaOH solution). 
Nuclear staining was obtained by using TO-PRO 3 Iodide (Invitrogen, Molecular Probes Eugene, 
Oregon, USA) diluted 1/1000 after 1 h of contact. 
For qualitative analysis of the intracellular iron, by means of light microscopy, cells were treated with 
PEG-NE@IONC for 30 min, 4h, 8h and 24 h. After the incubation time, cells were washed three 
times with PBS, in order to remove the non-internalized NE@IONC and then were fixed with a 2.5% 
glutaraldehyde in PBS for 20 min. Internalized NPs were stained incubating cells at room temperature 
for 1 h with Prussian blue working solution (1:1 mixture of 5% hydrochloric acid aqueous solution 
and 5% potassium ferrocyanide (II) trihydrate). After that, cells were washed twice with PBS and 
counterstained with Nuclear Fast Red solution at room temperature for 1 h. Each sample was then 
washed three times with PBS and images were acquired using a light microscope. 
 
In vitro photo-acoustic analysis. 
 For photo-acoustic analysis, acquisitions were performed by using the VEVO-2100 LAZR 
(VisualSonics – Fujifilm System) photo-acoustic system. As the first step, a threshold value has been 
detected, to discriminate the photo-acoustic signal from the background noise. This operation has 
been carried out with a phantom, studied and performed with specific material characterized by 
acoustic impedance interfaces.6 For PA acquisitions a 20 Hz tunable laser was used, with a 
wavelength range of 680-970 nm, a resolution of 40 μm and US transducer (LZ-250) which operates 
between 13 and 24 MHz. The values of parameters such as frequency, power output, gain, and height 
have been set constant for all PA acquisitions.  To increase the statistic significance of in vitro scan 
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results, five measurements for each sample were performed in different points of a silicone tube, with 
internal diameters of 0.3 mm. Phantom structure and its features are compatible with the physics 
ultrasound and laser interaction. Samples consisting of PEG-NE@IONC were tested with this 
technique. Subsequent dilutions obtained different concentrations of PEG-NE@IONC with PBS and 
blood, respectively. The blood used was obtained from a mouse donor – Balb/C mouse in compliance 
with the protocols set by the Ethics Committee of IRCCS Hospital Pascale in Naples. 
 
In vivo MRI analysis: Cancer cells culture and xenograft tumor model induction. 
Human Colon Carcinoma cells (HT-29) purchased by ATCC (Manassas, VA), were cultured using 
Dulbecco’s Modified Eagle’s Medium with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 
100 µg/mL streptomycin (all from GIBCO, Life Technologies, USA) and incubated at 37°C/5% CO2 
in 25 cm2 plates. When at confluence, cells were washed twice with phosphate-buffered saline (PBS), 
treated with trypsin-EDTA 1% (GIBCO, Life Technologies, USA) and centrifuged at 1200 rpm for 
5 min. The supernatant was discarded and cells pellet was resuspended in 2 mL of complete medium 
and counted. For xenograft tumor model induction, four nude homozygote male mice (Harlan 
Laboratories, Udine, Italy) were used. Mice were maintained under standard environmental 
conditions (temperature, humidity, 12 hours/12 hours light/dark cycle, with water and food ad 
libitum) and veterinarian assistance. The experimental plan received authorization from the Italian 
Ministry of Health (approval numbers 27/2012-B) and was approved by the Animal Care and Use 
Committee of the University of Verona. One million HT-29 cells, resuspended in 200 µL of sterile 
PBS, were subcutaneously injected in the right flank of anesthetized mice. Two weeks after tumor 
cells inoculation, mice were monitored by MRI to measure the tumor size and when tumor volumes 
ranged between 0.4 and 0.5 cm3, PEG-NE@IONIC was injected intra-tumorally. MR images were 
acquired using a Bruker Tomograph (Bruker Optik GmbH, Ettlingen, Germany) equipped with a 4.7 
T, 33 cm bore horizontal magnet (Oxford Ltd, Oxford, UK) having a maximum gradient strength of 
40 G/cm. Animals were anesthetized by 1% isofluorane inhalation in a mixture of oxygen and 
nitrogen, placed in a prone position over a heated bed and inserted into a 3.5-cm internal diameter 
birdcage radiofrequency coil. T2 weighted images were acquired before and after intratumoral 
injection (200 µL, 11% w/v of oil in water emulsion containing iron nanocubes at concentration of 
~20 ng/mL corresponding to ~ 0.4 μmol of Fe) of PEG-NE@IONIC to detect the tumor mass and the 
presence of nanoparticles. T2 weighted images were acquired in the coronal plane using a RARE 
sequence with TR= 5000 ms, TEeff = 47.5 ms, NEX = 1, field of view =3.5x7 cm2, matrix 
size=140x280, slice thickness = 1mm, flip angle = 180°, Number of slices = 10. 
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Histological analysis of tumor tissue. After in vivo MRI, the presence of PEG-NE@IONIC in the 
tumor tissues was confirmed by histological analysis. Mice were sacrificed and the tumor mass was 
dissected out, washed with PBS 0.1 M and fixed in 10% formalin for 4 hours. Tissues were embedded 
in paraffin and cut in 5 µm thick sections with a microtome and dried at 37°C for 24 h. In order to 
evaluate the presence of iron nanoparticle in the tissue, Prussian Blue (PB) staining was performed: 
sections were incubated with PB solution (5% hydrochloric acid and 5% potassium ferrocyanide) for 
40 minutes and counterstained with nuclear fast red (Bioptica) for 10 minutes. Sections were 
examined under a light microscope (Olympus BXS1) equipped with a charge-coupled device camera. 
 
Statistical Analysis. In Figure 4.3 data are presented as Mean ± SD, n = 3. Graphs of Figure 4.9 are 
obtained by the average over 5 scans in the spectral range of 650-1000 nm; SEM = 9.5%, n = 5. 
Cellular uptake has been performed in triplicate (n=3) in order to check eventual statistical 
differences. The difference between experimental groups was investigated by a one-way analysis of 
variance (ANOVA) and by a subsequent Turkey's multiple comparison test in Sigma Plot Software. 
For statistical analysis of all data, p < 0.05 was regarded as the lowest acceptable threshold for 
significance. All statistical analysis has been performed using Origin software (OriginPro 2017, 
OriginLab Corporation). 
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Supporting Information  
DLS measurements.  
 
 
Figure S1. Comparison of the particle size growth between samples obtained with a standard procedure (blue 
bars), obtained by shielding the natural light (red bars) and by dialyzing the sample after 3 days (green bar). 
The sample dialyzed has been tracked for only 7 days because, due to the very thin shell, it resulted unstable 
for longer time. Error bars are derived from PDI value (PDI = (SD/d)2) over 3 measurements of the same 
sample; see Tables below for the complete DLS reports. 
 
Table S1. Size distribution (mean diameter, PDI and SD, n = 3) as a function of the time of PEG-NE prepared 
by the conventional method. 
 
Time 
[days] 
Size 
[d.nm] 
PDI SD 
[d.nm] 
1 102.9 0.106 33.5 
3 117.0 0.073 29.0 
5 129.2 0.053 25.1 
7 163.6 0.047 35.4 
9 181.8 0.048 39.6 
11 202.4 0.032 36.0 
13 211.5 0.034 39.0 
15 209.2 0.012 22.6 
17 221.7 0.040 44.3 
19 224.7 0.046 48.2 
21 235.4 0.028 38.4 
23 225.1 0.018 30.2 
25 218.2 0.050 48.9 
27 214.2 0.055 50.0 
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Table S2. Size distribution (mean diameter, PDI and SD, n = 3) as a function of the time of PEG-NE prepared 
by adding an acrylate dye (Methacryloxyethyl thiocarbonyl rhodamine B). 
 
Time 
[days] 
Size 
[d.nm] 
PDI SD 
[d.nm] 
1 113.4 0.041 23.0 
3 128.2 0.035 24.0 
5 174.5 0.014 20.6 
7 179.0 0.022 26.3 
9 186.1 0.008 16.1 
11 206.2 0.025 32.6 
13 228.0 0.050 51.0 
15 242.9 0.035 45.2 
17 251.9 0.024 39.3 
19 256.9 0.062 64.1 
21 336.5 0.209 153.7 
23 264.8 0.028 44.3 
25 269.7 0.025 42.9 
27 303.1 0.156 119.9 
 
 
Table S3. Size distribution (mean diameter, PDI and SD, n = 3) as a function of the time of PEG-NE prepared 
by shielding the ambient light and by dialyzing the sample after 3 days of polymerization. The sample dialyzed 
has been tracked for only 7 days because, due to the very thin shell, it resulted unstable for longer time. 
 
 No light Dyalized 
Time 
[days] 
Size 
[d.nm] 
PDI SD  
[d.nm] 
Size 
[d.nm] 
PDI SD 
[d.nm] 
1 106.3 0.099 33.5    
3 105.5 0.086 31.0 108.8 0.080 30.8 
5 107.2 0.075 29.4 109.5 0.050 24.4 
7 109.2 0.087 32.3 110.2 0.048 24.1 
9 105.7 0.107 34.5 110.1 0.048 26.2 
11 110.5 0.107 36.1    
13 110.5 0.112 37.0    
15 110.8 0.084 32.1    
17 110.5 0.089 33.0    
19 110.2 0.065 28.1    
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TEM micrographs. 
 
Figures S4. A: TEM micrograph of PEG-NE, stained with OsO4, obtained after 30 days of shell growth. B: 
Cryo-TEM micrograph of the starting nano-emulsion. C and D: TEM micrographs of Iron Oxide Nano-Cube 
(IONC). 
 
STED image. 
 
 
Figure S5. STED image of nano-capsules containing FITC in the oil-core. Scale bar 5 μm. 
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Photoacoustic spectra. 
 
 
Figure S6. In vitro experiments showing the PA response of PEG-NE@IONC, in the stock formulation and 
in PBS (50 µL + 50 µL). Studying trends spectra with different dilutions can help to identify the smaller signal 
that PA system could detect. 
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Appendix. 
 
 
 
 
 
 
Future perspectives using a molecular formulation of 
Fe (III) in O/W nanoemulsion for MRI applications. 
 
 
 
 
 
 
 
 
 
 
 
This work is performed in collaboration with Dr. Luca Menichetti (CNR-IFC, National Research Council Institute of 
Clinical Physiology) and Dr. Alessandra Flori ("G. Monasterio" Foundation - Regione Toscana - CNR Research Area) 
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Starting idea, preliminary results and outlooks. 
As discussed in Chapter 1 and just demonstrated in Chapter 4, known the benefits of MRI as 
diagnostic tools and the safety of iron based nanoparticles as contrast agents, we are moving to 
explore a new design of our O/W LbL nanoemulsions. In this new strategy, we wish to study the 
possibility to prepare O/W LbL nanoemulsions encapsulating a molecular form of Fe(III), Fe(III)-
oleate as contrast agent, and to study its MRI performance. Being a reddish-brown viscous oil, it is 
soluble in soyben oil, the oil core of our nanoemulsion. Furthermore, being a molecule, it permits us 
to scale more our nanoemulsion dimensions, improving their bioavailability. Fe(III)-oleate synthesis 
recalls some works in which it had applied to obtain with specific procedures iron nanoparticles.1,2 
The principal advantage of this protocol is the use of non-toxic and economical reagents, such as 
metal chloride and sodium oleate. We had followed this approach to synthetize Fe(III)-oleate but 
stopping before the subsequent preparation of iron nanoparticles. In fact, as said, our aim is to exploit 
the magnetic properties of iron in a molecular safe form able to be encapsulated in our smallest 
nanoemulsion formulation (less than 100 nm). In this appendix, we show some preliminary results, 
in terms of synthesis of Fe(III)-oleate, its encapsulation in our O/W nanoemulsions and the first MRI 
results of the O/W nanoemulsion loaded with it as contrast agents. This work is in coming and new 
experiments to encapsulate higher concentrations of Fe(III)-oleate, the MRI response of the new 
formulated O/W nanoemulsions and ICP characterizations of the synthetized molecule are in 
progress.   
 
Preparation on the iron oleate complex loaded in O/W nanoemulsion. 
Synthesis of iron oleate complex. The followed protocol was taken from literature, with slight 
modifications, in particular the use of FeCl3 anhydrous (Mw=162.20 g mol
-1) to a better control of 
ferric environment as compared to an iron chloride hydrated (FeCl3•6H2O).1,2 Briefly, 20 mg of 
anhydrous iron chloride (0.123mmol) and sodium oleate (3.3eq, Mw=304.44) are dissolved within a 
solvent mixture of 147 μL ethanol, 110 μL Milli Q water and 257 μL hexane. Each reagent and solvent 
were purchased from Sigma-Aldrich. The resulting solution was heated at 70°C in reflux for 4 h under 
controlled atmosphere conditions. After that, to help the workup phase, 28mL of hexane were added 
to the resulting product. Then, the mixture was put in a separatory funnel and washed 3 times with 6 
mL of MilliQ water. The organic phase containing the iron oleate mixture was then treated with 
MgSO4 anhydrous and then hexane was evaporated by rotary evaporator. Then iron oleate complex 
was dried in a vacuum oven at 30°C overnight.   
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O/W nanoemulsion loaded with iron oleate complex. 
As previously described,3 5.8 g of Lipoid E 80 (egg lecithin powder 80-85% enriched with 
phosphatidylcholine and 7–9.5% content in phosphatidylethanolamine) was dissolved in 24 mL of 
soy-bean oil (density at 20 °C of 0.922 g mL-1) at 60 °C. To obtain the control empty nanoemulsion, 
the oil phase was then added dropwise to the aqueous phase (Milli-Q water) and mixed using the 
immersion sonicator (Ultrasonic Processor VCX500 Sonic and Materials). The obtained pre-
emulsion was then homogenized at 2000 bar by a high-pressure homogenizer (110P series 
microfluidizer) to obtain the final 20% wt oil in water nanoemulsion. In the case of iron loaded 
nanoemulsion, the nanoemulsion was loaded with around 78 mg of iron oleate complex, dissolved in 
4-5 mL of ethanol, adding it in the oil phase in the pre-emulsion step, after lecithin.  This mixture was 
left under stirring at 70°C for 1 h to allow ethanol evaporation before continuing the pre-emulsion 
preparation with the addiction of the oil phase to the aqueous phase. The rest of the procedure was 
the same. By DLS analysis, the prepared samples were in accordance with our typical monodispersed 
nanoemulsion. No-loaded 20 %wt O/W nanoemulsion was characterized by: 98.61nm (st.dev.1.19), 
PDI 0.102 (st.dev. 0.022), ζ-Potential -24.9mV (st.dev. 0.7); Iron oleate loaded 20 %wt O/W 
nanoemulsion was characterized by: 98.23nm (st.dev. 1.30), PDI 0.079 (st.dev. 0.014), ζ-Potential -
30.8mV (st.dev. 5.2)  
 
Evaluation of relaxation performance of the O/W nanoemulsion at 3 and 7 T 
Samples preparation.  First of all the no-loaded and iron oleate complex loaded O/W nanoemulsions 
were manually resuspended using the pipette and by vortex for a few seconds. Then, dilutions of such 
samples are prepared at different final concentrations (dilution factors: 1:5, 1:10, 1:20, 1:40, 1:80, 
1:160) using Milli Q water. In order to proceed with MRI measurements, dilutions were prepared 
inside wells of a Cell culture plate (24 wells), taking appropriate volumes of nanoemulsions from the 
stock solutions and adding Milli Q water up to the volume of 2 mL for each well. In order to obtain 
a homogeneous distribution within the wells, the solutions were manually resuspended with the 
pipette. 
 
MRI analysis. The study of the relaxivity of the O/W nanoemulsion containing iron oleate complex 
was conducted both at clinical field strength (3 T) and high magnetic field (7 T). For the 3 T study, 
the plate containing the nanoemulsions in aqueous solution was placed in the center of the bore of the 
clinical scanner (GE HDxT, GE Healthcare, USA). Acquisitions was made using a commercial coil 
of head coil type (GE HDxT, GE Healthcare, USA) for neurological imaging. For the measurement 
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of relaxation times it was used respectively Fast Spin Echo Inversion Recovery sequences for the 
measurement of T1 and T2 map Spin Echo for T2,
4-6 with the following acquisition parameters: 
 T1 inversion recovery: FOV = 16 cm; slice thick = 5 mm; 2NEX; 256x256; TR = 8 s;                 
TE = 7ms; Echo Train Length = 24; Bandwidth = 62.5; inversion times (TI) = 50, 100, 300, 
500, 700, 900, 1100, 1300, 1500, 1700, 1900, 2100, 2500 ms 
 T2 map spin echo: FOV = 16 cm; slice thick = 5 mm; 2NEX; 256x256; TR = 8 s; Echo Train 
Length = 24; Bandwidth = 62.5; Echo Times (TE) = 10, 20, 40, 60, 80, 100, 160, 200 ms 
The images obtained were analyzed with the Matlab software (the Mathword Inc.). 
 
For the 7 T study, the previously analysed iron oleate loaded nanoemulsions solutions were 
transferred in 5 mm diameter NMR glass tubes, in turn inserted into a larger tube (diameter = 30 mm), 
in order to acquire more solutions at the same time. Acquisitions were carried out with a NMR Bruker 
AVANCE III 7-T wide bore (Bruker, Rheinstetten, Germany) 300 MHz spectrometer, operated by 
the ParaVision 6.0.1.software. The images were acquired using a 30 mm diameter microimaging 
quadrature coil (Bruker, Rheinstetten, Germany). 
FAIR RARE sequences for the measurement of T1 and Spin Echo (MSME) for T2 were used 
respectively for the measurement of relaxation times, with the following acquisition parameters: 
 FAIR RARE: FOV = 29x29 mm; slice thick = 2 mm; 4 NEX; 256x256; TR = 5 s; TE = 45 ms; 
Echo Train Length = 16; inversion times (TI) = 50, 200, 350, 500, 650, 800, 950, 1100, 1250, 
1400, 1550, 1700 ms, flat resolution = 113x113 μm. 
 MSME: FOV = 30x30 mm; slice thick = 2 mm; 2 NEX; 256x256; TR = 5 s; Echo Times (TE) 
= da 8 a 1600 ms con ΔTE = 8 ms, flat resolution = 117x117 μm. 
 
Post Processing of images. 
The images obtained at 3 T were analysed with the Matlab software (the Mathword Inc.) in the 
following procedure: 
a) On MRI images, a region-of-interest (ROI) is selected for each nanoemulsion dilution value 
and the average value of the signal within the ROI is estimated; 
b) The value of T1 is estimated by the fit of the curve of the average signal in ROI as a function 
of the TI, according to the following equation: M=M0*(1-2*exp(-TI/T1))+c, where M 
indicates the signal value; 
c) The value of T2 is estimated by the fit of the curve that shows the average of the signal in the 
ROI according to the different times of eco (TE) used during the acquisitions, according to 
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the following equation: M=M0*exp(– TE/T2)+c, where M indicates the signal value (Figure 
1). 
 
The same approach was followed for the analysis of the images obtained at 7 T, using the ParaVision 
software. 
Once obtained the values of T1 and T2 for the different dilution values, some parameters 
representative of the relaxometric capacities and of the transverse (r2) and longitudinal relaxivity (r1) 
can be estimated by the slope of the regression Ri line compared to nanoemulsions volumes for each 
dilution, according to the equation: Ri - Ri (H2O) = ri * V,   i = 1, 2, where Ri is the relaxation rate (= 
1/Ti) and V is the volume in μL. 
We cannot talk about real relaxation values because the latter are obtained from the slope of the 
regression line R1,2 [s
-1] compared to the concentration values of Fe-equivalent [in mM], they are in 
fact expressed in units of mM-1 ∙ s-1.7,8 In this preliminary analysis, ICP measurements to evaluate Fe 
concentration value are in progress, so not having the concentration values, we use a representative 
parameter.  
 
 
 
 
 
 
 
 
 
Figure 1: Analysis of the MRI images at 7 T for the estimation of the transverse relaxation time (T2). 
 
Preliminary MRI results. 
Figure 2 shows the fit of the R2 (s
-1) curves according to the nanoemulsions (NE) volume in the 
solution (in μL) for both the no-loaded and iron oleate complex loaded nanoemulsions; for the fitting 
it was eliminated the first value of TE (probable saturation). 
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Figure 2. Fit of the trasversal-relaxation curves R2 according to the nanoemulsions volume in the solution, obtained at 3 
T for the non-loaded and iron oleate complex loaded O/W nanoemulsions. 
 
It is observed that nanoemulsions called no-loaded have no effect on the relaxation T2 while the iron 
oleate loaded nanoemulsions seem to have an effect on the relaxation T2. To be able to correctly 
estimate the value of relaxivity and compare it to that of other commercial systems or similar, it would 
be necessary to have the Fe equivalent concentration values of the nanoemulsions.  
 
 
Figure 3. Fit of the longitudinal relaxation curves R1 as a function of the nanoemulsions volume in the solution, obtained 
at 3 T for no-loaded and iron oleate loaded nanoemulsions.  
 
Figure 3 shows the fit of the R1 (s
-1) curves according to the nanoemulsions volume in the solution 
(in μL) for both the no-loaded and iron oleate complex loaded nanoemulsions. Also in this case it is 
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observed that nanoemulsions called no-loaded have no effect on the T1 relaxation while the iron oleate 
complex loaded systems have an effect on the relaxation T2 leading to a reduction of the T1 relaxation 
time to the increase of the concentration. In this case it would be advisable to have the Fe equivalent 
concentration values of the nanoemulsions to be able to correctly estimate the value of relaxivity. 
 
                 
Figure 4. Fit of the trasversal relaxation curve R2 as a function of the nanoemulsions volume in the solution, obtained at 
7 T for the iron oleate complex loaded nanoemulsions. 
 
             
Figure 5. Fit of the longitudinal relaxation curve R1 as a function of nanoemulsions volume in the solution, obtained at 7 
T for the iron oleate complex nanoemulsions. 
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The fit of the lines of R2 and R1 respectively as a function of nanoemulsions volume in the solution 
(in μL) for the iron oleate complex loaded nanoemulsions are shown in Figure 4 and 5, for the images 
obtained at 7 T. These graphs substantially confirm the observed trend for 3 T acquisitions, with a 
decrease in the time of relaxation T1 and T2 as the concentration of nanoemulsions increases. 
 
Conclusion 
For MRI application, we have started studying a new contrast agent, synthesising molecule of ferric 
oleate which are soluble in soybean oil, safe and economic. In this way, we have the possibility to 
increase the Fe(III) concentrations in our O/W nanoemulsion and to scale their size to improve Fe(III) 
bioavailability. Nanoemulsion and ferric oleate characterizations are in progress, being this a new 
strategy started very recently. Meanwhile, we have started preliminary MRI analysis to evaluate if 
these nanocarriers could be interesting systems in such applications. We have observed that in general 
there is an increase of the values of r1 and r2 at 7 T compared to 3 T and the ratio between the 
parameters is comparable for the two magnetic field intensities employed. In general, for 
paramagnetic nanostructured systems, such as nanoparticles with magnetite cores, we expect a linear 
increase in the values of the relaxation rate as the concentration increases, particularly with regard to 
R2. ICP analysis and O/W nanoemulsion with higher ferric concentrations are in phase of preparation. 
The aim is to obtain systems with ratio r2/r1 greater than 10.
9 Therefore, our systems seems to be 
promising.  
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Nanomedicine is the field of action of this PhD project with particular attention to cancer therapy and 
prevention. In particular, we focused on drug delivery systems, as photo-stimuli responsive oil core 
polymer nanocapsules built via LbL technique. Moreover, the encapsulation in the oil core of drugs 
or contrast agents expand the use of these nanocarriers in specific therapeutic or diagnostic fields. At 
the same time, the synergistic use of photo-stimuli responsive loaded both with drugs and contrast 
agents open the door for interesting engineered nanocapsules for theranostic purpose. As discussed 
previously, LbL nanocarriers are of particular interest to reduce side effects and improve drug 
efficiency and bioavailability. Moreover, another strong point is the use of safe materials in our 
preparations in terms of biocompatible polymers, natural drugs and safe contrast agents reducing 
much more the undesirable effects for the patient. Additionally, the functionalized polymers have 
never shown toxicity and so seem to be in accordance with our biocompatible systems.  
As explained in ‘Aim of the PhD project’ (Chapter 1) to improve clinical performance and cancer 
detection, we have manipulated our oil core LbL multilayer shell by chemical modifications in the 
polymeric compositions and/or in the oil core formulations.  
Therefore, in Chapter 2 we have reported the fabrications and the functionality of cross-linked photo-
responsive LbL trilayer built on oil in water nanoemulsions, loaded with a natural drug, curcumin. In 
particular, we performed a chemical functionalization of the polymers of the shell, to engineer a 
photo-responsive nanocarrier with spatio-temporal control in the release of the drug. Starting from a 
biocompatible photoinitiator free ‘click’ reaction, already demonstrated in our group, we have 
stabilized our nanocarriers by a cross-linkage between an allylated heparin and a N-acetyl cysteine-
o-nitrobenzyl moiety on glycol chitosan. In different tests, including viability tests on melanoma cells, 
we also demonstrated that the photo-responsive moiety permits a nanocarriers’ destabilization by UV 
light and a more efficient release of the drug. This maybe a promising approach for the treatment of 
cancer skin or for the treatment of cancer tissues during surgery applications. On the other hand, in 
terms of use of natural drugs but in the field of oral delivery, in Chapter 3 we reported our recent 
published article, which is part of this PhD project. In this work, we studied curcumin and lycopene 
loaded in O/W nanoemulsions coated or no coated with chitosan. In vitro tests on cardiomyoblasts in 
presence of doxorubicine has demonstrated the cardioprotection and anti-inflammatory activity of 
these nutraceutical drugs.  
As pure diagnostic application of our O/W nanoemulsions, in Chapter 4 we reported a study on oil-
core-PEG shell nanocarriers encapsulating nanocubic iron oxide nanoparticles, as safe contrast agent. 
We have demonstrated their goodness in in vitro photoacoustic and in vitro and in vivo magnetic 
resonance imaging. Moreover, in the Appendix to Chapter 4, we showed a new approach that we are 
developing. It is about the use of a molecule, safe and economic, as contrast agent, ferric oleate and 
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in this Appendix we reported the preliminary data about simple synthesis, its loading into our 
nanoemulsions and the first MRI results. This is also an approach meant to allow scaling down of the 
size of our oil core nanocarrier since in this way the nanocarrier size is not limited by the size of 
contrast agents in nanoparticle version.  
On one hand, each part of this PhD project could be a single tool to apply in a single field but on the 
other hand, all the tools may be combined in a very flexible and open-minded way. We may think to 
induce a specific route of our nanocarrier in the desired diseased tissue by magnetic field or just wait 
a spontaneous accumulation; we could follow the nanocapsules accumulation by MRI, and induce a 
controlled release by a light external source. Furthermore, the cross-linkage of our nanocapsules can 
guaranty stability and no loss of their cargo, until they arrive in the specific sites. Engineering a photo-
responsive nanocarrier co-loaded with natural drugs and safe contrast agents, opens the doors to a 
promising theranostic approach. In the next future, our purpose is the preparation of those theranostic 
nanocapsules to prove in vitro ad in vivo their efficiency. 
 
 
 
 
 
 
 
 
 
